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With an annual incidence of 17.000 per year in the Netherlands, and 1.7 million 
worldwide, breast cancer is the most frequent malignancy in females, and the second 
most frequent cancer overall after lung cancer.1 Over the past years, there is a steady 
increase in incidence, together with steadily improving survival rates. A major factor 
in the improving survival rates is the concept of (neo)adjuvant therapy.2 
Currently, there are three cornerstones for the treatment of primary breast cancer: 
surgery, radiotherapy and systemic (neo)adjuvant therapy. The aim of surgery is to 
remove the primary tumour, thereby preventing future metastasis and locoregional 
complications. The aim of radiotherapy is the prevention of local and regional 
relapse, especially after breast-conserving surgery and in the presence of lymph node 
metastasis. The aim of adjuvant systemic therapy, either endocrine therapy, targeted 
therapy or chemotherapy, is to prevent relapse, in particular distant metastasis. In 
addition, the concept of neo-adjuvant therapy, in which systemic therapy is applied 
before the operation, also leads to tumour shrinkage. This could allow breast-
conserving surgery, as well as axillary downstaging and provides knowledge about 
the sensitivity of the tumour towards the therapy. 
Approximately 80% of all breast cancers are hormone-receptor positive, meaning 
that the tumour is expressing either the estrogen receptor (ER), progesterone 
receptor (PgR) or both.3 With this expression, the tumour is capable of stimulating 
its own growth by receiving a higher amount of estrogen-dependent growth signals.4
Endocrine therapy
Already in the 19th century, the concept of endocrine sensitivity of breast cancer was 
discovered, when Col. Sir George Thomas Beatson performed an oophorectomy at 
three patient with advanced breast cancer, thereby reducing their metastases.5 For 
decades, the oophorectomy became standard therapy for advanced breast cancer. In 
the 1960’s and 70’s, a first type of chemical endocrine therapy was first discovered. 
Tamoxifen, a selective estrogen receptor modulator (SERM) first developed as an 
oral anticonceptive, was shown to have growth inhibiting capacities in HR-positive 
breast cancer. Initially, this treatment was only used in advanced disease, to inhibit 
the growth of metastases. However, soon it was also discovered that preventive use of 
tamoxifen was able to lower the chance of disease recurrence.6-9 It was established that 
2 years, and later 5 years of tamoxifen was associated to a lower rate of recurrences.10, 11 
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In a post-hoc meta-analysis by the Early Breast Cancer Trialists Collaborative Group 
(EBCTCG), it was established that at 15 years after diagnosis, there was an absolute 
benefit of 12% on recurrence-free survival of tamoxifen 5 years (33% recurrence) 
versus no adjuvant endocrine therapy (45% recurrence).12
Meanwhile, a second class of endocrine therapy was being developed. Brodie et al 
first showed the concept of aromatase inhibition, in which the enzyme aromatase, 
which is responsible for the conversion from androgens to estrogens, is being 
inhibited.13 In case of a postmenopausal patient, for which aromatase-dependent 
androgen conversion is the only source of estrogens, this would lead to a theoretical 
full depletion of estrogen, thereby preventing any activation of the estrogen receptor.
The Intergroup Exemestane trial (IES trial) was the first trial to directly compare the 
effect of tamoxifen and aromatase inhibitors, in this case exemestane.  After 2-3 
years on tamoxifen, patients were randomized between either completing 5 years 
of tamoxifen, or switching to exemestane to complete 5 years of adjuvant endocrine 
therapy. Both at 5 and 10 years follow-up, there was a significant improvement for 
disease-free (DFS) and overall survival (OS) for the switch to exemestane.14, 15 The 
Arimidex, Tamoxifen, alone or in combination trial (ATAC) compared anastrozole 
and tamoxifen monotherapy, together with a third arm combining both agents. The 
combination arm was closed due to a lack of additional benefit. This study showed 
that for DFS and distant metastasis-free survival, there was a benefit of an AI over 
tamoxifen monotherapy.16, 17 These results were confirmed by the Breast International 
Group (BIG) 1-98, which additionally showed that a sequential therapy of tamoxifen 
followed by an AI, was also superior over tamoxifen monotherapy.18>
The Tamoxifen and Exemestane Adjuvant Multicenter Trial (TEAM) compared 
exemestane monotherapy with a sequential scheme of tamoxifen for 2.5 years, 
followed by exemestane to complete 5 years of therapy. Both at 5 and 10 years of 
follow-up, this trial showed no difference in DFS or OS.19, 20 In a recent meta-analysis 
performed by the EBCTCG, it was confirmed that there was a clinically and statistically 
significant benefit of both sequential therapy and AI monotherapy over tamoxifen 
monotherapy, both for DFS and OS. Moreover, a marginal benefit of AI monotherapy 
over sequential therapy was shown for DFS with an absolute risk reduction of 0.7% 
(HR 0.90, p=0.045), but not for OS (HR 0.89, p=0.11).21




Despite the success of adjuvant endocrine therapy, there is still a continuous risk for 
recurrences up to 15 years after diagnosis.22 Therefore, the concept of extended (i.e. 
longer than 5 years) adjuvant endocrine therapy was developed. Initially, extended 
therapy was mainly studied in the context of extended 5 years of tamoxifen. After 5 
years of tamoxifen, it was shown that extended therapy with either another 5 years 
of tamoxifen, or 5 years of an AI was beneficial in terms of disease-free survival, in 
particular in patients with node-positive disease.23-25 However, the effect on overall 
survival was marginal, and not statistically significant when data were pooled in a 
meta-analysis.26 After receiving an AI in the first 5 years of treatment, until date no 
study has shown that extended therapy has a significant benefit.
Biomarkers
In all studies mentioned above, it is apparent that there is only a small group of 
patients that benefits from (extended) adjuvant endocrine therapy. For example, 
when comparing 5 years of tamoxifen with no adjuvant therapy, the absolute 
reduction of 12% and the hazard ratio of 0.73 looks impressive, but also means that 
88% of the patients is treated in vain.12 This means that there is a lot of room for 
improvement. The guidelines for adjuvant therapy are relatively strict; both adjuvant 
chemotherapy and endocrine therapy are indicated quite easily, thereby lowering 
the risk for undertreatment. However, due to this approach many patients will be 
overtreated, which is especially concerning given the side effect profiles of adjuvant 
chemotherapy and endocrine therapy. Therefore, tailoring strategies are crucial in 
order to optimize adjuvant therapy, so that maximal benefits can be achieved with 
minimal harms.
Currently, the possibilities to tailor adjuvant (extended) therapy are limited. For 
adjuvant chemotherapy, the current tailoring strategies are mainly risk-based. In 
theory, patients with a higher risk of recurrence will benefit more from adjuvant 
chemotherapy compared to patients with a low risk of recurrence. Traditionally, 
clinicopathological factors like lymph node status, tumour size, receptor status, 
differentiation grade and age are used to determine the risk for recurrence. However, 
more recently, gene expression profiles have shown to be interesting prognostic tools, 
accurately predicting the risk for recurrence.27, 28 
Besides the risk-based tailoring approach, there is also a biology-based approach 
to tailor therapy. For endocrine therapy, ER and PgR are used as biomarkers to tailor 
49021 Erik Blok.indd   13 03-04-18   11:43
Chapter 1
14
endocrine therapy. However, since 80% of all breast cancer patients is either ER 
and/or PgR-positive, and all above-mentioned trials had ER and/or PgR-positivity as 
inclusion criterion, the level of tailoring reached with only ER and PgR is insufficient. 
One factor that could provide a biology-based tailoring approach, next to the hormone 
receptors, is the immune system. It is well known that the immune system, and the 
adaptation of the tumour to the immunological burden, is crucial in the development, 
growth and metastasis of a tumor.29 One of the many important aspects in the tumour-
immune system interaction, are tumour infiltrating lymphocytes (TILs). Although 
many different subcategories of lymphocytes are present within a tumour, T-cells, and 
specifically CD8-positive cytotoxic T-cells, are the most abundant. It has been shown 
for triple-negative breast cancer, and HER2-positive breast cancer, that higher levels 
of TILs are associated to a better prognosis, and a higher success rate of adjuvant 
chemotherapy and HER2-targeted therapy.30-37 Remarkably, this association was not 
observed for ER-positive breast cancer, in which TILs have no prognostic value.38, 39 
However, the predictive value of TILs on endocrine therapy has never been studied.
In this thesis we aimed to tailor adjuvant therapy, and in particular adjuvant endocrine 
therapy, using multiple approaches. We particularly focused on the benefits of 
extended endocrine therapy, and on new translational approaches for tailoring 
adjuvant therapy for postmenopausal patients with early breast cancer.
Outline of this thesis
Part I of this thesis is aimed at the clinical use of extended endocrine therapy. 
Chapter 2 provides an overview of all the current evidence for extended therapy, and 
the prospectives of the trials that will be reported in the future. Chapter 3 describes 
the primary results of the multicentre phase III IDEAL trial, in which patients who 
received any kind of 5 years adjuvant endocrine therapy, were randomized between 
either 2.5 or 5 years of extended therapy. Chapter 4 provides a more detailed subgroup 
analysis of the IDEAL trial, trying to identify a clinicopathological subgroup for which 
there is a benefit of longer extended therapy. Chapter 5 describes which factors are 
associated to choosing to participate in the IDEAL trial, which factors contributed to 
treatment compliance, and the impact of treatment compliance on survival. 




Part II of this thesis is aimed at tailoring both (neo)adjuvant chemotherapy and 
endocrine therapy, using biomarker-based approaches.
Chapter 6 describes the development and validation of a new platform, capable of 
assessing the activity of the estrogen receptor pathway. This platform was developed 
by determining the activity of downstream gene targets of the estrogen receptor, 
and thereby estimating the probability that the estrogen receptor is active. When 
the receptor is indeed active, it might predict for the benefit of endocrine therapy, 
whereas with an inactive pathway endocrine therapy would have little effect. Chapter 
7 explores the use of tumour-infiltrating lymphocytes (TILs) as a prognostic marker in 
ER-positive breast cancer, and as a predictive marker for endocrine therapy. Chapter 8 
further studies TILs as a prognostic marker, in combination with expression of the cell 
surface death receptor FAS. Chapter 9 provides a systematic review of gene expression 
profiles, in which the four major assays (Endopredict , MammaPrint, OncotypeDX, 
and Prosigna) are reviewed on the developmental procedure, prognostic and 
predictive capacities, clinical utility and the economic value of the tests. Chapter 10 
provides a critical interpretation of the results  of the MINDACT trial, a major clinical 
trial evaluating the use of MammaPrint in clinical practice.
Finally, a summary and discussion on the results of this thesis will be provided in 
chapter 11, addressing the future perspectives of tailoring adjuvant therapy.  
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The optimal duration and regimen of adjuvant hormonal therapy for premenopausal 
and  postmenopausal patients with hormone receptor positive early breast cancer has 
not yet been established. This review will give an overview of published and ongoing 
studies concerning extended endocrine treatment. Most of the currently published 
studies are based on the adjuvant treatment regime of 5 years tamoxifen, which has 
been proven to be inferior compared to aromatase inhibitor (AI)-containing regimes. 
Therefore, until today, there is no clear evidence for the extension of endocrine therapy 
after upfront AI-based adjuvant treatment regimes. Multiple clinical trials, which will 
be discussed in this review, are ongoing to elucidate on this matter. We emphasize the 
need for tailoring of extended adjuvant endocrine treatment. The quest for predictive 
biomarkers, which are currently being investigated in the context of decision-making 
whether or not to start adjuvant chemotherapy, should be expanded to include the 
feasibility of extended endocrine treatment based on these markers. By tailoring the 
extension of endocrine treatment,  overtreatment, side effects and unnecessary costs 
will be prevented.
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Introduction
Nowadays, endocrine treatment is one of the mainstays of breast cancer 
treatment, but the optimal duration is yet to be determined. It is estimated that 
75% of all breast cancer patients are hormone receptor-positive (HR+) breast 
cancer, and therefore might benefit from endocrine treatment.1 Endocrine therapy 
significantly reduced the risk of death among patients with HR-positive tumors 
compared to those with ER and PgR-negative tumors. Five years of adjuvant 
tamoxifen reduced the breast cancer mortality by about a third throughout the 
first 15 years.2 However, estimations for the long term risk of recurrence show 
that HR- positive breast cancer patients remain at a significant risk of recurrence 
until at least 15 years post diagnosis, whereas the risk for recurrence for ER/PgR 
negative patients is highest shortly after diagnosis but decreases below that of 
ER/PgR positive patients later on.2,3 There is scientific evidence that it is beneficial 
to use extended tamoxifen after 5 years of adjuvant tamoxifen4,5 and to start 
using an aromatase inhibitor after having received tamoxifen for 5 years, even if 
tamoxifen was stopped a considerable time ago.6
Adjuvant endocrine therapy
Ever since the first oophorectomy performed by dr. Beatson in 18967, endocrine therapy 
has been established as a treatment option for HR+ breast cancer. Currently, tamoxifen 
and aromatase inhibitors (AIs) are the two most important categories for endocrine 
treatment in postmenopausal patients. A third category of endocrine therapy, ovarian 
function suppression ( OFS by GnRH agonists, ablation or radiotherapy)  is used in 
premenopausal patients to diminish the ovarian function in combination with 
tamoxifen or AIs.8
After its introduction in 1970, the selective estrogen receptor antagonist tamoxifen 
soon became standard therapy in the treatment of advanced hormone receptor-
positive breast cancer9. Initially, treatment was based on 1-2 year strategies as this 
was the optimal duration in advanced disease.9,10 However, it became clear that 5 
year adjuvant treatment improved the clinical outcome, and for decades this has 
been the standard treatment for hormone receptor-positive breast cancer.11-13  Five 
years of adjuvant treatment with tamoxifen versus no treatment showed a relative 
risk reduction in 15 year recurrence risk of 40%, with an absolute gain of 13.2%.2 
Furthermore, a decrease of 15 year breast cancer mortality has been observed with a 
relative risk of 0.7, and an absolute benefit of 9.2%.
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While tamoxifen was introduced, the first AIs were developed and proven to be 
efficient in metastatic breast cancer patients.14 However, due to its inhibitory function 
on cytochrome P450, its effects on adrenal function and subsequent side effects, 
the first and second generation AIs did not become mainstream treatment for 
adjuvant treatment, and were only used in separate cases of metastatic disease.14,15 
AIs only became popular after the development of third generation compounds 
(anastrozole, letrozole and exemestane) which are less toxic. The first report of these 
third generation AIs in the setting of a large clinical trial was in the Anastrozole, 
Tamoxifen Alone or in Combination (ATAC) trial, in which anastrozole, tamoxifen and 
a combination of both were studied16. At initial 5 years and 10 years follow-up, this 
study showed the superiority of AIs over tamoxifen as a first line adjuvant treatment 
for early breast cancer in postmenopausal patients, and comparable results for the 
combination treatment.16-18 After these findings, multiple trials examined the effect 
of switching to an AI compared to continuing with tamoxifen. A meta-analysis by 
Dowsett et al in 2010 showed a superiority of this switch scheme above continuing 
with tamoxifen.19  This switch scheme consists of 2-3 years of tamoxifen, followed 
by 2-3 years of an AI.  Two other major trials, BIG 1-98 and TEAM-trial, initially 
focused on the same research question whether AIs would be superior to tamoxifen. 
However, due to the results that AIs appeared superior to tamoxifen, they changed 
their design into a comparison of five years AI with the before-mentioned  switch 
scheme. Both studies showed a borderline non-significant progressive decrease of 
disease free survival (DFS) or recurrence free survival (RFS) in the initial 2-3 years of 
tamoxifen. However, after the switch to an AI, the difference between both groups 
stabilized leading to a non-significant difference between both groups.20,21 Therefore 
there is no evidence for superiority of either 5 years AIs or a switch scheme at long 
term follow-up.
For premenopausal patients monotherapy with tamoxifen was the standard therapy 
for a long time with a possible benefit from ovarian suppression for patients of 40 
year and younger.22,23 Recently, the results of the TEXT and SOFT trial revealed that 
for premenopausal patients addition of ovarian function suppression should be 
considered for patients younger than 35 years (5 year breast cancer free interval of 
67.7% for tamoxifen vs 78.9% for tamoxifen plus OFS and 83.4% for exemestane 
plus OFS) or who received chemotherapy (5 year breast cancer free interval 78% for 
tamoxifen vs 82.5% for tamoxifen plus OFS vs 85.7% for exemestane plus OFS.24
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Side effects of aromatase inhibitors are different from those of tamoxifen. Generally, 
tamoxifen is well tolerated, with most reported events to be hot flushes, osteoporosis, 
arthralgia and gynaecologic symptoms like vaginal bleeding and discharge.17 More 
severe toxicities which have been described with the use of tamoxifen are venous 
thromboembolisms and a hazard ratio of approximately 2 for endometrial carcinomas 
and mood change or depression.25-29 For aromatase inhibitors, hypertension, 
dyslipidaemia, arthralgia and osteoporosis are more frequently described. 
Gynaecological symptoms and hot flushes are less common.16,17,30-32 Arthralgia is usually 
reported by patients as the most relevant side effect.30,33 Generally, just as tamoxifen, 
aromatase inhibitors are relatively well tolerated. In designated trials comparing 
the switch scheme with aromatase inhibitors only, no important differences in side 
effects or quality of life were shown.34 The TEAM trial showed that in general, there 
are more gynaecological and vascular side effects with the tamoxifen-containing 
switch scheme, while in the aromatase inhibitor group hypertension, dyslipidaemia 
and musculoskeletal complaints were more pronounced.20 Similar results were 
observed in the BIG 1-98 study.21 Therefore, regarding side effects and toxicity, therapy 
choices should be tailored on the individual patient  taking  co-morbidity and patients 
preference in consideration.
These findings have led to the conclusion that AIs should be included in the adjuvant 
treatment of early HR+ breast cancer in postmenopausal patients, and also in 
combination with ovarian suppression for premenopausal patients. However, there is 
no evidence for superiority of either 5 years aromatase inhibitors or a switch scheme 
of tamoxifen followed by an AI. This review will comment on the current evidence 
for therapy extension, ongoing studies and possible predictive markers suitable for 
decision-making concerning extended endocrine treatment. 
Extended therapy 
The current period of 5 or 10 years of adjuvant endocrine treatment for early breast 
cancer is based on early results of adjuvant tamoxifen.2,5,35 However, it was shown 
that approximately 50% of recurrences happened after the initial 5 years of adjuvant 
treatment.2,36 These findings initiated a debate on the optimal duration of therapy, 
and a number of studies was set up to elucidate on this matter. 
The NCIC CTG MA.17 trial in 5187 patients showed that 10 years of treatment (5 years 
of tamoxifen followed by 5 years of letrozole) was superior to five years of tamoxifen.6 
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After a median follow-up of 30 months, a hazard ratio of disease free survival of 0.58 
was found, with a non-significant HR of 0.76  for overall survival. Upon these interim 
results the study was unblinded, and cross-over was allowed. However, with a 66% 
cross-over from the placebo to treatment arm, there was a significant loss of power 
for further follow-up.  At 60 months of follow up, this has led to a HR for disease free 
survival of 0.68 (0.55-0.83), but no difference in overall survival (HR=0.98). With a 
statistical test called the inverse probability of censoring weighted analysis (IPCW-
analysis), they estimated that the HR for overall survival would have been 0.61 
(0.52-0.71) without cross-over.6,37,38 Although this was the first proof of principle for 
extended endocrine therapy, the interpretation of these findings is difficult. Starting 
five years of letrozole after 5 years of tamoxifen is basically the same strategy as the 
switch scheme described above, only with longer treatment intervals. It could be 
stated that this study confirms the benefits of a (late) switch scheme, rather than 
a general benefit for extended therapy. In 2006, Ingle et al showed that the hazard 
ratios for disease free survival when using letrozole decreased over time, which was 
attributed to an increasing risk of recurrence in the placebo-controlled group.39 These 
findings indicate a possible benefit for extending the treatment even further beyond 
the studied term of 5 years. Whether this also implies for patients who received up-
front AI treatment is only supported by circumstantial evidence, and has not been 
studied yet.
Three other, smaller studies have confirmed the results of the MA.17 study (Table 1). 
The Austrian Breast and Colorectal Cancer Study Group (ABCSG)-6a study, had a 
similar setup in which 856 patients after 5 years of tamoxifen were randomized 
between 3 years of anastrozole or regular follow-up.40 A reduction of 38% in the risk 
of breast cancer recurrence was observed (HR 0.62, 95% CI 0.4-0.96), which is in 
concordance with the MA.17 results. This study failed to show any benefit on overall 
survival, most likely due to the relative short follow-up of 5 years.  Two other studies, 
both evaluating exemestane as extended therapy after 5 years of tamoxifen, were 
closed prematurely due to the results of the MA.17 trial.41,42 One of them however 
published their underpowered results, already showing a borderline significant 
decrease in DFS at 30 months of follow-up42. A meta-analysis conducted with the 
four trials mentioned above, has led to an overall decrease in breast cancer recurrence 
of 43% (absolute decrease of 2.9%) and a (not statistically significant) decrease in 
mortality of 11% (absolute decrease of 0.5%) at 2.5 years of follow-up.43 The consistent 
results in these four trials using letrozole, anastrozole and exemestane as AIs, lead to 
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another conclusion that the advantage of AIs is not limited to one specific type, but is 
a class effect. There appears to be no difference between the separate agents, making 
future comparisons and meta-analyses less complicated.
Extended therapy after 5 years of tamoxifen has comprehensively been studied. Early 
small studies did not show a benefit for extended tamoxifen, with an increase in 
toxicity. In 2013, the 15-year follow-up results from Adjuvant Tamoxifen: Longer Against 
Shorter (ATLAS) trial were published4. This study, which randomized nearly 7000 ER-
positive patients between 5 or 10 years tamoxifen, showed a benefit for continuing 
tamoxifen with an absolute benefit of 3.7% (21.4% vs 25.1%) on recurrence risk, and 
an absolute mortality reduction of 2.8% (12.2% vs 15%). Remarkably, these benefits 
were mainly observed in the period after 10 years when treatment was ceased. This 
was attributed to a carryover effect, which is well known for tamoxifen.2 Similar results 
were observed in the British Adjuvant Tamoxifen - To Offer More (ATTOM) trial.5 
Clinical implications
The interpretation of these extended therapy studies is difficult. As shown in Table 1, 
all available studies are based on 5 years of tamoxifen, before therapy was extended. 
Extended tamoxifen has shown a small but consistent overall survival benefit. The 
results of the ATAC, BIG 1-98 and TEAM trial clearly show that AI-containing adjuvant 
regimes, either as a monotherapy or as a switch-scheme, are preferred above 
tamoxifen monotherapy. As a result, there is no clear evidence for therapy extension 
of modern ‘regular’ AI-containing adjuvant treatment, and no direct evidence for 
extended therapy with an AI longer than 5 years. Furthermore, there are no studies 
available with a direct comparison between the extension with tamoxifen or letrozole.
The most recent ASCO guidelines, published in July 2014, support –based on recent 
literature data-multiple treatment strategies for the type and length of adjuvant 
endocrine therapy.44 They offer four options: tamoxifen for 10 years, tamoxifen for 
5 years followed by an AI for 5 years, AI for 5 years or a switch scheme starting with 
tamoxifen for 2-3 years followed by an AI for up to 5 years. Little evidence is available 
to compare these four options. Only a comparison between the switch scheme and 5 
years of AI is available, which has led to no significant differences as discussed earlier. 
In a review published in 2013, Strasser-Weippl et al performed an unofficial analysis 
comparing extended therapy using AIs with tamoxifen after 5 years of tamoxifen. 
Comparing hazard ratios of two separate studies, they state that switching to an AI 
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after 5 years of tamoxifen appears beneficial over continuing with tamoxifen, and 
that it would lead to a larger recurrence rate reduction and a better overall survival.45 
Although comparing hazard ratios of different studies is controversial, this would be 
in accordance with the findings in ‘regular’ adjuvant treatment that AI-containing 
regimes have better outcomes compared to tamoxifen monotherapy.
For premenopausal women the evidence based choices are: tamoxifen 5-10 years, 
tamoxifen 5 years followed by AI 5 years, ovarian suppression with tamoxifen or AI 
which should be considered for higher risk patients (<35 years, premenopausal after 
prior chemotherapy and multiple positive axillary nodes). The optimal duration of 
ovarian suppression based therapy is uncertain; the SOFT and TEXT trial both studied 
5 years.
Ongoing studies
Now that the first studies have reported a benefit of extended adjuvant endocrine 
therapy in early breast cancer, many challenges lie ahead. Basically, it comprises three 
main topics: (1) To validate the findings of earlier studies in modern AI-containing 
adjuvant therapy, (2) to determine the optimal duration of extended therapy and (3) 
to identify and further explore predictive factors for patients that would benefit most 
of extended therapy46. Figure 1 summarizes the ongoing and unpublished trials.37,47,48 
The main study focussing on validation of extended therapy after modern, AI-
containing, regimes is the NSABP B42 trial, in which nearly 4000 patients were 
randomized between 5 years of letrozole or placebo, after 5 years of regular 
adjuvant therapy either consisting of aromatase inhibitors or tamoxifen followed 
by aromatase inhibitors.49 Also the Letrozole Adjuvant Therapy Duration (LEAD) and 
the Different Durations of Anastrozole after Tamoxifen (DATA) trials have the same 
perspective, by randomizing patients after 2-3 years of adjuvant tamoxifen between 
standard treatment (additional 2-3 years AI) and extended treatment (5-6 years of 
AI), respectively.50,51 This creates a situation in which standard therapy is compared 
with 2.5 years extended therapy. Both the Secondary Adjuvant Long-term Study 
with Arimidex (SALSA; ABCSG-16) and Investigation on the Duration of Extended 
Adjuvant Letrozole treatment (IDEAL) randomize between 2-2.5 and 5 years of 
therapy extension, after any prior adjuvant endocrine treatment of 5 years.52,53 The 
Study of Letrozole Extension (SOLE) trial compares 5 years of continuous AI therapy 
extension with intermittent letrozole extension. This intermittent scheme consists of 
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an annual cycle of 9 months therapy and a 3 months break, while the final (5th) year 
is 12 months of therapy.54 Combined, these studies will presumably answer whether 
therapy extension after 5 years of AI-containing adjuvant treatment is relevant, and 
what would be the optimal duration of extension (2.5 vs 5 years). Finally, there is also 
an extension of the MA.17 trial, called the MA17R.37 This study will extend the adjuvant 
therapy even further with another 5 years of letrozole versus placebo, which counts up 
towards 15 years of adjuvant therapy. 
The MINDACT-trial, a large trial with the main purpose on decision making based on 
either epidemiological data or genetic data, also has a substudy in which 7 years of AI 
is compared to 2 years of tamoxifen followed by 5 years of AI.55 Although this study is 
not focused on the optimal duration of therapy (both arms have the same treatment 
length), it will add more value to extended AI beyond 5 years. 
Predictive markers
Because luminal breast cancer is a heterogeneous disease it is important to be able 
to select those patients that will benefit most from extended adjuvant therapy. For 
adjuvant endocrine treatment, many efforts have been made to identify biomarkers 
or molecular profiles capable of predicting response to endocrine treatment and the 
risk of recurrence after treatment.56,57 Although research is still ongoing, established 
methods comprise both immunohistochemical and genetic approaches. However, 
most of these platforms are only validated for use in regular endocrine therapy, or for 
adjuvant chemotherapy. None of them is validated for extended endocrine treatment.
Classical risk factors like age and nodal status were analysed in the MA.17 trial, both showing 
no statistical differences between the subgroups.6,37 Regular immunohistochemical (IHC) 
markers in breast cancer comprise the Estrogen Receptor (ER), Progesterone Receptor 
(PgR) and the Human Epidermal growth factor Receptor 2 (HER2). For the ER receptor 
it was shown in the TEAM trial, that a semi-quantitative expression analysis using IHC 
is predictive for adjuvant endocrine therapy response.58 HER2, initially discovered as a 
predictive marker for poor prognosis and later on developed as a target for monoclonal 
antibodies against the Her2 receptor, such as trastuzumab (Herceptin®), was also associated 
with resistance against endocrine treatment.59-61 Ki-67 also showed to be predictive for the 
response on endocrine treatment, and the difference in Ki-67 measurement after 2 weeks 
of neo-adjuvant endocrine therapy appeared to be predictive for the long term effect of 
endocrine treatment.62,63 
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Based on the immunohistochemical markers mentioned above, a number of multi-
marker assays has been developed to predict recurrence risk. IHC4, which consists of 
a single score based on the expression of ER, PgR, HER2 and ki-67, has been developed 
as a platform to predict recurrence risk in early breast cancer.64,65 This assay has been 
validated retrospectively in the setting of adjuvant endocrine treatment in the ATAC 
study. IHC4 is of value in clinical decision making, especially in combination with 
clinicopathologic parameters like tumour grade, size, nodal status and age.66,67 
A similar platform, called the preoperative endocrine prognostic index (PEPI), was 
developed specifically for neo-adjuvant treatment. It comprises  a combination of 
post-treatment ER expression, Ki67, histological grade, tumour size, nodal status, 
and treatment response. This platform was able to stratify patients in three risk 
groups, with relapse risks of 10%, 23%, and 48%68. The authors suggest that this 
assay would assist in the decision of starting adjuvant chemotherapy, but it could 
also be worthwhile to validate this platform for use in decisions concerning endocrine 
treatment extension. 
Both the Mammaprint and Oncotype DX have been established as commercially 
available genetic testing platforms, depending on the expression of respectively 70 
and 21 genes known to be correlated with recurrent disease. Both tests are capable of 
stratifying the risk of recurrence in low, medium (only for the Oncotype DX) and high. 
This stratification indirectly represents the likelihood of benefit from chemotherapy. 
Both tests are currently being validated in a prospective study, with regard to 
decision-making for adjuvant chemotherapy.55,69 Another genetic platform called 
the Endopredict, which was developed as specific for endocrine therapy using eight 
genes involved in ER-signalling, was used to calculate risk of recurrence after 5 years of 
endocrine treatment.70 Furthermore, the Breast Cancer Index (BCI) and Prosigma Risk 
of Recurrence (ROR), are multigene assays capable of predicting recurrence, although 
only the ROR-score provided significant prognostic information for late recurrences 
(5-10 years).71,72 
To the authors’ knowledge, none of these markers and platforms has been validated 
in a cohort of patients on extended endocrine treatment. It would not be unlikely 
that all these markers and platforms described, might also be valuable to assist in 
deciding whether or not to extend endocrine treatment. For this, validation in the 
setting of extended endocrine treatment is necessary. Although this is an expensive 
49021 Erik Blok.indd   32 03-04-18   11:43
2
Extended adjuvant endocrine therapy review
33
and elaborative procedure, it is a crucial step towards tailoring of adjuvant endocrine 
treatment.
Furthermore, research into new predictive and prognostic markers like (epi)genetics, 
proteomics, circulating  tumour DNA, circulating tumour cells (CTCs) and other 
promising techniques could be valuable in the setting of extension of endocrine 
treatment.
Conclusion
After almost 5 decades of endocrine therapy, there is still debate on the optimal 
combination and length of adjuvant therapy. Although studies currently available 
give strong suggestions that extension of endocrine therapy has benefits, there is 
actually no strong evidence to support this in the current clinical setting using AIs in the 
initial adjuvant treatment. Nonetheless, extended endocrine therapy is a promising 
strategy to further reduce the risk of recurrence. In future studies, emphasis should 
be laid on selection of subpopulations who benefit most from therapy extension. 
Patient tailored decision-making will eventually prevent overtreatment, side effects 
and costs, and add great value to the treatment of breast cancer.
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Background: The optimal duration of extended endocrine therapy beyond 5 years after 
initial aromatase inhibitor based adjuvant therapy for postmenopausal women with 
hormone-receptor positive breast cancer is still unknown. Therefore, we conducted a 
clinical trial to compare two different extended endocrine therapy durations.
Methods: In the randomized phase III IDEAL trial, postmenopausal patients with 
hormone-receptor positive breast cancer were randomly allocated to either 2.5 or 
5 years of letrozole after the initial 5 years of any endocrine therapy. The primary 
endpoint was disease free survival (DFS), and secondary endpoints were overall 
survival (OS), distant metastasis free interval (DMFi), new primary breast cancer, 
and safety. Hazard ratios (HRs) were determined using Cox regression analysis. All 
analyses were by intention to treat principle. 
Results: 1824 patients were assigned to either 2.5 years (n=909) or 5 years (n=915) of 
letrozole, with a median follow-up of 6.6 years. A DFS event occurred in 152 patients 
in the 5-years group, compared to 163 patients in the 2.5 years group (HR 0.92, 95%CI 
0.74-1.16). OS (HR 1.04, 95%CI 0.78-1.38) and DMFi (HR 1.06, 95%CI 0.78-1.45) were not 
different between both groups. A reduction in occurrence of second primary breast 
cancer was observed with 5 years treatment (HR 0.39, 95% CI 0.19-0.81). Subgroup 
analysis did not identify patients that benefit from 5 year extended therapy.
Conclusion: This study showed no superiority of 5 years over 2.5 years of extended 
adjuvant letrozole, after initial 5 years of adjuvant endocrine therapy. 
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Introduction 
Multiple large clinical trials showed superiority of AI-based adjuvant therapy (either 
upfront or after 2-3 years of tamoxifen) over 5 years tamoxifen monotherapy. 1-4 Just 
recently, an EBCTCG meta-analysis showed the superiority of AI monotherapy for 
5 years over the sequential therapy of tamoxifen followed by an AI, although the 
absolute benefit was marginal.5 
Despite the success of adjuvant endocrine therapy, still 50% of all recurrences occur 
after the first 5 years, especially in HR-positive breast cancer.6 Randomized trials 
showed that 10 years of adjuvant tamoxifen was superior over 5 years, although 
the benefit on overall survival was not observed.7-9 The MA.17 study investigated 
extended endocrine therapy with an AI after 5 years of tamoxifen, by randomly 
assigning patients to 5 years of letrozole or placebo. At interim-analysis after 2.4 
years it was observed that letrozole was superior, leading to early closure and cross-
over which hampered the power for long-term follow-up.10 Although this trial was 
broadly interpreted as evidence for 5 years therapy extension, the actual evidence 
before cross-over is only until 2.4 years. The actual benefit of 5 years vs placebo, or 
the difference in effect between 2.5 and 5 years has never been shown, except for 
extrapolated subgroup analyses.10-13 
Until now, all evidence for extended endocrine therapy was obtained in clinical 
trials that included patients who received tamoxifen monotherapy during the 
first 5 years of adjuvant therapy. As shown recently in the EBCTCG meta-analysis, 
adjuvant therapy containing AIs in the first 5 years of adjuvant therapy is superior to 
tamoxifen monotherapy.5 However, limited evidence is available for extending AI-
based adjuvant therapy beyond 5 years of AI-containing therapy, in particular for the 
optimal duration of therapy.14 
We report the results of the phase 3 open label multicenter trial: Investigation on the 
Duration of Extended Adjuvant Letrozole treatment (IDEAL) trial, which randomly 
assigned patients to either 2.5 or 5 year letrozole, after receiving any adjuvant 
endocrine therapy for 5 years. The aim of this trial is to determine the optimal duration 
of extended endocrine therapy, in particular after receiving AI-based adjuvant therapy.




Patients and study design
Postmenopausal women who completed  5 years (± 3 months) of any adjuvant 
endocrine therapy for early stage hormone-receptor positive (ER and/or PR positive 
in ≥10% of the nuclei) early breast cancer, were randomized between extending 
treatment with either 2.5 or 5 years of letrozole (2.5mg daily) (Figure 1). Other inclusion 
criteria were no evidence of breast cancer recurrence at time of randomization, a 
WHO performance status of 0 or 1, and the initial adjuvant endocrine therapy should 
be completed for no longer than 2 years.  Details on trial design were reported earlier.15
Figure 1: An overview of the trial design. 
This study was conducted in 73 hospitals in the Netherlands. Data were collected 
by the LUMC Datacenter Department of Surgery. The data safety and monitoring 
board, constituted by an independent statistician, surgeon, and medical oncologist 
monitored the efficacy endpoints halfway through the trial. Central ethical approval 
was provided by the ethical committee of the LUMC. All patients provided written 
informed consent, and were excluded from analysis when consent was withdrawn.
This trial is registered in the Netherlands with the Netherlands Trial Register, 
NTR3077, the Dutch Breast Cancer Research Group (BOOG 2006-05) and Eudra-
CT 2006-003958-16. The study was conducted in compliance with the guidelines of 
the Declaration of Helsinki, International Conference on Harmonisation and Good 
Clinical Practice. 
Randomization and masking
Randomization was performed by the LUMC Datacenter Department of Surgery in 
a 1:1 ratio using ALEA software, stratified for prior endocrine therapy regime (5 years 
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tamoxifen, 5 years AI, or 2-3 years of tamoxifen followed by an AI), time after completion 
of treatment (0-6 months vs 6-12 months vs 12-24 months), nodal status and the use 
of adjuvant chemotherapy. All stratification factors were weighted similarly. Pocock’s 
minimisation strategy was used to ensure similar factors in both arms.16
Data collection
After providing informed consent, baseline records concerning medical history 
(including the earlier endocrine therapy), physical examination, mammography, and 
bone densitometry were collected. Follow-up was conducted annually for at least 5 
years with an evaluation of adverse events, disease status, a physical examination, 
and mammography, with extra visits at 6 and 30 months (latter only for patients in 2.5 
year arm to stop allocated therapy). 
Endpoints
The primary endpoint of this trial was disease free survival (DFS), defined as the time 
from randomization to recurrence (either local, regional or distant), new primary 
breast tumors (DCIS or invasive) or death due to any cause, whichever comes first. 
Similar to most adjuvant endocrine therapy trials, but in contrast to the definitions 
defined by Hudis et al, second primary non-breast cancer was not included in the 
definition of DFS.1, 3, 4, 10, 17 Secondary endpoints were overall survival (OS), distant 
metastasis free interval (DMFi), new primary breast malignancies (contralateral or 
new ipsilateral breast cancer), and safety. For safety analysis, adverse events were 
recorded during active treatment of the patients.
Statistics
It was expected that recurrence rates would be similar in both AI containing arms 
during the first 2.5 years after randomization, and therefore the power calculations 
were based on the period after these initial 2.5 years. The objective was to detect an 
annual decrease of 3.3% in DFS rate in the control arm and 2.0 % in the extended 
treatment arm (hazard ratio (HR) = 0.60), with a two-sided type I error of 0.05 and 
power of 80%. Allowing for an annual 2% dropout rate due to loss to follow-up, 126 
events, and therefore 1276 patients, were required to detect this difference. Since 
these 1276 patients needed to be disease free and on treatment after 2.5 years, and 
with an expected dropout of 30% during the first 2.5 years (due to patients stopping 
therapy or having a DFS-event in the first 2.5 years after randomization), a number of 
1823 patients was required to be randomized. 
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Despite the fact that the power analysis was performed based on follow-up starting 
at 2.5 years, it cannot be ruled out that randomization had an influence on either 
the patient or treating physician during the first 2.5 years since the trial was not 
blinded. Therefore, all analyses were performed in two parallel ways; the primary 
analysis starting with all randomized patients on intention-to-treat principle, 
and the secondary analysis starting at 2.25 years (2.5 years with 10% margin) post-
randomization with patients being disease free and on therapy at that time point, 
after which the treatment arms diverge. Kaplan-Meier analyses were performed 
for DFS and OS, using stratified log-rank test to determine the level of statistical 
significance. For DMFi and new primary breast malignancies cumulative incidence 
curves were estimated, accounting for death as competing risk. Furthermore, for all 
endpoints, univariate stratified Cox regression analysis was used to determine the 
hazard ratio (HR). The proportional hazards assumption for treatment (the only 
variable for which proportional hazards was assumed) was checked using Schoenfeld 
residuals. Stratified Cox regression within subgroups was used to perform subgroup 
analysis. For analyses of the adverse events, chi-square tests were used to assess which 
AE occurs more frequently in which treatment arm, applying Bonferroni correction 
to correct for multiple testing. All analyses were performed using SPSS 23.0, data 
visualization was performed using GraphPad Prism 6.05 and R 3.2.2.




As planned, 1824 patients were randomized between April 2007 and November 
2011 in 73 participating hospitals in the Netherlands (909 patients in 2.5 years group, 
915 patients in 5 years group). The median follow-up of these patients was 6.6 year 
(inter quartile range (IQR) 5.3-7.5 years). Of these, 3 patients withdrew their consent 
and were excluded for the primary analysis starting at randomization, leaving 908 
patients in the 2.5 years group and 913 patients in the 5 years group (Figure 2). All 
other patients were included in the intention-to-treat analysis. Furthermore, 482 
patients encountered a DFS event or stopped with therapy before they reached 2.25 
year, leaving 1339 patients for the secondary analysis after 2.25 years. In this secondary 
analysis, the median follow-up was 6.6 years (IQR 5.2-7.5 years)
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• IC withdrawn (n=3)















Stopped before 2.25 year (n=229)
DFS event without stop (n=4)
Never started (n=7)
Stopped before 2.25 year (n=232)
DFS event without stop (n=1)
Lost to follow-up (n=3)
Figure 2: A consort diagram showing the flowchart of the trial.
N:number,  IC: informed consent, ITT: intention-to-treat, DFS: disease-free survival 
Baseline characteristics for the randomized eligible patients are shown in Table 1. 
There were no statistically significant differences observed between both arms. The 
majority of patients received AI-based adjuvant therapy, either upfront (28.8%) or 
after 2-3 years of tamoxifen (59.0%). Only 12.2 percent were AI-naïve and received 5 
years of tamoxifen. Most patients (88.6%) continued with extended therapy within 6 
months after regular adjuvant endocrine therapy. 
Compliance
To assess the capacity of patients to endure extended endocrine therapy, compliance 
was monitored closely in this trial. A total of 629 patients stopped therapy earlier than 
planned (34.6%). In the group allocated to 2.5 years, 241 (26.5%) patients stopped 
early, for which the main reasons were symptoms or adverse events (n=156), a study 
endpoint (recurrence, new primary tumor or death) (n=30), and treatment refusal 
(n=24). In the 5-years group 388 patients (42.5%) stopped before 5 years of treatment, 
for which the main reasons were symptoms or adverse events (n=212), a study endpoint 
(recurrence, new primary tumor or death) (n=78), and treatment refusal (n=46) (Figure 
3). Furthermore, 104 patients continued with therapy beyond their allocated treatment 
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duration with a median overtreatment of 4 months, 13 patients never started therapy 
and 3 patients withdrew consent, limiting the total compliance to 59.9%.
Table 1. Baseline clinicopathological features of all randomized patients per treatment arm
Subgroups Treatment Arm
2.5 years letrozole 5 years letrozole
N (%) N (%)
Age at randomization, y
<55 250 (27.5%) 260 (28.5%)
55-65 386 (42.5%) 375 (41.1%)
65-75 210 (23.1%) 201 (22.0%)
>75 62 (6.8%) 77 (8.4%)
Nodal status
pN0 227 (25.0%) 223 (24.4%)
pN0(i+) 10 (1.1%) 12 (1.3%)
pN1(mi) 105 (11.6%) 105 (11.5%)
pN1: 1-3 pos 433 (47.7%) 431 (47.2%)
pN2: 4-9 pos 97 (10.7%) 104 (11.4%)
pN3: >=10 pos 30 (3.3%) 29 (3.2%)
Tumor type
ductal 683 (75.2%) 732 (80.2%)
mucinous 9 (1.0%) 7 (0.8%)
medullar 3 (0.3%) 4 (0.4%)
lobular 165 (18.2%) 131 (14.3%)
other 47 (5.2%) 39 (4.3%)
Histological grade
grade 1 156 (17.2%) 130 (14.2%)
grade 2 380 (41.9%) 394 (43.2%)
grade 3 270 (29.7%) 296 (32.4%)
unknown 102 (11.3%) 93 (10.1%)
Progesterone receptor status
Negative 160 (17.6%) 182 (19.9%)
Positive ≥10% 712 (78.4%) 697 (76.3%)
HER2 status
0 193 (45.7%) 199 (47.0%)
1+ 95 (22.5%) 93 (22.0%)
2+ 47 (11.1%) 51 (12.1%)
3+ 81 (19.2%) 78 (18.4%)
Performed final surgery
breast conserving 445 (49.0%) 443 (48.5%)
mastectomy 460 (50.7%) 468 (51.3%)
Prior chemotherapy
no 291 (32.0%) 287 (31.4%)
yes 617 (68.0%) 626 (68.6%)
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2.5 years letrozole 5 years letrozole
N (%) N (%)
Prior endocrine treatment
5 years tamoxifen 109 (12.0%) 113 (12.4%)
5 years AI 261 (28.7%) 263 (28.8%)
2-3 years tam-> 3-2 years AI 538 (59.3%) 537 (58.8%)
Time after stop hormonal therapy, mos
0 to <6 803 (88.4%) 811 (88.8%)
6 to <12 48 (5.3%) 47 (5.1%)
12-27 57 (6.3%) 55 (6.0%)
Endpoints
At the moment of database lock (December 22th, 2016), 315 out of 1821 patients in 
the primary analysis had encountered a DFS event, of which 163/908 (18.0%) in 
the 2.5 year arm and 152/913 (16.6%) in the 5 years arm (Table 2). The hazard ratio 
(HR) for DFS was 0.92 (95% CI 0.74-1.16, Log-rank P=0.49) for patients in the 5 year 
group, compared to the 2.5 year group (Figure 4A). A preplanned subgroup analysis 
showed that there is no individual subgroup which benefits statistically significant 
from extended adjuvant endocrine therapy up to 5 year (Figure 5). The proportional 
hazards assumption for treatment was not found to be violated.
Furthermore, no statistically significant effect on either overall survival (Figure 4B) 
or distant recurrences (Figure 4C) was shown with respective HRs of 1.04 (OS, 95% 
CI 0.78-1.38, Log-rank P=0.79) and 1.06 (DMFi, 95% CI 0.78-1.45, Log-rank P=0.71). For 
second primary breast malignancies (Figure 4D), 27 (3.1%) events were observed in 
the 2.5-year group and 10 (1.1%) in the 5-year group, which was statistically significant 
(HR 0.39, 95% 0.19-0.81, Log-rank P=0.01).
In the secondary analysis (Figure 6), in which patients who encountered an event or 
stopped therapy before 2.25 years were excluded, 86 DFS events were observed during 
follow-up in the 2.5 year arm, and 74 events in the 5 year arm (HR 0.88, 95% CI 0.64-
1.21) (Table 2). Of these events, 15 second primary breast malignancies were observed 
in the 2.5 year arm, and 6 in the 5 year arm (HR 0.42, 95% CI 0.16-1.11). 
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Table 2. An overview of the number of events in both arms and the subsequent hazard ratio (HR), both for the 
primary population, and the secondary population who were disease free and on therapy at 2.25 years*
Endpoints Treatment arm HR (95% CI)
5 year letrozole 2.5 year letrozole
No. of events No. of events
DFS (full population) 152/913 163/908 0.92 (0.74-1.16)
local recurrence 14 12 1.06 (0.49-2.31)
regional recurrence 14 10 1.27 (0.55-2.92)
distant recurrence 86 78 1.06 (0.78-1.45)
2nd primary breast cancer 10 27 0.39 (0.19-0.81)
death any cause 104 96 1.04 (0.78-1.38)
DFS (after 2.25 year) 74 86 0.88 (0.64-1.21)
local recurrence 10 8 1.17 (0.46-2.98)
regional recurrence 6 7 0.92 (0.30-2.76)
distant recurrence 35 47 0.75 (0.48-1.17)
2nd primary breast cancer 6 15 0.42 (0.16-1.11)
death any cause 45 40 1.06 (0.68-1.65)
*CI=confidence interval; DFS=Disease free survival
Figure 4: Kaplan Meier analysis. Results are shown for (A) disease free survival (DFS), (B) overall survival (OS), (C) 
distant metastasis free interval (DMFi), and (D) new primary breast cancer, including all randomized patients 
based on intention-to-treat principle. Log-rank tests were used to assess the differences between groups within 
each graph (reported as p-value). 
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Figure 5: A pre-planned subgroup analysis. All values were determined using two-sided Cox-regression analysis. 
Error bars represent 95% confidence intervals.
HR: hazard ratio, CI: confidence interval, T size: tumor size, PgR: progesterone receptor, HT: hormonal therapy, 
AI: aromatase inhibitor, tam: tamoxifen
Figure 6: Secondary analysis. Results are shown for (A) disease free survival (DFS), (B) overall survival (OS), (C) 
distant metastasis free interval (DMFi), and (D) new primary breast cancer, including all patients that were 
disease free and on therapy at 2.25 years. Log-rank tests were used to assess the differences between groups 
within each graph (reported as p-value).
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Safety
In all patients who started therapy (n=1806), 3440 adverse events were reported by 
1289 patients. Of these events, 1580 were reported by 640 (70.1%) patients in the 2.5 
year arm during active treatment, and 1860 were reported by 649 patients (71.8%) in 
the 5 year arm during treatment. Of all events, 90.3% was graded as 1 or 2, and there 
was no difference in the proportion of grade 3/4 events between both groups (2.5yr: 
8.8%, 5yr: 10.0%, X2 p=0.43) (data not shown).
A total of 368 patients stopped therapy due to AEs, of which 156 in the 2.5-years arm 
(17.3%) and 212 in the 5-years arm (23.5%) In patients allocated to 5 years of therapy, 
the majority of events (n=1481, 79.6%) occurred during the first 2.5 years. In total, 
85.8% of the patients (n=182) in the 5 years group that ceased therapy due to side 
effects, did this before 2.5 years. The frequency of adverse events is reported in Table 
3, in which all events with a frequency over 5% in one of the arms are shown. Most 
frequently reported AEs were arthralgia, reported by 252 patients (14.0%) , hot flashes 
(n=214, 11.8%) and osteoporosis (n=184, 10.2%). The most reported grade 3/4 AEs were 
arthralgia (n=22) and fractures (n=21).
Discussion
This study has shown that, after receiving any adjuvant endocrine therapy for 5 years, 
there is no statistically significant difference in disease related outcomes between 
patients treated with either 2.5 or 5 years of letrozole at a median follow-up of 6.6 years, 
with the exception of preventing new primary breast malignancies. Subgroup analysis 
showed that there was no benefit of 5 years of extended therapy regarding DFS for any 
specific subgroup. Furthermore, no interaction between subgroups was observed. 
Additionally, we observed a statistically significant decrease in second primary breast 
malignancies in patients treated with 5 years of extended therapy. This observation 
was in agreement with the MA.17R trial, in which most of the effect of 5 years 
letrozole after 10 years of earlier therapy was accounted to prevention of contralateral 
breast cancer.18 It could be argued that extended endocrine adjuvant therapy with 
aromatase inhibitors beyond 7.5 years is secondary prevention rather than actual 
adjuvant therapy preventing relapse of the earlier breast cancer. This preventive effect 
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has already been shown in multiple clinical trials in healthy women without breast 
cancer, using both tamoxifen and AIs.19-25
This study did not question whether AI-containing adjuvant therapy should be 
extended beyond the first 5 years. The MA.17 and MA.17R trials already showed 
that 5 years of letrozole was superior to placebo after the initial 5 years of tamoxifen 
monotherapy, and that a further extension up to 10 years of AIs led to a further 
improvement in DFS.13, 18 However, death from any cause was not included in their 
definition of DFS, and the statistically significant effect on DFS in MA.17R was mainly 
attributed to a decrease in second primary breast cancers.18 Furthermore, the results 
of both MA.17 and MA.17R are not valid for the majority of patients, who nowadays 
receive upfront AI as adjuvant endocrine therapy.26 
The B42 trial, presented recently at SABCS 2016, compared 5 years of letrozole to 
placebo after initial AI-containing adjuvant therapy. They did not show a benefit on 
DFS in the overall patient group and subgroups 27The DATA trial, presented at the 
same conference, showed that there is no statistically significant benefit of 6 years 
anastrozole over 3 years anastrozole, after initial 2-3 years of tamoxifen.28 In contrast 
to the B42 trial and our results, their subgroup analysis suggested a statistically 
significant benefit for higher risk patients (node positive, tumor size larger than pT2) 
and for tumors expressing both ER and PR.
Combining these recent results, there is no evidence for therapy extension for the 
general hormone receptor positive postmenopausal breast cancer patient after an 
AI in the first 5 years. Data on high-risk subgroups, reflected by tumor size, nodal 
status, or hormone receptor subgroups are discordant. It is unclear why, in general, 
there is a lack of extended therapy effect in the population that received AIs earlier. 
A possible explanation could be the relative inferiority of tamoxifen during the first 5 
years, which leaves a possibility for benefit of extended therapy. A second explanation 
might be therapy resistance. In metastatic disease, it is well known that mutations in 
the gene encoding for ER, are associated to resistance against AIs.29, 30 Although this 
has not been studied, a similar mechanism could play a role in dormant tumor cells, 
making them resistant against the adjuvant treatment and causing the extended 
therapy to have no additional benefit. 
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A number of clinical trials studying the extension of AI-based adjuvant therapy are still 
ongoing.14 In case future studies will show a benefit of extended AI adjuvant therapy, 
the results of this trial show that the effect is limited to 7.5 years of total treatment 
duration. However, it cannot be ruled out that there is an effect in a subgroup of 
patients. For this, future explorative subgroup analyses will be performed, and follow-
up will be extended up to 10 years. Furthermore, a translational side study is initiated, 
to explore biomarkers capable of predicting extended therapy benefit.
The rate of patients reporting AEs is similar in both arms, although the absolute 
count of AEs is higher in the 5 year group. However, since adverse events were only 
recorded during active treatment, the frequency of AEs in the 2.5 years group might 
be underreported since there was no registration of side effects in the second 2.5 years 
in which there was no therapy. The frequency of specific adverse events, like e.g.  hot 
flashes, is lower than expected based on earlier studies. In the MA.17 trial, 5 year of 
letrozole was associated to 47% of patients reporting hot flashes, whereas in this trial 
only 12% of patients reported these symptoms.31 Most likely, these differences are due 
to differences in trial design. In the MA.17 trial, all patients where AI-naïve, whereas 
88% patients in this trial had earlier received treatment with an AI and were therefore 
less likely to report the side effects. Furthermore, selection bias might have occurred, 
since patients that experienced side effects during regular adjuvant therapy, would 
have been less likely to participate in this trial. 
A limitation of this trial is the upfront randomization. After randomization, there was 
approximately 30% drop-out before the moment that the treatment arms actually 
diverged, which could have led to additional random differences between both arms. 
However, this drop-out was accounted for in the sample size calculation, and therefore 
did not influence the statistical power of the analyses. A second limitation is the 
open-label design. In combination with the upfront randomization, this could have 
influenced the patient or clinician in their decisions. However, drop-out was similar 
in both groups during the first 2.5 years, although a small bias cannot be excluded. 
In order to prevent an attrition bias during the first 2.5 years, the primary analysis 
started at randomization and not at the moment that the treatment arms diverged. 
In summary, we have shown that the effect on any disease-related outcomes of 5 
years of extended letrozole was not superior over 2.5 years of extended therapy with 
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letrozole, after 5 years of any regular adjuvant endocrine therapy, except for a small 
difference in the occurrence of new primary breast malignancies. Although this study 
did not show the added value of extended use of AI-containing adjuvant therapy 
in itself, it has shown that whenever extended AI-containing adjuvant therapy is 
considered, extended therapy longer than 2.5 years will not lead to a further reduction 
in disease free or overall survival.
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For postmenopausal patients with hormone-receptor positive early breast cancer, 
the optimal subgroup and duration of extended endocrine therapy is not clear yet. 
The aim of this study using the IDEAL patient cohort, was to identify a subgroup for 
which longer (5 years) extended therapy is beneficial over shorter (2.5 years) extended 
endocrine therapy.
In the IDEAL trial, 1824 patients who completed 5 years of adjuvant endocrine therapy 
(either 5 years of tamoxifen (12%), 5 years of an AI (29%) or a sequential strategy of 
both (59%)), were randomized between either 2.5 or 5 years of extended letrozole. For 
each prior therapy subgroup, the value of longer therapy was assessed for both node-
negative and node-positive patients using Kaplan Meier and Cox regression survival 
analyses. 
In node-positive patients, there was a significant benefit of 5 years (over 2.5 years) 
of extended therapy (disease-free survival (DFS) HR 0.67, p=0.03, 95% CI 0.47-0.96). 
This effect was only observed in patients who were treated initially with a sequential 
scheme (DFS HR 0.60, p=0.03, 95% CI 0.38-0.95). In all other subgroups, there was no 
significant benefit of longer extended therapy. Similar results were found in patients 
who were randomized for their initial adjuvant therapy in the TEAM trial (DFS HR 
0.37, p=0.07, 95% CI 0.13-1.06), although this additional analysis was underpowered 
for definite conclusions. 
This study suggests that node-positive patients could benefit from longer extended 
endocrine therapy, although this effect appears isolated to patients treated with 
sequential endocrine therapy during the first 5 years and needs validation and long-
term follow-up.
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In hormone receptor-positive (HR+) breast cancer, adjuvant endocrine therapy is 
used to decrease the risk for recurrence, and improve the overall survival (OS). Where 
tamoxifen for five years has been the standard adjuvant endocrine therapy for a 
long period of time, currently, treatment regimens for adjuvant endocrine therapy 
are mostly based on 5 years of an aromatase inhibitor (AI), or a sequential strategy 
of tamoxifen followed by an AI. Among others, the Tamoxifen Exemestane Adjuvant 
Multinational (TEAM) trial showed that after 5 and 10 years of follow-up, there was 
no difference in disease-free survival (DFS) between patients randomized to either 
tamoxifen followed by exemestane, or exemestane monotherapy.1, 2 These results 
were confirmed in a meta-analysis performed by the Early Breast Cancer Trialists 
Collaborative Group (EBCTCG).3
Despite the value of adjuvant endocrine therapy, it is known that the risk for recurrence 
in HR+ breast cancer remains linear up to at least 15 years after diagnosis prompting 
to study the value of extended endocrine therapy. After 5 years of tamoxifen, it has 
been established that extended therapy beyond 5 years leads to a modest reduction 
in recurrences, but not in overall survival.4, 5 This has been particularly observed for 
patients with node-positive disease.6 
The value of extended endocrine therapy after a 5-years regimen including an AI 
(either upfront or after 2-3 years of tamoxifen) is less clear. Recently, three independent 
studies did not show a significant benefit of (longer) extended endocrine therapy for 
the total study population.7-9 In the NSABP B-42 trial, patients who earlier received 
either 5 years of an AI, or a sequential treatment of tamoxifen followed by an AI 
until 5 years, were randomized between 5 years of extended letrozole, or placebo. 
After 5 years, there was no significant benefit of 5 years of letrozole over placebo. In 
the subgroup analysis however, a significant benefit for patients who received prior 
tamoxifen followed by an AI (HR 0.75, p=0.04) was found, which was not observed in 
patients who were treated upfront with AI monotherapy for 5 years (HR 0.91, p=0.34).7 
In the Dutch ‘Investigation on the Duration of Extended Adjuvant Letrozole treatment’ 
(IDEAL) trial, 1824 postmenopausal patients who received any form of primary 
adjuvant endocrine therapy for 5 years, were randomized between extended letrozole 
for 2.5 or 5 years. The results of this trial were published recently by our group, and 
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identified no subgroup that benefitted significantly from 5 instead of 2.5 years of 
extended therapy.9 In the IDEAL trial, approximately 60% was treated initially with 
the sequential scheme, whereas 30% was treated with an upfront aromatase inhibitor 
only, and approximately 10% was treated with tamoxifen monotherapy.
In the Dutch study on ‘Duration of Anastrozole therapy after two to three years Tamoxifen 
as Adjuvant therapy’ (DATA), postmenopausal patients were randomized after 2-3 years 
of tamoxifen between 3 years of anastrozole (standard arm, duration endocrine therapy 
5-6 years in total) or 6 years of anastrozole (extended duration, 8-9 years in total). Also 
in this trial, no effect of extended AI (anastrozole) therapy was shown for the total 
population. However, this study did observe a significant benefit of longer AI therapy in 
high-risk subgroups, in particular patients with lymph-node positive disease.8 
Combining the conclusions on the subgroup analyses of the NSABP B-42 and DATA 
trials, it is suggested that extended therapy might be the most beneficial for node-
positive patients who were previously treated with tamoxifen followed by an AI. 
However, the optimal duration of extended therapy is not clear, since the regimens 
and populations in both trials differ too much for direct comparisons. In view of the 
above mentioned data, we performed an additional subgroup analysis in the IDEAL 
trial. The aims of the current subanalyses were to investigate the effect of primary 
adjuvant treatment and nodal status on the optimal duration of extended adjuvant 
endocrine therapy. Furthermore, similar analyses were conducted in the subgroup 
of patients that previously participated in the TEAM trial, as this subgroup was 
randomized for the initial therapy.
Methods
IDEAL trial cohort
In the phase 3 IDEAL trial, 1824 postmenopausal patients were randomized between 
2.5 or 5 years of letrozole, after 5 years of any type of adjuvant endocrine therapy 
for early HR+ breast cancer. Patients needed to be disease-free at the moment of 
randomization. Furthermore, a maximum of 2 years was allowed between finishing 
earlier endocrine therapy and starting extended therapy. As the treatment arms 
during the first 2.5 years were equal, no differences can be expected during this 
period. Therefore for the current analysis, patients that encountered an event or 
stopped therapy during the first 2.5 years were excluded, and the survival analysis 
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started at 2.5 years after randomization at which time point the treatment arms 
diverge. Details of the trial, data collect and the primary results have recently been 
reported elsewhere.9, 10
A total of 438 IDEAL patients (24%) also participated in the TEAM-trial during the first 
5 years of their adjuvant endocrine therapy. In that phase III study, postmenopausal 
patients with early HR+ breast cancer were randomized at diagnosis between 5 years of 
exemestane, or 2.5 years of tamoxifen followed by 2.5 years of exemestane (sequential 
scheme). In case they were disease-free and finished 5 years of therapy, and their 
hospital participated in the IDEAL trial, they were eligible for inclusion in the IDEAL trial. 
In order to correct for a possible allocation bias in the distribution of previous endocrine 
therapy between node-negative and node-positive patients, all analysis were repeated 
in the cohort of patients that participated in the TEAM trial as these patients were not 
subjected to allocation bias due to the randomization already at primary diagnosis.
The IDEAL trial is registered in the Netherlands with the Netherlands Trial Register, 
NTR3077, the Dutch Breast Cancer Research Group (BOOG 2006-05) and Eudra-CT 
2006-003958-16. The original study was conducted in compliance with the guidelines 
of the Declaration of Helsinki, International Conference on Harmonisation and Good 
Clinical Practice. 
Endpoints
The primary endpoint of the IDEAL trial was disease-free survival (DFS) defined as 
the time from randomization to recurrence (either local, regional or distant), new 
primary breast tumors (DCIS or invasive) or death due to any cause. For the current 
analysis, DFS was also the primary study endpoint, with follow-up starting at 2.5 years 
after randomization with a 10% margin. The secondary outcomes for this analysis 
were overall survival (OS), defined as time to death due to any cause starting at 2.5 
years after randomization, and distant metastasis-free interval (DMFi), defined as 
time to distant recurrence starting at 2.5 years after randomization.
Statistical analysis
The analyses for primary and secondary outcomes (DFS, OS and DMFi) of the current 
study were performed using Kaplan Meier analysis, stratified for the type of endocrine 
therapy during the first 5 years, and nodal status at diagnosis. Hazard ratios (HRs) and 
treatment-by-marker interactions were estimated using Cox regression analysis. 





Of the 1824 postmenopausal patients enrolled in the IDEAL trial, 1339 were disease-
free and on letrozole therapy at 2.5 years after randomization and were eligible 
for the current analysis. There were no significant differences in patient baseline 
characteristics between the randomized treatment arms in this subcohort (table 1). 
Of the 438 patients who also participated in the TEAM trial, 311 patients were 
disease-free and on therapy at 2.5 years after randomization in the IDEAL study, and 
therefore eligible for our additional analysis. Patient characteristics of the IDEAL-only 
and IDEAL/TEAM patients are described in table 2. As compared to the IDEAL-only 
cohort (not participating in TEAM), IDEAL/TEAM patients were significantly older at 
randomization, more often treated with breast conserving therapy (55% vs 47.5%, X2 
p=0.037) and less often treated with chemotherapy (42.1 vs 77.6%) (table 2).
Regarding the prior endocrine therapy strategy, 816 IDEAL patients (60.9%) were 
treated with a sequential scheme of tamoxifen followed by an AI, 369 patients 
(27.6%) were treated with AI monotherapy, and 154 patients (11.5%) were treated with 
tamoxifen monotherapy. In the TEAM subgroup, 46.3% was treated with a sequential 
scheme, and 52.4% with AI monotherapy, as expected due to the TEAM trial design. 
Another four TEAM patients were treated with tamoxifen monotherapy because of 
refusal of switch to AI after 2.5 years of tamoxifen. 
Main subgroup analysis in all patients
In the total selected IDEAL patient group (n=1339), 167 patients encountered a DFS 
event during follow-up (median follow-up of 7 years, including the first 2.5 years). 
For node-negative patients, no benefit of longer endocrine therapy was found (HR 
1.53, p=0.16, 95% CI 0.84-2.80). In contrast, for node-positive patients we observed 
a beneficial effect of longer extended therapy (HR 0.67, p=0.03, 95% CI 0.47-0.96), 
with a HR for interaction between nodal subgroups of 0.44 (95% CI 0.22-0.88, p=0.02) 
(table 3, figure 1).
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Table 1: Characteristics of the IDEAL study cohort of patients who were disease-free and on therapy after 2.5 years 
of extended treatment.
N 2.5 years 5 years
% N %
Age at randomisation <55 years 191 28.6% 197 29.4%
55-65 years 288 43.0% 283 42.2%
65-75 years 151 22.6% 136 20.3%
>75 years 39 5.8% 54 8.1%
Nodal status pN0/pN0(i+) 176 26.3% 171 25.5%
pN1(mi)/N1/N2/N3 493 73.7% 499 74.5%
Tumor type ductal 508 75.9% 547 81.6%
mucinous 5 .7% 6 .9%
medullar 1 .1% 2 .3%
lobular 113 16.9% 87 13.0%
other/unknown 42 6.2% 28 4.2%
Histological grade grade 1 115 17.2% 102 15.2%
grade 2 278 41.6% 281 41.9%
grade 3 205 30.6% 217 32.4%
Gx 71 10.6% 70 10.4%
Progesteron receptor status negative 113 16.9% 136 20.3%
positive >=10% 528 78.9% 510 76.1%
HER2 status Negative 242 36.2% 246 36.7%
Positive 67 10.0% 63 9.4%
unknown 360 53.8% 309 53.9%
Performed final surgery breast conserving 335 50.1% 324 48.4%
mastectomy 331 49.5% 344 51.3%
Prior chemotherapy no 212 31.7% 198 29.6%
yes 457 68.3% 472 70.4%
Prior endocrine treatment 5 years tamoxifen 76 11.4% 78 11.6%
5 years AI 177 26.5% 192 28.7%
2-3 years tam-> 3-2 years AI 416 62.2% 400 59.7%
Time after stop hormonal therapy (months) 0 to <6 602 90.0% 610 91.0%
6 to <12 30 4.5% 27 4.0%
12-27 37 5.5% 33 4.9%
When stratified for nodal status and type of endocrine therapy during the primary 
adjuvant therapy, we only observed the benefit of 5 years over 2.5 years of letrozole 
for node-positive patients in patients treated with prior sequential endocrine therapy 
(8 year DFS after randomization 89% vs 83.4%, HR 0.61, p=0.037, 95% CI 0.38-0.97) 
(figure 2). In this subgroup, the p-value for the treatment by subgroup interaction test 
based on nodal status was 0.05, indicating a significantly higher treatment effect in 
node-positive compared to node-negative patients. In all other considered subgroups, 
no benefit of longer extended therapy was observed (table 3).
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Table 2: Characteristics of the IDEAL patients that participated earlier in the TEAM trial.
Participation in TEAM trial
no yes X2 p-value
N % N %
Age at randomisation <55 years 380 37.0% 8 2.6% <0.001
55-65 years 445 43.3% 126 40.5%
65-75 years 163 15.9% 124 39.9%
>75 years 40 3.9% 53 17.0%
Nodal status pN0/pN0(i+) 273 26.6% 74 23.8% 0.33
pN1(mi)/N1/N2/N3 755 73.4% 237 76.2%
Tumor type ductal 803 78.1% 252 81.0% 0.84
mucinous 9 .9% 2 .6%
medullar 2 .2% 1 .3%
lobular 160 15.6% 40 12.9%
other/unknown 54 5.3% 16 5.1%
Histological grade grade 1 161 15.7% 56 18.0% 0.06
grade 2 422 41.1% 137 44.1%
grade 3 322 31.3% 100 32.2%
Gx 123 12.0% 18 5.8%
Progesteron receptor status negative 179 17.4% 70 22.5% 0.19
positive >=10% 807 78.5% 231 74.3%
HER2 status negative 403 39.2% 85 27.3% <0.001
positive 125 12.2% 5 1.6%
unknown 500 48.6% 221 71.1%
Performed final surgery breast conserving 488 47.5% 171 55.0% 0.04
mastectomy 535 52.0% 140 45.0%
Prior chemotherapy no 230 22.4% 180 57.9% <0.001
yes 798 77.6% 131 42.1%
Prior endocrine treatment 5 years tamoxifen 150 14.6% 4 1.3% <0.001
5 years AI 206 20.0% 163 52.4%
2-3 years tam-> 3-2 
years AI
672 65.4% 144 46.3%
Time after stop hormonal therapy 
(months)
0 to <6 928 90.3% 284 91.3% 0.63
6 to <12 43 4.2% 14 4.5%
12-27 57 5.5% 13 4.2%
For the endpoint DMFi, similar results were observed (table 3). In node-positive 
patients previously treated with sequential therapy, a benefit of 5 years over 2.5 
years of letrozole was shown (HR 0.50, p=0.03, 95% CI 0.27-0.94), but no differential 
effect between the treatment durations was observed for all other subgroups (p for 
interaction 0.14). For the endpoint OS, no benefit of longer extended therapy was 
shown for any of the subgroups (table 3).
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Figure 1: Kaplan-Meier analysis for disease-free survival of all patients that were disease-free and on therapy 
after 2.5 years, stratified for nodal status. Log-rank tests were used to assess the differences between treatment 
arms for each subgroup (reported as P values).
Figure 2: Kaplan-Meier analysis of the main analysis in all patients that were disease-free and on therapy after 
2.5 years.  Results are shown for disease-free survival, for the subgroups stratified on prior endocrine therapy and 
nodal status. Log-rank tests were used to assess the differences between treatment arms for each subgroup 
(reported as P values).
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Additional subgroup analysis in TEAM patients
With respect to the additional analysis in the TEAM patient subgroup (n=311), 50 
patients had a DFS event, of which 19 were DMFi events and 31 OS events. For DFS, 
a benefit of longer extended therapy was observed for node-positive patients pre-
treated with sequential therapy, however without statistical significance (8 year DFS 
after randomization 90% vs 76.1%, HR 0.37, p=0.07, 95% CI 0.13-1.06). For DMFi, a 
similar non-significant benefit of longer therapy was found for the same subgroup 
(HR 0.14, p=0.07, 95% CI 0.02-1.15). Regarding OS, no benefit was shown for any of the 
subgroups (table 3).
Discussion
In this analysis of IDEAL patients, we found a significant benefit of longer (5 years, 
versus 2.5 years) extended letrozole therapy on disease-free and distant-metastasis 
free survival, for node-positive patients, and in particular those who received 
sequential adjuvant endocrine therapy during the first 5 years. In contrast, patients 
treated with AI monotherapy had no benefit of longer extended therapy, irrespective 
of nodal status. For overall survival no significant benefit of longer extended letrozole 
was observed in any subgroup, although the follow-up is relatively short for definite 
conclusions hereon.  
The distribution of patients pre-treated with tamoxifen (followed by an AI) or with 
AI monotherapy in the full IDEAL cohort, might have been subject to allocation 
bias. Therefore, we performed an additional analysis in the IDEAL patients who 
also participated in the TEAM trial. Using the randomization of the TEAM trial, we 
balanced the previous endocrine therapy subgroups for baseline characteristics. In 
this additional analysis, similar numerical results were observed, although without 
statistical significance. This is most likely explained by the lack of power due to 
the smaller population size, and the low number of events in general. However, 
the similarity between the HRs for the total IDEAL cohort and the TEAM subgroup 
indicates that the results from the IDEAL cohort are not explained by an allocation 
bias. 
The observation that (longer) extended therapy was only of value for node-positive 
patients, being at higher risk of recurrent disease, is in line with previous observations. 
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In a meta-analysis by Ibrahim et al, in which all patients were pre-treated with 
tamoxifen monotherapy, a subgroup analysis showed that the positive effect of 
extended endocrine therapy on breast cancer recurrence was only observed in node-
positive patients (OR 0.70, 95% CI 0.58-0.84), and not in node-negative patients (OR 
0.96, 95% CI 0.71-1.29).6 Remarkably, in our analysis there was no benefit of longer 
extended therapy in either node-negative or node-positive patients that were treated 
with tamoxifen monotherapy. However, tamoxifen monotherapy for the first 5 years 
was not considered as standard therapy anymore during the conduct of the IDEAL 
trial, and most likely there might have been a selection bias of very-low risk patients 
who remain on tamoxifen after 2-3 years instead of switching to an AI. In these low-
risk patients, a benefit of extended therapy is unlikely. Furthermore, tamoxifen 
monotherapy as prior endocrine therapy was a very small subgroup (12%) in the 
IDEAL trial, leading to a lack of power for conclusions in this subgroup.
The results of our analysis suggest that when patients were pre-treated with AI 
monotherapy for 5 years, there was no additional effect of 5 over 2.5 years of extended 
AI therapy. A possible explanation could be that the maximal treatment effect of 
aromatase inhibitors is reached after approximately 7.5 years. Therefore, after 5 
years of AI monotherapy, an additional 5 years would have no benefit over 2.5 years. 
However, the results from this relative small subgroup analysis need to be interpreted 
with care, and should be validated in a meta-analytical setting before final conclusions 
can be drawn.
In all node-negative subgroups, there is a trend towards worse outcome for longer 
therapy, although none of these effects are statistically significant (table 3). For overall 
survival, this might be explained by the fact that in this low-risk subgroup, letrozole 
adverse events possibly leading to mortality outweigh the benefit of letrozole on 
breast cancer-related mortality. However, this does not explain why we see the same 
trend for longer therapy on distant metastasis-free interval. Further evaluation 
in larger analyses from collaborative groups, in the setting of a meta-analysis, are 
required to validate this effect.
A limitation of this trial is that the analyses were performed in a subgroup of the 
original trial population, and this subgroup analysis was therefore not powered 
to detect small differences and might have suffered from multiple-testing error. 
Furthermore, In view of the design of the IDEAL study (having two treatment arms 
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and no placebo arm), it was not possible to investigate the value of extended therapy 
versus no extended therapy.
In conclusion, the results of the current exploratory analysis in IDEAL patients suggest 
that longer (versus shorter) extended endocrine therapy might be of value for node-
positive patients, and in particular for those who were treated with tamoxifen followed 
by an AI for the first 5 years, which was not observed in the AI monotherapy subgroup. 
For all node-negative patients, there was no beneficial effect of longer therapy, and 
even a trend towards a worse outcome. Future studies, and future meta-analyses, are 
warranted to validate these results, and to further identify for which subgroup there 
is an effect of extended endocrine therapy after optimal endocrine therapy over the 
first 5 years.
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Background: Extended endocrine therapy beyond 5 years for postmenopausal breast 
cancer has been studied within multiple phase-III trials. Treatment compliance in 
these trials is generally poor. In this analysis, we aimed to determine which factors 
were associated with participation in the phase-III IDEAL trial, which factors are 
associated with early treatment discontinuation, and how this influenced survival 
outcome. 
Methods: In the IDEAL trial, postmenopausal patients were randomized between 
2.5 or 5 years of extended letrozole, after completing 5 years of endocrine therapy 
for hormone receptor-positive early breast cancer. A subgroup of this population 
participated earlier in the TEAM trial (5 years of exemestane, or 2.5 years of tamoxifen 
followed by exemestane as primary adjuvant therapy), in which we explored which 
factors were determinative for enrolment in the IDEAL study.  In the IDEAL cohort, we 
evaluated which factors predicted for early treatment discontinuation, and the effect 
of early treatment discontinuation on disease-free survival (DFS). 
Results: Nodal status, younger age and adjuvant chemotherapy were significantly 
associated with higher enrolment in the IDEAL trial. In the IDEAL cohort, adverse 
events, the type of primary endocrine therapy and the interval between primary and 
extended therapy were associated with early treatment discontinuation. Among the 
reported adverse events, depressive feelings (56%) was most frequently associated 
with early treatment discontinuation . Early treatment discontinuation was not 
associated with worse DFS (HR 1.02, 95%CI 0.76-1.37).
Conclusions: In this analysis, we found that risk factors were most strongly associated 
enrolment in the IDEAL trial. In contrast, patient experiences were the most significant 
factors leading to early treatment discontinuation, with no effect on DFS.
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Extended endocrine therapy for hormone receptor-positive (HR+) early breast cancer, 
beyond the standard 5 years,  is more frequently being used over the recent years. 
After five years of tamoxifen, it has been shown that extended therapy with either 
5 additional years of tamoxifen or 5 years of an aromatase inhibitor (AI) has clinical 
benefit, in particular in high-risk (lymph node positive) disease. 1-5 However, less data 
are available on the value of extended adjuvant endocrine therapy after primary 
adjuvant therapy including an AI. Recently, results of trials studying extended therapy 
after an optimal primary adjuvant regimen (including AIs during the first 5 years) 
were presented and partly published, showing no significant benefit of extended 
therapy for the total group, and suggesting that mainly high-risk subgroups might 
benefit from this extended therapy. 6, 7
One of the problems regarding adjuvant endocrine therapy, both during primary and 
extended therapy, is early treatment discontinuation. In the trials reporting on 5 years 
of extended therapy, patient compliance (finishing 5 years of extended therapy) was 
consistently low. 4, 6-8 In most studies this is considered to be attributed to the side 
effects of endocrine therapy. However, in the placebo-controlled NSABP B42 trial, in 
which patients after 5 years of AI-based therapy were randomized between 5 years 
of letrozole or placebo, the early treatment discontinuation in the placebo- arm was 
similar as in the letrozole-group (62% and 60% on therapy at 5 years). 8 A similar 
effect was observed in the MA.17 trial, in which patients were randomized between 
5 years of letrozole or placebo after 5 years of tamoxifen, reporting a discontinuation 
rate of 9.9% vs 9.8% in the letrozole and placebo groups respectively. 3, 9 This 
indicates that other factors than actual treatment toxicity also play a role in the early 
discontinuation of extended adjuvant endocrine therapy. Knowledge of these factors 
would enable the clinician and health care workers to  tailor the support of patients 
during extended adjuvant endocrine therapy, in order to decrease early treatment 
discontinuation.
In the Dutch ‘Investigation on the Duration of Extended Adjuvant Letrozole’ (IDEAL) 
trial in which postmenopausal patients were randomly allocated to either 2.5 or 5 
years of letrozole after 5 years of any type of adjuvant endocrine therapy, 629 (35%) 
patients stopped therapy earlier than planned (27% in 2.5 years group, 43% in the five-
year group), of which the majority (59%) reported side effects as the main reason for 
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early treatment discontinuation. 7 A preliminary evaluation after 2.5 years of follow-
up suggested that nodal status, type of earlier endocrine therapy and the interval 
between primary and extended adjuvant therapy could influence patient compliance 
10 A number of patients in the IDEAL trial earlier participated in the Tamoxifen 
Exemestane Adjuvant Multinational (TEAM) trial, in which postmenopausal 
early breast cancer patients were randomized between either 5 years of adjuvant 
exemestane, or a sequential scheme of tamoxifen for 2.5 years followed by 2.5 years 
of exemestane. 11, 12 At that time, extended adjuvant therapy was not yet standard of 
care in the Netherlands, but Dutch TEAM patients were allowed to be enrolled in the 
IDEAL study thereafter. 
The present analyses were performed to explore factors contributing to treatment 
decisions at enrolment in, and during the course of the IDEAL trial. The first aim 
was to identify which factors were associated with enrolment in the IDEAL trial 
after participation in the TEAM trial. The second aim was to identify which baseline 
factors were associated with early treatment discontinuation in the IDEAL trial. The 
third aim was to assess which specific adverse events are associated with either the 
decision to extend endocrine therapy after TEAM participation, and  early treatment 
discontinuation during the IDEAL trial. Finally, we investigated the effect of adverse 
event-based early treatment discontinuation on disease-free survival (DFS).
Methods
Patient cohorts and data collection
In the IDEAL trial, 1824 postmenopausal early HR+ breast cancer patients were 
randomly allocated to either 2.5 or 5 years of letrozole, after receiving any type of 
5-years primary adjuvant endocrine therapy. The eligibility criteria were: completion 
of 5 years (±3 months) of primary adjuvant endocrine therapy (either within a 
regular or clinical trial setting), end of primary adjuvant therapy within 24 months 
before inclusion, and disease-free status without other malignancies at the time of 
randomisation. 
In the international TEAM trial, 2754 Dutch patients were included of whom 
2363 were treated in a center that later on also participated in the IDEAL trial. The 
flowchart of the selection procedure used for determination of the cohort of TEAM 
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patients being theoretically eligible for the IDEAL study and the current analyses is 
depicted in figure 1. The selection criteria included:  be treated in a center that later 
on would also participate in IDEAL, be free of any recurrence or new primary breast 
tumour at the end of active TEAM trial medication, completion of 5 years (± 3 months) 
of endocrine therapy within the TEAM trial, no other malignancy within previous 5 
years, and available follow-up data until the time of randomization in the IDEAL (not 
lost to follow-up). Using these criteria, we defined a cohort of 1216 patients that were 
theoretically eligible for IDEAL enrolment after TEAM participation (figure 1).
Dutch TEAM 
trial (n=2754)
Not eligible for IDEAL 




DFS event during 





Missing DFS status 
or treatment 
duration (n=19)
Eligible for IDEAL based on 






DFS event during first 5 years (n=2)
TEAM treatment <4.75 year (n=54)
TEAM treatment >5.25 year (n=28)
Figure 1 – An overview of the relation between the TEAM and IDEAL trial patient cohorts
For both studies, data were locally registered on the clinical record forms (CRFs) and 
centrally collected at the LUMC Datacenter Department of Surgery. Details on data 
collection for both studies were reported earlier 7, 12 Relevant for the current analysis 
is the datacollection at baseline of patient, tumor and treatment characteristics, 
the registration of adverse events (AEs) during active treatment using the Common 
Terminology Criteria for Adverse Events (TEAM: version 2.0, IDEAL: version 4.0), and 
registration of details on the stop of therapy (date and reason, “stopped due to adverse 
event” was an option to select on the CRF).
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Data handling and endpoints
All adverse events, irrespective of grade, were considered for the analyses. Cardiac 
disorders were combined into categories based on the CTC categories (‘cardiovascular 
general’ and ‘cardiovascular arrhythmia’ in CTC version 2.0, and ‘cardiac disorders’ 
in CTC version 4.0). For the analyses on AEs, the most frequently occurring AEs and 
most relevant for the given endocrine therapy were included, as based on the primary 
publications of both trials. 7, 12
Early treatment discontinuation was defined as a definite stop of trial-based letrozole 
before the designated  treatment stop date as reported by the treating physician on 
the CRF, except when the medication stop was caused by recurrence or death. Some 
patients stopped letrozole in the IDEAL study, and continued with a different aromatase 
inhibitor off-trial. These patients were still regarded as being early stopped with therapy 
for all analyses, since registration of off-trial medication was not assured for all patients.
The primary endpoint of the IDEAL trial was disease-free survival (DFS), defined as 
the time from randomization to recurrence (either local, regional or distant), new 
primary breast tumors (DCIS or invasive) or death due to any cause. 7 
Statistical analysis
In the cohort of TEAM patients that was eligible for inclusion in the IDEAL trial, 
baseline clinicopathological parameters were tested for  association with enrolment 
in the IDEAL. Statistical independence was tested using Chi-square (X2) tests with an 
alpha of 0.05. Furthermore, we determined the percentage of patients that continued 
with extended therapy in the IDEAL, for the patients who reported the most frequent 
and relevant adverse events associated with endocrine therapy. 
In the cohort of IDEAL patients, baseline clinicopathological parameters were tested 
for association with the occurrence of adverse events and with early treatment 
discontinuation, using Chi-square (X2) tests with an alpha of 0.05 and multivariate 
logistic regression modelling. Furthermore, for each selected (most frequent) adverse 
event we determined the percentage of patients that stopped therapy because of 
adverse events, thereby showing which adverse events are related to early treatment 
discontinuation . In the patients who encountered and adverse event, Kaplan-Meier 
and univariate stratified Cox-regression analysis( stratified for earlier endocrine 
therapy, chemotherapy, time between regular and extended therapy, and nodal 
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status) were used to determine the effect of early treatment discontinuation due 
to an adverse event on DFS. A Cox-regression interaction test was used to test for 
interaction between treatment arms.
Statistical analysis was performed using SPSS 23.0 (IBM), and a 2-sided p-value of 
0.05 or lower was regarded as statistically significant for each analysis. 
Results
Of the Dutch TEAM cohort, 1216 patients were theoretically eligible for participation 
in the IDEAL study (figure 1), of which 345 indeed were enrolled in IDEAL (28%). 
As described in table 1, we observed that patients who were younger, received 
chemotherapy, underwent an axillary dissection or had node-positive disease, were 
significantly more likely to be enrolled in the IDEAL study and therefore to continue 
with extended endocrine therapy (table 1). The occurrence of an adverse event (AE) 
during the TEAM trial was not associated to participation in the IDEAL trial (table 1). 
Table 1 – Baseline clinicopathological characteristics of TEAM patients eligible for participation in the IDEAL 
trial. Multivariate logistic regression modelling used to determine odds ratios.
IDEAL study participation
no yes





Randomisation 5y exemestane 489 71.2% 198 28.8% 0.69 1.00
2.5y tamoxifen, 
2.5y exemestane
382 72.2% 147 27.8% 0.83 0.09
Age <50 years 12 46.2% 14 53.8% <0.001 1.00
50-59 270 67.7% 129 32.3% 0.61 0.13
60-69 309 69.3% 137 30.7% 0.57 0.10
>=70 280 81.2% 65 18.8% 0.31 0.00
ECOG Performance 
Status**
0 682 70.9% 280 29.1% 0.22 1.00
1 150 77.7% 43 22.3% 0.59 0.003
unknown 16 66.7% 8 33.0% 1.43 0.12
Tumour type ductal 645 71.5% 257 28.5% 0.45 1.00
lobular 128 69.2% 57 30.8% 1.71 0.50
mixed ductal/
lobular
43 74.1% 15 25.9% 1.90 0.42
other 41 82.0% 9 18.0% 1.94 0.42
NOS adenocarci-
noma
8 80.0% 2 20.0% 1.59 0.62













Grade 1 139 68.5% 64 31.5% 0.54 1.00
Grade 2 408 72.6% 154 27.4% 0.80 0.17
Grade 3 260 71.6% 103 28.4% 0.77 0.15
Tumoursize T1 427 71.6% 169 28.4% 0.24 1.00
T2 400 71.7% 158 28.3% 0.86 0.21
T3 27 64.3% 15 35.7% 1.02 0.96
T4 15 88.2% 2 11.8% 0.22 0.04
Nodal status N- 278 79.2% 73 20.8% <0.001 1.00
N+ 593 68.6% 272 31.4% 1.71 0.008
Hormonereceptor 
Status ER/PgR
ER+/PgR+ 637 71.7% 252 28.3% 0.06 1.00
ER+/PgR- 154 67.2% 75 32.8% 0.98 0.87
ER+/PgR 
unknown
65 80.2% 16 19.8% 0.64 0.11
ER-/PgR+ 13 92.9% 1 7.1% 0.23 0.05
ER-/PgR-* 2 100.0% 0 0.0% 0.00 1.00
HER2 status negative 730 72.9% 272 27.1% 0.28 1.00
positive 86 68.3% 40 31.7% 1.21 0.29
Adjuvant 
Chemotherapy
no 649 76.0% 205 24.0% <0.001 1.00
yes 222 61.3% 140 38.7% 1.25 0.14
Most Extensive 
Surgery
mastectomy 450 72.6% 170 27.4% 0.61 1.00
wide local 
excision
420 70.6% 175 29.4% 1.39 0.008
Axillary Dissection no 211 76.7% 64 23.3% 0.03 1.00
yes 660 70.1% 281 29.9% 0.97 0.90
Adverse event 
during treatment
no 264 71.5% 105 28.5% 0.97 1.00




1 = symptomatic, full ambulatory
Regarding inclusion in the IDEAL study in relation to AEs experienced during the 
TEAM study medication, we  considered hot flashes, fatigue, arthralgia, lymphedema, 
nausea and alopecia (most frequently occurring), together with relevantly endocrine 
therapy-associated adverse events (depressive feelings, fractures and cardiac disease) 
(table 2). Of these factors, only cardiac arrhythmias showed a lower participation rate 
in the IDEAL trial (table 2).
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Table 2 – Most frequently reported adverse events in the TEAM trial, associated with participation in the 
extended endocrine therapy IDEAL trial.
IDEAL study participation
no yes
N % N %
Hot flashes 277 68,6% 127 31,4%
Fatigue 208 78,5% 57 21,5%
Arthralgia 110 69,2% 49 30,8%
Cardiovascular disease (general) 125 71,8% 49 28,2%
Lymphedema 116 75,8% 37 24,2%
Nausea 57 71,3% 23 28,8%
Alopecia 45 70,3% 19 29,7%
Fracture 51 78,5% 14 21,5%
Cardiovascular disease (arrhythmia) 45 83,3% 9 16,7%
Mood alteration-depression 32 71,1% 13 28,9%
Regarding the question which factors contributed to early letrozole discontinuation, 
we observed that patients who received tamoxifen monotherapy as primary adjuvant 
therapy, or had a longer break between initial and extended therapy reported 
significantly more frequently adverse events, and also stopped therapy significantly 
more often due to adverse events or treatment refusal (table 3). Of all patients 
reporting one or more adverse events, 31% stopped therapy early, compared to 6.6% 
of patients that did not report an adverse event (table 3).
We explored the most frequently reported and most relevantly AI-associated adverse 
events 7 , and determined the percentage of patients that stopped letrozole therapy 
early due to adverse events. The most pronounced specific AEs associated with early 
treatment discontinuation  were depressive feelings (55.8% of patients reporting a 
depression stopped due to an adverse event), alopecia (47.4%) and arthralgia (44.3%). 
In contrast, osteoporosis (14.1%), fractures (12.9%) and back pain (11.9%) were seldom 
associated with early treatment continuation due to adverse events (figure 2). 
For patients who stopped letrozole therapy early due to adverse events, the mean 
treatment duration was 13 months (8 months for patients randomized to 2.5 years, 
and 18 months for patients randomized to 5 years). In contrast, in patients who did 
not stop due to an adverse event, the average treatment duration was 42 months (30 
months for 2.5 years group, and 55 months for 5 years group). The effect of this shorter 
therapy duration on DFS was studied comparing patients who stopped early due to 
an AE with patients who did not stop early due to an AE (figure 3). Early treatment 
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discontinuation due to an AE had no effect on DFS (HR 1.02, 95%CI 0.76-1.37, p=0.90). 
This effect was similar in both IDEAL therapy arms (HR for interaction 0.85, 95%CI 
0.47-1.51, p=0.57).
Figure 2 – Most frequently reported adverse events in the IDEAL trial, associated with early treatment 
discontinuation. For each adverse event, the percentage of patients that stopped therapy early due to adverse 
events is shown.
Figure 3 –Kaplan Meier survival analysis in the group of patients who encountered an adverse event, comparing 
patients who stopped therapy early due to an AE with patients who did not stop early due to an AE. Log-rank test 
is used to determine the p-value.
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In this explorative analysis, we found that classical risk factors for recurrent disease 
such as nodal status were more associated with starting extended endocrine 
therapy in the IDEAL study, whereas patient-centred factors like adverse events and 
experiences with earlier endocrine therapy were more driving factors regarding early 
treatment discontinuation. 
We observed that the factors associated with enrolment in the IDEAL trial after 
completion of the TEAM study medication, were in general risk factors for disease 
recurrence (like nodal status and previous adjuvant chemotherapy) as well as a 
younger age. Remarkably, the occurrence of adverse events during primary adjuvant 
treatment (not leading to early stopping of endocrine therapy) did not appear to 
influence enrolment in the IDEAL trial. Only cardiac events during the TEAM trial, were 
associated with a lower rate of enrolment in the IDEAL trial, which can be explained 
by the fact that uncontrolled cardiovascular disease was an exclusion criterion for 
the IDEAL trial. The decision whether or not to extend endocrine therapy, was most 
likely a risk/benefit-based decision. In contrast, exploration of factors associated with 
early discontinuation of extended endocrine therapy revealed that the occurrence 
of adverse events played a major role in early treatment discontinuation. Without 
adverse events, 6.6% of patients stopped early, whereas 31% with an adverse event 
stopped prematurely. Other factors with impact on early treatment discontinuation 
were the type of primary adjuvant endocrine therapy, the interval between primary 
and extended therapy, and the allocated treatment. The latter could be explained by 
the fact that patients who were allocated to 5 years of extended letrozole, had twice 
as much time to stop therapy early, compared to the patients who were allocated to 
2.5 years of letrozole.
In general, there is concordance between the reporting of adverse events in a 
particular subgroup, and the rate of early treatment discontinuation. For example, 
tamoxifen monotherapy and a longer interval between regular and extended therapy, 
are both associated with the reporting of adverse events  and with early treatment 
discontinuation. For both of these factors, the explanation for a higher rate of reported 
adverse events might be that the patients were not familiar (anymore) with the side 
effects of aromatase inhibitors, and therefore reported them more often and were more 
likely to stop therapy due to these complaints. The only discordance in the association 
49021 Erik Blok.indd   87 03-04-18   11:43
Chapter 5
88
between adverse events and early treatment discontinuation is the type of surgery. 
Patients who underwent a mastectomy reported significantly more adverse events 
compared to patients treated with a lumpectomy, but did not differ with regard to 
early treatment discontinuation rate. Most likely, adverse events in the mastectomy 
group were not associated with endocrine therapy but with the local therapy itself, and 
therefore did not lead to a difference in early endocrine treatment discontinuation.
Of the adverse events associated with early treatment discontinuation, arthralgia, 
fatigue, alopecia and in particular depressive feelings/mood alterations were the most 
pronounced. These adverse events probably caused the highest (subjective) impact 
on the quality of life. Remarkably, osteoporosis and fractures were associated with a 
lower rate of early treatment discontinuation, while these are well known side effects 
from AI therapy. Apparently, osteoporosis has less impact on the life of patients, and 
is not considered to be a major problem as it can be treated with calcium, vitamin D 
and bisphosphonates. 
In the patients who reported one or more adverse events, early treatment 
discontinuation did not lead to a worse disease-free survival. On one hand this is 
remarkable, since it has been suggested that patients who stop earlier than planned, 
are at a higher risk for recurrent disease. 13, 14 However, these latter studies were 
performed in the context of standard (5 years) adjuvant endocrine therapy, in which 
it has been shown that 5 years of therapy is superior over 2 years of therapy. 15 On the 
other hand, our data are derived from the IDEAL patient cohort, and the primary 
evaluation of this trial did not show a difference in DFS between 2.5 and 5 years of 
extended letrozole either. 7 Our results therefore support that for extended therapy 
with letrozole after optimal primary adjuvant endocrine therapy, a longer extended 
treatment does not lead to an improved survival for the total group. However, in view 
of this unplanned analysis, it is warranted to study this further in collaboration with 
other extended endocrine therapy trials.
We observed that a number of patients (n=93) were enrolled in both the TEAM and 
IDEAL trial, without being part of this IDEAL-eligible TEAM-population. However, 
this doesn’t mean that they were ineligible for the IDEAL. For example, patients could 
have went off-study in the TEAM trial, but continued with endocrine therapy outside 
the TEAM-trial, becoming then eligible for the IDEAL study after 5 years of endocrine 
therapy. 
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A limitation of this analysis is that when a patient experienced multiple adverse 
events, and stopped due to the occurrence of an adverse event, it was not registered 
which specific adverse event was responsible for the discontinuation of therapy. 
Another limitation is that adverse events were only collected during active treatment 
in the IDEAL trial. Therefore, the registration period for the 5-years arm was twice as 
long as the 2.5 years arm, and quantitative comparisons regarding specific adverse 
events cannot be made.
In summary, our study demonstrates that the decision to enrol patients in an extended 
endocrine therapy trial is mainly influenced by high-risk factors and a sufficiently 
expected benefit, reflecting a risk-/benefit-based decision making process. In 
contrast, compliance to complete extended endocrine therapy is mainly influenced by 
adverse events, and type and timing of earlier therapy. Noteworthy, early treatment 
discontinuation due to adverse events did not lead to a worse DFS in our analysis, 
which should be investigated further. In our opinion, these results can contribute 
towards a better understanding of and improving early treatment discontinuation of 
extended endocrine therapy both in clinical trials and in standard care.
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NTR3077, the Dutch Breast Cancer Research Group (BOOG 2006-05) and Eudra-CT 
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Endocrine therapy is an important asset in the management of estrogen receptor (ER) 
positive breast cancer. Currently, patients are selected for endocrine therapy based on 
immunohistochemical expression of ER and progesterone receptor (PR). However, 
this does not necessarily imply an active ER pathway, which is the target of endocrine 
therapy. The aim of this study was to validate a recently described computational 
model that infers ER pathway activity based on the expression of its target genes.
Two cohorts were analyzed: a cohort of 61 patients treated with 3 months of neo-
adjuvant letrozole for which a public dataset containing gene expression and 
ultrasound-based tumor-response data is available, and the TEAM-IIA trial cohort in 
which 102 patients were treated with up to 6 months of neo-adjuvant exemestane. 
The original ER pathway model was adapted to process Affymetrix HGU133A data 
from the public dataset, and qPCR data obtained from TEAM-IIA samples.
Mean ER pathway activity decreased significantly during therapy. Furthermore, in 
the public dataset, both baseline activity and decrease in ER pathway activity was 
significantly higher in responding patients. In the TEAM-IIA cohort, palpation-based 
progressive disease and radiology-based non-response after therapy were associated 
with lower levels of baseline ER pathway activity.
Our results indicate, in two independent cohorts, that low baseline ER pathway activity 
is associated to an inferior response to endocrine therapy. Upon prospective validation, 
this model could be used in a clinical setting to predict response to endocrine therapy 
and thereby better select patients who will benefit from this treatment.
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Endocrine therapy is one of the mainstays in the treatment of both early and 
metastatic breast cancer. Especially the use of tamoxifen and aromatase inhibitors 
(AI) has resulted in increased survival rates.1-3 Patients are currently selected for 
endocrine therapy using immunohistochemical analysis of estrogen receptor (ER) 
and progesterone receptor (PR) expression, which was developed more than a decade 
ago.4 Both the American Society for Clinical Oncology (ASCO) and the European 
Society for Medical Oncology advise a threshold of 1% ER positive tumor cells.5, 6 In 
practice, many clinicians and countries choose a threshold of 10%.7-9 More quantifiable 
analyses like the Allred scoring and H-score have been developed and suggested for 
clinical application, but are currently not routinely used.5
Despite the success of endocrine therapy in ER-positive breast cancer, there are still 
patients that do not respond to endocrine therapy, regardless of the presence of ER 
or PR in the investigated tissue sample. In addition to cancer tissue heterogeneity, 
several mechanisms have been proposed to explain lack of therapy response, like 
emergence of activating mutations in ESR1 or activation of other signal transduction 
pathways upon pharmacological inhibition of the ER pathway.10, 11 Standard 
immunohistochemical analysis only detects presence of ER and PR; however, the issue 
of how well a positive nuclear ER staining, accompanied or not by a positive nuclear 
PR staining, actually indicates an active ER pathway, as an alternative explanation, has 
not yet been satisfactorily addressed. The development of tests to predict response to 
endocrine therapy based on measuring actual activity of the ER pathway will provide 
additional information that might be useful in the decision to treat with endocrine 
therapy and whether to add additional targeted therapy. 
A possible approach towards predicting the response of endocrine therapy would 
be to assess activity of the ER pathway by measuring expression of downstream ER 
pathway target genes. After all, it is likely that if this pathway is highly active, endocrine 
therapy will be more effective than when the pathway is barely active or inactive, 
irrespective of the presence of the estrogen receptor itself. So far, no test has been 
developed for assessing ER pathway activity, although numerous studies have been 
performed.12-15 Recently, Verhaegh et al have developed a computational model for the 
ER pathway, enabling assessment of this pathway in tumor tissue. This computational 
Bayesian network model uses mRNA expression of 27 genes which are proven target 
49021 Erik Blok.indd   97 03-04-18   11:43
Chapter 6
98
genes of the ER pathway.16, 17 The aim of the current work is to evaluate this model in 
a clinical setting. We hypothesize that ER pathway activity at baseline as measured 
by this computational model is capable of predicting response to therapy and that 
a decrease in pathway activity during treatment represents a successful treatment.
To test our hypothesis, we investigated publicly available Affymetrix datasets 
containing baseline and outcome data from neoadjuvant studies on AIs in breast 
cancer patients.18, 19 After initial confirmation of our hypothesis we proceeded to test 
it in the TEAM IIA clinical trial cohort of ER positive breast cancer patients treated 
with neo-adjuvant endocrine therapy. We assessed the value of baseline ER pathway 
activity to predict response to neo-adjuvant therapy with an AI and whether the 
decrease in activity could be used to assess clinical response to neoadjuvant therapy.
Materials & Methods
Publicly available dataset
Search of the GEO repository yielded one dataset appropriate for our proof-of-
principle analysis: the GSE20181 dataset.18, 19 This dataset contains Affymetrix 
HGU133A gene expression and outcome data of 61 post-menopausal patients that 
underwent neo-adjuvant letrozole treatment. Those patients were treated in a neo-
adjuvant setting with 2.5 mg daily letrozole for three months. The GSE20181 dataset 
contains gene expression data from biopsies, containing at least 20% tumor collected 
at baseline, 14 days, and three months of treatment. Clinical response was determined 
by ultrasound assessment of the tumor size and patients with more than 50% tumor 
reduction were considered responders. Raw Affymetrix data from the GSE20181 
dataset was retrieved from the GEO repository and normalized with fRMA.20 
Study cohort
The Dutch TEAM IIA trial is a neo-adjuvant phase II trial for which the details have been 
previously described.21 Briefly, 102 ER positive patients were randomized for either 3 
or 6 months of neo-adjuvant exemestane. Due to unforeseen slow accrual, the study 
changed to a single arm design with 6 months of therapy. Standard clinicopathological 
baseline characteristics, including PR and HER2 status were known. Pre-treatment 
biopsies and post-treatment resection specimens were collected by the investigators. 
Change in tumor size assessed by palpation was the primary objective. Secondary 
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outcomes were clinical response rates measured by mammography, ultrasound and 
MRI. Assessment was performed according to RECIST 1.1 criteria. 
Laser Capture Microdissection 
In order to accurately determine the activity of the ER pathway within tumor 
cells, those cells were separated from surrounding stromal tissue using Laser 
Capture Microdissection (LCM), as described by Espina et al.22 Briefly, slides were 
cut in quintuplicate from tumor-containing formalin fixed paraffin embedded 
(FFPE) blocks from both pre-treatment biopsies as well as from post-treatment 
resection material. The slides were cut and placed onto PEN Membrane slides (Life 
Technologies), which contain a special membrane making it suitable for LCM. Slides 
were stained with hematoxylin and eosin using standard RNase free protocols. All 
slides were microscopically assessed and tumor regions (at least 1mm2 per slide) were 
dissected from the slides using LCM. For each sample, the dissected tumor regions 
were collected in an RNase-free microfuge tube (Life Technologies) and were stored 
at -20 degrees Celsius.
ER pathway models
The methodology used to develop the ER pathway models used in this study was 
described in detail earlier.16 The basic idea behind this methodology is to construct a 
Bayesian network model of the ER transcriptional program, which uses the pathway 
target genes’ mRNA levels in a certain sample to infer the probability that the ER 
pathway is transcriptionally active in the respective sample. This Bayesian network 
structure is a simplified model of the transcriptional program of the ER signal 
transduction pathway, consisting of three types of nodes: (i) ER transcription complex 
activation node, (ii) target gene regulation node (with states ‘down’ and ‘up’), and (iii) 
expression intensity level nodes (with states ‘low’ and ‘high’) each corresponding to a 
target gene. The final model describes (a) how target gene regulation depends on ER 
transcription complex activity and (b) how expression level intensities in turn depend 
on regulation of the respective target genes (Supplemental Figure 1).
The original paper described this methodology for mRNA expression levels measured 
using the Affymetrix HGU133Plus2.0 microarray platform.16 This methodology was 
adapted to be used with both RT-qPCR and Affymetrix HGU133A platforms. This 
adaptation consisted of modifying and re-calibrating the ER pathway Bayesian network 
model for each platform. For the RT-qPCR platform the original 27 target gene ER 
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pathway Bayesian network was reduced to a 12 ER target gene network. The genes 
included in this network were chosen based on literature evidence and discriminative 
power. RT-qPCR assays were developed and validated for each of these target genes plus 
7 other genes used as reference genes. The model was calibrated using mRNA expression 
data of MCF7 cell cultures exposed to 1nM E2 for 16h or DMSO after being maintained in 
estradiol deprived (charcoal treated FBS, phenol red free) medium for 48h, as described 
before.23 For the Affymetrix HGU133A platform the network was adapted by selecting 
Affymetrix probe sets representing the original 27 ER target genes that were available 
in the HGU133A platform and the resulting network model was calibrated using fRMA 
transformed Affymetrix HGU133A mRNA expression data from publicly available 
dataset GSE9936. These Affymetrix HGU133A calibration samples were from MCF7 cell 
cultures exposed to 6nM E2 for 24h or vehicle control after being maintained in estradiol 
deprived (charcoal treated FBS, phenol red free) medium for at least 48h.24
Suppl Figure 1: schematic representation of ER pathway network. Left: RT-qPCR model consisting of 12 target 
genes with expression levels measured by RT-qPCR assays. Center: Node type description. Right: Affimetrix 
model consisting of 27 target genes with expression levels measured by Affymetrix hgu133a probesets.
Pathway analysis of PCR samples
For the analysis of the ER pathway activity on the samples of the TEAM IIA cohort, 
mRNA was extracted from the micro dissected samples (Siemens VERSANT Tissue 
Prep. Reagent kit, according to manufacturer’s instructions) and the expression of the 
12 target genes and 7 reference genes was determined using RT-qPCR. Those values 
were used as input to the RT-qPCR ER pathway model with which the probability and 
the odds that the ER pathway is active was calculated. These data were interpreted 
with respect to ER pathway activity in a blinded manner at Philips Research and 
returned to the Leiden University Medical Center, in order to be correlated to tumor 
size, as assessed by palpation and mammography.
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Statistical analysis was performed using R25 and SPSS 23.0 (IBM). ER pathway analysis 
was calculated in two ways: the probability (P) that the ER pathway is active and its 
pathway activity index (PAI, defined as log2(P/(1-P)), i.e., the log2 of the odds in favor that 
the ER pathway is active, PAI=0 indicates a 50% chance of ER pathway activation, PAI=2 
and -1 indicate, respectively, a chance four times as large and  twice as small of the ER 
pathway being active than of it being inactive). For the purpose of comprehensibility, 
the probability is used as a visual representation of the likelihood that the ER pathway 
is active. However, the activity index is used for all statistical calculations since these 
data are generally more appropriate for statistical computations and more normal-
like distributed (Supplemental Figure 2). For simplicity, we use ‘ER pathway activity’, 
or simply, ‘ER activity’ as a short form of ‘the inferred probability that the ER pathway 
is active’. Paired t-tests were used to assess differences between baseline and post-
treatment ER pathway activity. Two sample t-tests were used to assess correlations 
between outcome categories and average ER pathway activity. Two sample t-tests 
and ANOVA were used to access ER activity and decrease in activity association with 
baseline parameters. Presented p-values are 2 sided and refer to PAI quantities, unless 
explicitly indicated otherwise. All tests assume unequal variance.







































Suppl Figure 2: histograms of ER-pathway activity at baseline. Upper: GSE20181 data, using Affymetrix model; 
Lower: TEAM II A cohort, using RT-qPCR model; Left: activity presented as a probability (P); Right: activity 
presented as Pathway Activity Index, i.e.: log2(P/(1-P)). 





We first assessed, in a public dataset, whether the ER pathway model based on 
Affymetrix HGU133A microarray data, was able to detect a decrease in ER pathway 
activity in ER positive patients following neoadjuvant endocrine therapy. ER pathway 
activity significantly decreased during letrozole therapy on ER positive patients of the 
GSE20181 dataset (table 1) presents the mean ER pathway activity at baseline, 2 weeks, 
and 3 months. Overall, ER pathway mean activity decreased significantly between 
baseline (P=0.62) and 2 weeks (P=0.32) of treatment (with PAI decrease from 1.6 to -1.6, 
paired t-test p-value <0.001, n=58) as well as between baseline and 3 months (P=0.36) 
of therapy (with PAI decrease from 1.8 to -1.3, p-value <0.001, n=56). No significant 
difference was seen between 2 weeks and 3 months of treatment, suggesting an early 
maintained response to letrozole. Both baseline ER pathway activity and decrease 
in ER activity from baseline was significantly higher in responders than in non-
responders (Table 1 and Figure 1). 
Table 1: Average activity and decrease in activity of ER pathway for GSE20181. ER pathway activity is presented as 
probability that the ER pathway is active (P) and as activity index (PAI). R: responders, NR: non-responders;; sd: 
standard deviation; pv:  p-value for t-test on PAI for R vs. NR
  P PAI
N Mean sd Range Mean sd Range  p-value*
Baseline 0.02
all 58 0.62 0.33 [0.02,1] 1.6 3.8 [-5.8,12]
   
R 37 0.65 0.34 [0.02,1] 1.9 3.9 [-5.8,10]
NR 15 0.46 0.31 [0.06,0.92] -0.3 2.4 [-3.9,3.5]
2 weeks 0.86
all 58 0.32 0.27 [0.01,0.96] -1.6 2.6 [-6.7,4.5]  
   
R 37 0.33 0.29 [0.01,0.96] -1.6 2.9 [-6.7,4.5]
  NR 15 0.32 0.23 [0.01,0.76] -1.5 2 [-6.2,1.7]  
3 months 0.86
all 60 0.38 0.28 [0.01,1] -1.1 2.6 [-6.6,8.2]
   
R 36 0.36 0.26 [0.03,0.86] -1.2 2 [-4.8,2.7]
NR 14 0.40 0.33 [0.01,0.91] -1.0 3 [-6.4,3.4]
Base - 2 w 0.02
all 58 0.30 0.35 [-0.56,0.93] 3.2 3.5 [-3.9,10]  
   
R 37 0.31 0.33 [-0.33,0.93] 3.5 3.5 [-3.1,10]
NR 15 0.14 0.35 [-0.56,0.68] 1.2 2.7 [-3.9,5.1]
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      P     PAI    
    N Mean sd Range Mean sd Range  p-value*
Base - 3 m 0.04
all 56 0.28 0.37 [-0.8,0.89] 3.1 3.8 [-6.4,12]  
   
R 36 0.31 0.31 [-0.46,0.88] 3.3 3.4 [-4.3,10]
  NR 14 0.07 0.43 [-0.8,0.82] 0.76 3.8 [-6.4,8.6]  
2 w - 3 m 0.96
all 56 -0.03 0.23 [-0.66,0.41] -0.29 2.2 [-5.1,3.8]
   
R 36 -0.02 0.23 [-0.63,0.41] -0.35 2.1 [-5.1,3.7]
  NR 14 -0.07 0.25 [-0.66,0.23] -0.39 2.5 [-5,3.8]  
*p-value represents a t-test comparing responders (R) with non-responders (NR)
Figure 1: ER-pathway activity as a function of treatment time for GSE20181 dataset. Upper: line plot of activity per 
sample. Lower: box plots of activity in responders and non-responders per time point. Blue: responders, red: non-
responders. Solid lines: activity went down during treatment, dashed lines: activity went up during treatment.
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Subsequently we analyzed the tissue samples from the TEAM IIA clinical trial, using 
the RT-qPCR ER pathway model. 
TEAM IIA cohort characteristics 
The TEAM IIA cohort consists of 102 patients, all of which received at least 3 months 
of neoadjuvant endocrine therapy with exemestane. The majority of patients (n=83) 
received 6 months of therapy. Both biopsies and resection samples were collected 
and analyzed retrospectively. Thirty-three biopsies and 38 resection samples could 
not be retrieved, leading to a cohort of 69 patients from whom a biopsy sample was 
available and a cohort of 64 patients from whom a resection specimen was available. 
During LCM another 16 resection samples and 11 biopsies were excluded, mainly due 
to absence of tumor tissue in the specimen. Upon subsequent RT-qPCR, 9 biopsy 
samples yielded amounts of RNA too low to perform the required set of qPCRs, 
making them ineligible for further analysis, resulting in 49 biopsy and 48 resection 
samples eligible for analysis, of which 28 samples were matched cases from the same 
patient (Figure 2).
Figure 2 : consort diagram of tissue amples collected in the TEAM IIA trial
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Baseline and post treatment ER pathway activity TEAM IIA
At baseline, the average probability of the ER pathway being active was 0.48, ranging 
from 0.02 to 0.89. After therapy, the average ER activity decreased to 0.32, ranging 
from 0.01 to 0.86 (Table 2). Of the 28 matched cases, the mean activity of ER decreased 
by 35% (absolute difference of -0.16), ranging from a decrease of 0.70 to an increase of 
0.31 (mean PAI decrease from -0.3 to -1.8, paired t-test p-value <0.001).
ER pathway activity at baseline and decrease in activity during therapy were 
correlated with clinicopathological baseline characteristics (Table 3). Baseline mean 
ER pathway activity was significantly higher in PR positive samples (P=0.55) than PR 
negative samples (P=0.29), with PAI=0.3 vs. -1.8, two sample t-test p-value=0.003; and 
in patients with higher BMI (P=0.53) than in patients with lower BMI (P=0.38), with 
PAI=0.2 vs. -1, p-value=0.04. There was no significant difference in baseline activity 
between age categories, HER2-status, tumor type, tumor grade and tumor or nodal 
status.
Interestingly, the mean decrease in ER pathway activity in the available paired cases 
was neither significantly higher in baseline PR postive patients than in baseline PR 
negativepatients nor in patients with higher baseline BMI than in patients with lower 
baseline BMI (Table 3). 
Correlation with TEAM IIA outcome assessed by palpation
To test the predictive value of the ER pathway model, the computed ER pathway 
activities were correlated to primary and secondary outcome measures of the 
TEAM IIA trial. The primary outcome of the trial was response to therapy based on 
palpation. Analysis showed that, at the end of therapy, patients with a palpation-
based progressive disease (PD) had a significant lower ER pathway activity at 
baseline (P=0.16) compared to patients with complete remission (CR; P=0.59), partial 
remission (PR; P=0.48) or stable disease (SD; P=0.53); mean PAI PD=-2.5 vs non-
PD=0.1, p-value=0.03 (Figure 3). Similar prognostic effects of ER pathway activity were 
shown at three months, as a measure of early response; p-value=0.038.
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ER pathway activity decreased in all six patients with complete remission, while 29% 
(two of seven) patients with partial remission and 38% (three of eight) of patients 
with stable disease showed an increase in ER activity. Most notably, the decrease in 
ER pathway activity was significantly higher in the combined CR/PR/SD group than 
in the PD group, whereas ER activity did not change significantly in the two patients 
with progressive disease (mean decrease in probability = 0.18 vs -0.002; PAI = -0.1 vs 
-3.2, paired t-test p-value=0.003) (Table 4). These observations are in accordance with 
the hypothesis that hormone therapy is only effective in patients with an active ER 
pathway and that success of response is associated with a decrease in ER pathway 
activity during treatment. 
Table 4:  Welsh two samples t-test for mean ER activity and mean decrease in ER activity during treatment for the 
TEAMIA cohort. ER pathway activity is presented as probability that the ER pathway is active (P) and as pathway 
activity index (PAI ). Evaluation is performed on baseline biopsies, post-treatment resection samples, and the 
difference between those timepoints. The response is evaluated by palpation and mammography at 3 months 
and at last therapy. CR: complete remission, PR: partial remission, SD: stable disease, PD: progressive disease; 
p-values were computed based on PAI data. 









Stratified by response assessed by palpation at 3 months
Baseline CR/PR/SD 27 0.53 (0.23) 0.14 (1.7) PD 3 0.17 (0.12) -2.5 (1.2) 0.04
Stratified by response assessed by palpation at last measurement
Baseline CR/PR/SD 35 0.53 (0.11) 0.13 (1.7) PD 3 0.16 (0.11) -2.5 (1.1) 0.03
Resection CR/PR/SD 37 0.31 (0.26) -1.7 (2.2) PD 3 0.08 (0.5) -3.8 (1.2) 0.07
Baseline-
Resection
CR/PR/SD 21 0.18 (2.28) 1.6 (2.2) PD 2 -0.002 (0.003) -0.02 (0.05) 0.003
Stratified by response assessed by mammography at 3 months
Baseline CR/PR 6 0.71 (0.17) 1.5 (1.2) SD/PD 12 0.44 (0.24) -0.49 (1.7) 0.015
Stratified by response assessed by mammography at last measurement
Baseline CR/PR 11 0.5 (0.31) -0.12 (2.3) SD/PD 13 0.48 (0.25) -0.28 (1.8) 0.86
Resection CR/PR 10 0.29 (0.26) -1.8 (2.4) SD/PD 12 0.28 (0.26) -2 (2.2) 0.85
Baseline-
Resection
CR/PR 6 0.18 (0.21 1.7 (2.4) SD/PD 7 0.21 (0.34) 1.7 (2.4) 0.99
Correlation with TEAM IIA outcome assessed by mammography
Since response based on mammography served as a secondary outcome in the 
TEAM IIA trial, mammography was not mandatory for every patient. Due to the 
lower number of available observations in the CR and PD categories, CR and PR were 
combined into a category of responders, whereas SD and PD were combined into a 
category of non-responders. At three months, responders and non-responders could 
be clearly separated, based on the ER activity at baseline (responders P=0.71 vs non-
responders P=0.44; PAI=1.5 vs 0.5, two samples t-test p-value=0.015). At 6 months 
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however, no distinction could be made (responders P=0.5 vs non-responders P=0.48; 
PAI=-0.1 vs -0.2, p-value=0.9). 
Clinical validation
In summary, we performed an ER pathway analysis in two distinct AI neoadjuvant 
settings: the first, a proof of principle, public Affymetrix dataset derived from a cohort 
of patients undergoing letrozole AI therapy for three months; the second, a trial 
cohort of patients that underwent 3 to 6 months exemestane AI therapy. Both cohorts 
where assessed using adapted ER pathway models based on the original Affymetrix 
ER pathway model 16. While the proof-of-concept dataset analysis used Affymetrix 
HGU133A gene expression data from fresh-frozen tissue, the TEAM IIA trial cohort 
analysis used RT-qPCR data from FFPE tissue obtained by LCM. Furthermore the two 
models used a different number target genes (27 vs. 12) and were calibrated using 
data from MCF7 cell cultures stimulated different estradiol concentration (6 nM vs. 
1 nM). 
Despite the differences between cohorts and methods, both analyses detected a 
significant decrease in ER pathway activity during AI treatment and indicated that the 
decrease in activity, as well as baseline ER pathway activity were significantly higher 
in responders than in non-responders, though response was assessed differently in 
the two studies. The proof-of-concept study defined response as a reduction in tumor 
size of at least 50% measured by ultrasound, while the TEAMII  A cohort adopted 
the RECIST 1.1 criteria (at least 30% tumor reduction) using response measured 
by palpation as primary outcome and measured using radiological modalities as 
secondary outcomes. 
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Figure 3: ER-pathway activity in patients of the TEAMIIA cohort stratified by response assessed by palpation at 
last measurement. Left: Line plots of ER-pathway activity at baseline and resection. Right: box plots of ER activity 
at baseline.  Red: complete remission, orange: partial remission, green: stable disease, blue: progressive disease. 
Solid lines: activity went down during treatment, dashed lines activity went up during treatment.
Discussion
Duration of treatment and resistance
In the GSE20181 cohort, a significant difference in ER pathway activity between 
baseline and both two weeks and three months of letrozole therapy, but not 
between two weeks and three months, indicating an early and maintained response. 
A remarkable finding is the observation that baseline ER pathway activity was 
predictive for therapy response as measured by mammography at three months, 
but not at six months of therapy. This difference may be explained by mechanisms 
of treatment resistance. During the course of endocrine therapy, over 20% of breast 
cancers are known to acquire resistance against aromatase inhibitor treatment due 
to activating mutations in the estrogen receptor, resulting in reactivation of the ER 
pathway driving tumor growth. Alternatively other signal transduction pathways, like 
the PI3K pathway may take the lead in driving tumor growth.11 
Another reason for loss of treatment effect during prolonged therapy, could be lower 
compliance at the end of therapy, resulting in reactivation of the ER pathway and the 
subsequent regrowth of the tumor. Although data on compliance are not available 
in this trial, it seems unlikely that non-compliance has occurred since patients were 
monitored closely during the trial. 
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Correlation with baseline parameters
The significantly higher baseline ER pathway activity in PR positive cases in the TEAM 
IIA cohort was expected, since PGR, the gene that codes for PR, is a target gene of 
the ER pathway. However, the decrease in ER pathway activity was not significantly 
higher in PR positive cases and the lack of correlation between baseline PR status and 
therapy response indicates that PR status by itself it is not sufficient to accurately infer 
pathway activation, or its deactivation in connection with AI therapy. 
Study limitations
Drawbacks of this study are the retrospective setting, the limited availability of 
sample with sufficient quality, and the lack of a reliable read-out for the primary 
and secondary clinical outcome, that is, reduction in tumor size. Although the entire 
TEAM IIA cohort comprises 102 patients, due to described logistical reasons only 
28 paired cases were available for analysis, limiting statistical power. Palpation was 
the primary outcome in this trial, whereas tumor reduction assessed by radiological 
imaging modalities was a secondary outcome, and therefore not performed in all 
patients. In addition, it is generally accepted that radiological evaluation using 
MRI in particular, may not be optimal in terms of accuracy for evaluation of therapy 
response in neo-adjuvant treatment of ER positive breast cancer.26, 27 In this specific 
cohort, a comparison of tumor size at resection versus its estimated size by palpation, 
mammography, US, and MRI suggested that palpation and mammography were the 
most accurate methods, while in many cases, various methods provided discordant 
results.28 Therefore only evaluations based on palpation and mammography were 
included in this analysis. 
Another point of concern is tumor heterogeneity. ER activity as measured in the 
biopsy setting may not be representative of the whole tumor, which could be a source 
of error in the analysis, and could explain why some patients with low baseline ER 
activity showed some response to treatment.
Future perspectives
Having comparable results from two distinct ER positive breast cancer cohorts, a 
validated Affymetrix gene expression dataset and a trial cohort with daily practice 
FFPE tissue samples for mRNA qPCR analysis, this study offers a robust clinical 
validation of the ER pathway model, developed by Verhaegh et al16, both when the 
full spectrum of target genes is measured using Affymetrix microarray on fresh tissue, 
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and when the selected subset of target genes is measured using multiple qPCR assays 
on FFPE material. 
Further prospective validation of the ER pathway model is necessary before this 
approach can be used in a routine clinical setting to predict endocrine therapy 
response. A  prospective study to validate the use of the ER pathway test to predict 
response to neo-adjuvant endocrine therapy is being planned as a side study in a 
CDK4/6 inhibitor clinical trial. This side study will investigate to which extent the ER 
pathway is capable of defining which patient benefits most from endocrine therapy 
alone, which patient should be offered a combination therapy with targeted agents 
such as CDK4/6 inhibitors, or which patient should be offered chemotherapy directly.
Upon extended clinical validation, our findings could lead to a new diagnostic test to 
quantify ER pathway activity in a cancer tissue sample, with clearly defined clinical 
utility, to be implemented in stratification of ER positive breast cancer patients. 
For example, some studies suggest that neo-adjuvant hormonal therapy is a good 
alternative for chemotherapy for specific forms of breast cancer.29, 30 Measuring ER 
pathway activity could be used to help decide on treatment course. Low baseline 
ER pathway activity wouldindicatea low chance of response to hormonal therapy, in 
which case chemotherapy could be indicated. In addition, in case hormonal therapy is 
selected, a second biopsy after one month of therapy to determine the remaining ER 
pathway activity could be implemented to assess therapy response. Persistent high 
levels of ER pathway activity could indicate resistance to therapy or non-compliance. 
This would lead to a tailored neo-adjuvant treatment with improved response 
monitoring, and a stepping stone towards personalized management of breast cancer.
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Background Tumour-infiltrating lymphocytes (TILs) have been shown to be prognostic 
for disease-free survival and predictive for the benefit of chemotherapy in patients 
with early breast cancer. The current study was performed to assess the predictive 
value of the number of CD8-positive TILs for the benefit of endocrine therapy with 
either tamoxifen or exemestane in two independent trial-cohorts. 
Methods The number of CD8-positive TILs was assessed in a cohort of 236 Dutch 
breast cancer patients in the Intergroup Exemestane Study. After initial 2-3 years 
of adjuvant tamoxifen, patients were randomized between continuation up to 5 
years with tamoxifen or switch to exemestane. The number of TILs was analysed 
for correlations with disease-free survival (DFS) and overall survival (OS). A similar 
analysis was performed on a cohort of 2596 Dutch patients in the TEAM trial who were 
randomized between the sequential scheme or exemestane monotherapy, for which 
follow-up was limited to the first 2.5 years in which treatments differed. 
Findings In the first cohort, patients with below median number of CD8-positive 
TILs had a hazard ratio (HR) for DFS of 0.27 (95%CI 0.13-0.55) in favour of treatment 
with exemestane as compared to tamoxifen, whereas this benefit was not observed 
in patients with above median number of TILs (HR 1.34, 95%CI 0.71-2.50, HR for 
interaction 5.02, p=0.001). In the second cohort, patients with below median number 
of CD8-positive TILs also showed a clinical benefit of exemestane treatment on 
recurrence-free survival (RFS HR 0.67, 95%CI 0.45-0.99), and again not with above 
median number of CD8-positive TILs (HR 0.86, 95%CI 0.59-1.26, HR for interaction 
1.29, p=0.36). 
Interpretation This study is the first to suggest the number of CD8-positive TILs as 
a potential predictive marker for endocrine therapy, with a low presence of CD8-
positive TILs associated to a benefit for exemestane-containing therapy. However 
treatment-by-marker interactions was only significant in one cohort, indicating the 
need for further validation.
Funding None.
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Approximately 75% of all breast cancer patients have estrogen receptor (ER)-
positive tumours, and are candidates for adjuvant endocrine treatment with either 
an aromatase inhibitor (AI) or the selective estrogen receptor modulator (SERM) 
tamoxifen. Among other studies, the phase III Intergroup Exemestane Study (IES), 
which randomized 4724 postmenopausal patients with early stage breast cancer 
after 2-3 years of tamoxifen therapy between either continuing on tamoxifen or to 
switch to exemestane to complete 5 years of endocrine therapy, showed a significantly 
improved disease-free survival (DFS) for a switch to exemestane after 2-3 years  of 
tamoxifen, compared to 5 years of tamoxifen monotherapy.1-4 A second study, the 
Tamoxifen Exemestane Adjuvant Multinational (TEAM) phase 3 trial, was performed 
to assess the benefit of 5 year exemestane monotherapy over the switch scheme, and 
showed no statistical differences in survival between both groups.5 
A recent meta-analysis in which both of the above studies are included showed that 
adjuvant therapy with 5 years of AI is superior to any 5 year treatment strategy with 
tamoxifen.6 However, the absolute differences in recurrence and overall survival 
are small (between 1% and 3% on overall survival at 10 years of follow-up6), leaving 
options for biomarkers able to stratify for the benefit of either AI or tamoxifen, or 
predict the need for therapy extension.7  Classic prognostic factors  like TNM-stage, 
tumour grade, and expressional status of hormone receptors or the human epidermal 
growth factor receptor 2 (HER2) do not predict which adjuvant endocrine treatment 
is best for which patient.5 
One of the factors that could act as a new prognostic or predictive biomarker may be 
derived from the immune system. The importance of the local immune system, in 
particular the role of tumour-infiltrating lymphocytes (TILs), on the outcome of (neo) 
adjuvant treatment of breast cancer has recently been validated.8-15 Cytotoxic (CD8-
positive) T-cells appear to play a major role in this phenomenon.9, 11 Most of the studies 
reported a clinical benefit for tumours with a higher infiltration of TILs, although 
this effect seems to be isolated to rapidly proliferating, ER-negative tumours.9-14 
Especially in triple negative tumours, TILs are a promising biomarker for the success 
of (neo)adjuvant chemotherapy.8, 15 However, no data are available which assesses the 
predictive value of TILs for endocrine treatment. 
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The aim of the current study was to determine the prognostic value of CD8-positive TILs 
in ER-positive breast cancer, and predictive value of CD8-positive TILs on the outcome 
of endocrine therapy with either tamoxifen or exemestane in two independent 
cohorts. For this, we evaluated the number of CD8-positive TILs in the Dutch subsets 
of the IES and TEAM trials, and used this for a stratified survival analysis for tumour 
recurrence and survival time of patients treated with either exemestane or tamoxifen. 
Material and methods
Patients and tumour tissues
IES trial
In the IES trial, 4724 patients, who were treated with surgery for early breast cancer 
and who were disease-free after 2-3 years of adjuvant treatment with tamoxifen, 
were randomized between either continuing tamoxifen up to 5 years, or to switch 
to exemestane to complete 5 years of therapy. For the Dutch fraction of this cohort 
(n=236), formalin-fixed paraffin-embedded (FFPE) tumour tissue was collected and 
was separately converted into a tissue microarray (TMA). This TMA was created as 
described earlier.16 Briefly, two 0.6mm core needle punches were obtained from the 
FFPE tumour blocks, and transplanted into an empty recipient block. Follow-up for 
disease free survival (DFS, defined as any local, regional or distant recurrence, new 
contralateral breast cancer or death due to any cause) and overall survival (OS) started 
at randomization after 2-3 years of tamoxifen treatment. For this analysis, follow-up 
data were used which were described earlier.4
TEAM trial
The TEAM trial consists of 9779 patients who were randomized for adjuvant treatment 
between the switch scheme (2.5 years tamoxifen followed by 2.5 years of exemestane) 
or 5 years of exemestane. FFPE tumour tissue was collected for the Dutch part of this 
trial (n=2596), and embedded in triplicate on a TMA with 0.6mm punches. Since 
both randomization arms were similar after the moment of switch, we censored the 
follow-up at 2.75 years (which was the middle between 2.5 and 3 years, the timeframe 
for patients in the switch group to switch to exemestane) in order to solely compare 
the differential effect of exemestane and tamoxifen. Beyond these 2.75 years, both 
treatment groups were treated with exemestane, which could interfere with the 
marker-by-treatment interaction. Due to the censoring at 2.75 years, only recurrence-
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free survival (RFS), defined as any breast cancer recurrence or death due to breast 
cancer if no recurrence was reported before death, was used as a parameter of clinical 
outcome in this study since this censoring did not allow sufficient time to have an 
effect on mortality outcomes. All samples of both cohorts were handled in a coded 
fashion, according to national ethical guidelines (‘‘Code for Proper Secondary Use of 
Human Tissue’’, Dutch Federation of Medical Scientific Societies).
Immunohistochemical staining
The procedures for the used immunohistochemical staining have been described 
before by our group in multiple different cohorts.10, 17 In short, 4 µm sections from 
FFPE TMA blocks were deparaffinised in xylene and subsequently hydrated using 
graded alcohol washes, before endogenous peroxidase was blocked using hydrogen 
peroxide. Antigen retrieval was performed at 95 degrees Celsius for 10 minutes in a pH 
low target retrieval solution (DAKO, Glostrup, Denmark). The sections were incubated 
overnight at room temperature with primary antibodies against CD8 (clone 144B, 
Abcam, Cambridge, UK) at a predetermined optimal dilution using proper positive 
and negative controls. After washing, the sections were incubated with specific 
horseradish peroxidase-labeled Envision+ System-HRP (DAKO) for 30 minutes, before 
they were stained using 3,3’-diaminobenzidine (DAB) solution (DAKO). Subsequently, 
the slides were counterstained for 30 seconds in haematoxylin, dehydrated using 
inverse graded alcohol washes and xylene, and mounted in Pertex before they were 
dried and stored until analysis.
Evaluation of immunohistochemical staining
Slides were scanned using an automated scanner (Philips, Eindhoven, Netherlands), 
and obtained digital images were stored on an internal server until analysis. Each 
punch, of which at least 30% of the total area were tumour cells, was individually 
assessed for the number of CD8-positive cells in the punch by a trained investigator. 
Results from duplicate (IES) or triplicate (TEAM) punches were then combined in 
order to determine the average score per patient. The median cohort value was used 
as a cut-off for dichotomous analysis for infiltrating cells. Since the evaluation in the 
TEAM trial was intended as a proof of principle and not as a formal validation, the 
median value of this second cohort was used as the cut-off for this second cohort. 
One-third of all measurements were scored by an independent second observer, and 
in case of disagreement about the dichotomous classification the punch was reviewed 
and discussed by both observers until agreement was reached. 




The study was a non-planned, retrospective, explorative project, for which all available 
cases were used without a predefined sample size calculation to detect a specific effect 
size or reach a certain level of power. ANOVA and post-hoc Bonferroni tests (corrected 
for multiple testing) were used to assess the mean number of CD8-positive TILs per 
subgroup. The kappa measurement for overall inter-observer agreement was used 
to assess the inter-observer variation for the dichotomized scores in one-third of all 
cases. Cox regression modelling was used to assess DFS and OS in the IES cohort, and 
RFS in the TEAM cohort, correct for possible confounders, and perform a treatment-
by-marker interaction test. Missing data were included in models when they were 
missing in more than 10% of cases. Kaplan-Meier curves and the corresponding Log-
rank tests were used to visualize these survival effects. Reverse Kaplan-Meier was 
used to determine the median follow-up duration. Furthermore, a post-hoc analysis 
was performed at which every threshold was tested to determine which cut-off point 
would lead to the most discriminate HR for interaction. All statistical analyses were 
performed using SPSS version 23 (IBM).
Role of the funding source
The original trials (IES and TEAM) were both funded by Pfizer, which had no role in 
this translational side study. There was no funding source for this study. The authors 
had full access to all the data and had the final responsibility for the decision to 
submit for publication.
Results
The Dutch IES-cohort consisted of 236 post-menopausal patients with early breast 
cancer (figure 1A). After creating the TMA, cores containing sufficient tumour tissue 
(>30%) were available from 190 patients. Patient and tumour characteristics are 
shown in table 1. The median age was 64 years (range 30–96 years). The median follow-
up was 10.1 years (range 0.49–11.34 years). No significant differences in the number 
of CD8-positive TILs were observed between clinicopathological subgroups (Table 1). 
The median number of CD8-positive cells per punch was 4, which is equivalent to 14 
cells/mm2.
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Table 1: The clinicopathological features of both cohorts are shown, including the mean number of CD8-positive 
TILs per punch for each subgroup. Statistical testing was performed using X2, ANOVA and post-hoc bonferroni 
testing. Each significant association is indicated by a separate character (a, b and c). No significant differences 
were observed between subgroups of both cohorts. 
  IES cohort patients CD8+ TILs TEAM cohort patients CD8+ TILs
n % Mean (n) n % Mean (n)
Age <50 3 1.6% 24 52 2.2% 9
50-59 60 31.6% 13 713 30.4% 17*a
60-69 60 31.6% 15 810 34.5% 16*b
>70 67 35.3% 13 770 32.8% 12*a,b
Histological 
subtype
ductal 132 69.5% 13 1758 78.7% 15
lobular 36 18.9% 15 368 16.5% 14
other 22 11.6% 18 109 4.9% 13




grade 1 14 13.6% 11 350 16.0% 10*a,b
grade 2 50 48.5% 11 1022 46.6% 15*b,c
grade 3 38 36.9% 12 820 37.4% 18*a,c
grade 4 1 1.0% 43 2 0.1% 37
missing 87 - - 151 - -
Tumor size 0-3 cm 134 73.2% 15 1833 78.5% 15
3-5 cm 38 20.8% 11 399 17.1% 14
>5 cm 11 6.0% 9 103 4.4% 16
  missing 7 - - 10 - -
Nodal status N0 56 30.3% 19 714 31.3% 17
1-3 N+ 90 48.6% 11 1172 51.4% 14
≥4 N+ 39 21.1% 9 394 17.3% 15
  missing 5 - - 65 - -
PgR expression 
(>10%)
no 36 21.6% 19 509 23.0% 17
yes 131 78.4% 13 1702 77.0% 15
  missing 23 - - 134 - -
HER2 expression no - - - 1991 88.4% 15*
yes - - - 261 11.6% 19*
  missing 190 - - 93 - -
Type of surgery wide local excision 83 46.1% 16 1039 44.3% 17
mastectomy 97 53.9% 12 1305 55.7% 14
  missing 10 - - 1 - -
Allocated 
treatment
Exemestane 94 49.5% 17 1187 50.6% 16
Tamoxifen 96 50.5% 11 1158 49.4% 15
*post-hoc bonferroni test <0.05 (each association is indicated by a separate character)
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Figure 1: Flowcharts of the used cohorts for this study. The Dutch part of the Intergroup Exemestane Study (IES) 
(A) and the Dutch part of the international TEAM trial (B) were assessed for the number of CD8-positive TILs and 
its predictive value for endocrine therapy.
In the TEAM cohort, tumour tissue of 2596 patients was stained and scored for the 
presence of CD8-positive TILs. Sufficient cores (a minimum of 2 cores, containing at 
least 30% tumour tissue) were available for 2345 patients (90%). Punches showing 
artefacts or lack of tumour cells in the punches were excluded from analysis. The 
median follow-up, as determined by reverse Kaplan Meier analysis, was 2.75 years 
(range 0-2.75). The distribution of clinicopathological subtypes was comparable to 
the IES cohort (table 1). A number of significant differences in the number of CD8-
positive TILs was observed between subgroups; patients above the age of 70 had a 
lower number of TILs compared to patients aged either 50-59 or 60-69 (Table 1). 
Furthermore, there was a significant association with tumour grade (more TILs with 
higher grade) and with HER2 expression (more TILs in HER2-positive tumours). 
The median number of CD8-positive TILs in this cohort was 6 per punch, which is 
equivalent to 20 cells/mm2.
In the IES cohort, there was no prognostic value in the number of CD8-positive TILs 
for the full population for either DFS or OS (figure 2A, B). One of the aims of this 
study was to show the predictive value of the number of CD8-positive TILs. Therefore, 
we stratified the survival analysis on the number of CD8-positive TILs (table 2). It 
was shown that patients having a below-median number of CD8-positive TILs had 
a significantly better DFS when treated with exemestane after earlier tamoxifen 
compared to tamoxifen monotherapy (figure 3A). In 97 patients with a below-median 
number of CD8-positive TILs, 10 out of 45 patients on exemestane experienced a 
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DFS-event, whereas 31 out of 52 patients allocated to tamoxifen encountered a DFS-
event.  Univariate cox regression showed a hazard ratio (HR) for DFS of 0.27 (95% 
CI 0.13-0.55, p<0.001) in favour of exemestane treatment in these patients, with an 
adjusted HR (corrected for age, histological subtype, tumour size, lymph node status, 
tumour grade and PgR-status) of 0.35 (95% CI 0.16-0.78) (table 2). In contrast, in 
patients with above median numbers of CD8-positive TILs there was no significant 
difference in benefit of either therapy (events: 23 out of 49 on exemestane, 17 out of 
44 patients on tamoxifen) with a HR of 1.34 (95% CI 0.71-2.50, p=0.36) and an adjusted 
HR of 1.21 (95% CI 0.58-2.51, p=0.97) (figure 2B). The HR for treatment-by-marker 
interaction between these groups was 5.02 (95% CI 1.93-13.02 p=0.001), showing that 
the difference in treatment effect between the two marker groups was statistically 
significant. Although underpowered due to the small cohort size and relative low 
numbers of events, the adjusted HR for interaction was 3.34 (95% CI 1.17-9.56, p=0.02) 
when corrected for age, histological subtype, tumour size, lymph node status, tumour 
grade and PgR-status.
Figure 2: The general prognostic effect of CD8-positive TILs on either RFS (left) or OS (right) for all (ER-positive) 
patients using Kaplan-Meier survival analysis. The number of CD8-positive TILs was stratified in low (below 
median) and high (above median) by the median value. Event rates are provided in the graph, numbers at risk 
below the graph. P-values were determined using a Log-rank test.
Similar results were shown for overall survival, where a statistically significant benefit 
was shown for patients with a below median number of CD8-positive TILs when 
treated with the switch scheme. In 97 patients with a below-median number of CD8-
positive TILs, 9 out of 45 patients on exemestane had died at the end of follow-up, 
whereas 23 out of 52 patients allocated to tamoxifen were not alive at the end of 
follow-up (HR 0.38, 95% CI 0.17-0.82, p=0.014; adjusted HR 0.48, 95% CI 0.19-1.18, 
p=0.15). In patients with an above median number of CD8-positive TILs there was no 
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difference (HR 1.13, 95% CI 0.56-2.30, p=0.73; adjusted HR 1.07, 95% CI 0.46-2.49, 
p=0.78), with 17 out of 49 patients died on exemestane and 14 out of 44 patients 
died on tamoxifen (figure 3C, D). Also for overall survival, a significant treatment-by-
marker interaction was observed (HR for interaction 3.01, 95% CI 1.05-8.58, p=0.04). 
The (underpowered) adjusted HR for interaction was 2.43 (95% CI 0.75-7.88, p=0.14).
Figure 3: The predictive value of CD8-positive TILs on endocrine therapy in the IES cohort using Kaplan-Meier 
survival analysis. Patients with below median (low) numbers of CD8-positive TILs are shown in the left graphs 
(RFS above OS), patients with above median (high) numbers of CD8-positive TILs in the right graphs. Event rates 
are provided in the graph, numbers at risk below the graph. P-values were determined using a Log-rank test.
In a post-hoc analysis, it was established that the median value of 4 cells per punch 
(14 cells/mm2) was close to the optimal threshold level of 3 cells per punch (11 cells/ 
mm2), which would have resulted in the highest predictive effect of CD8-positive TILs 
(supplemental figure 1) in the Dutch IES cohort. 
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Supplemental figure 1: A graph showing the HR for interaction (blue line, right y-axis) and 1/p-value (green line, 
left y-axis) for all cut-off values of the CD8-positive cell count, in order to determine the optimal cut-off value. The 
x-axis shows all possible cut-off points (cells/punch) to divide the number of CD8-positive TILs in two groups. The 
solid vertical line represents the optimal cut-off value of 3 cells per punch (highest HR for interaction and highest 
1/p-value), whereas the dashed line represents the median value which is used as cut-off value for this study.
In order to further explore the observed interaction between the outcome of endocrine 
therapy and the number of CD8-positive TILs, a similar analysis was performed in the 
Dutch TEAM-cohort. Only the first 2.75 years of follow-up were considered for survival 
analysis, since after this timepoint patients in both groups received exemestane 
which would diminish any biological interaction. 
It was established that also in this cohort, the number of TILs had no prognostic 
effect on recurrence either censored at 2.75 years (HR 0.91, 95% CI 0.69-1.19, p=0.47) 
or at full length of follow-up (HR 1.0, 95% CI 0.85-1.18 p=0.97). With regard to the 
predictive value, it was shown that patients with a below-median number of CD8-
positive TILs, had a HR for tumour recurrence of 0.67 (95% CI 0.45-0.99, p=0.048) in 
favour of exemestane treatment, whereas patients with above median numbers of 
CD8-positive TILs had a HR of 0·86 (95% CI 0.59-1.26, p=0.44), which was similar to 
the findings of the first cohort (figure 4A, B). The adjusted HRs were not significant 
in either the CD8-low or CD8-high group (low numbers of CD8-positive TILs: 0.71, 
95% CI 0.47-1.07, p=0.10; high numbers of CD8-positive TILs: 0.82, 95% CI 0.56-1.21, 
p=0.32). The treatment by marker interaction was not significant in this cohort (HR 
for interaction 1.29, 95% CI 0.75-2.22, p=0.36, adjusted HR for interaction 1.20, 95% CI 
0.68-2.11, p=0.52). 
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Figure 4: The predictive value of CD8-positive TILs on endocrine therapy in the TEAM cohort using Kaplan-Meier 
survival analysis, stratified on the median number of CD8-positive TILs. Patients with below median (low) 
numbers of CD8-positive TILs are shown on the left, and patients with above median (high) numbers of TILs on 
the right. Inserts show a more detailed graph with a range of 80-100% survival. Event rates are provided in the 
graph, numbers at risk below the graph. P-values were determined using a Log-rank test.
Discussion
This study is the first to investigate TILs as a predictive biomarker for the type of 
adjuvant endocrine therapy in postmenopausal patients with early breast cancer. In 
the first IES cohort, patients with a low number of CD8-positive TILs had significantly 
greater treatment benefit from aromatase inhibitors (AIs) than from tamoxifen, 
whereas the type of therapy did not make any difference in patients with high 
numbers of TILs. The treatment by marker interaction, comparing the clinical benefit 
in both subgroups, was significant despite the low number of events in this analysis, 
suggesting a predictive capacity of TILs for endocrine therapy. In the second TEAM 
cohort, it was similarly suggested that patients with low levels of CD8-positive TILs 
had greater treatment benefit from exemestane. However, the treatment-by-marker 
interaction in this cohort was not significant, indicating that the benefit of exemestane 
in the CD8-low group was not significantly different from the benefit in the CD8-high 
subgroup. 
The difference in significance between both cohorts can be explained by several 
factors. First, the IES cohort was smaller, and thereby underpowered for definite 
conclusions since it is more sensitive for random variation and artefactual findings. 
Secondly, all patients in the IES cohort were pre-treated with 2-3 years of tamoxifen, 
whereas the TEAM patients were treatment-naïve at the time of randomization. This 
pre-treatment, and the subsequent carry-over effect known from tamoxifen, could 
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have influenced the differences between both cohorts. Finally, in the TEAM cohort 
the follow-up was censored to 2.75 years, which limited the number of events and 
therefore hampered the power for survival and interaction analysis. In contrast, the 
analysis in the IES cohort started at 2-3 years after diagnosis, and was continued up 
to almost 12 years post-diagnosis. This difference in follow-up periods could have 
influenced the comparison between both cohorts as well.
Earlier studies showed that TILs have no prognostic value in ER-positive disease.11, 14 
We confirmed these findings in both of our cohorts, showing that the number of CD8-
positive TILs on itself had no prognostic value in both ER-positive cohorts. Interestingly, 
the suggestion that treatment with exemestane could be particularly beneficial for 
patients with a low number of infiltrating CD8-positive T-cells as suggested by some 
of our results has never been shown before in a trial-based translational study. 
The mechanism behind the possible better effect of aromatase inhibitors in case of low 
levels of CD8 positive cells is unknown yet. Various hypothesis can be made. In accordance 
to our findings, one earlier study has suggested that the effect of AIs is dependent on 
immune suppression rather than activation.18 In this study, Dunbier et al. obtained 81 
paired samples before and after two weeks of neo-adjuvant anastrozole, and performed 
a multigene expression profile of these samples. In total, 1327 genes were differentially 
expressed. Although the gene expression changes varied greatly between all patients, 
it was observed that a higher baseline expression of pro-inflammatory genes correlated 
to a poor therapeutical effect of anastrozole. Upon further analysis by a pathologist, it 
was shown that lymphocytic infiltration correlated to a poorer therapeutical response 
to AIs, which was similarly observed by Tsang et al.18, 19 Further on, Gao et al. validated 
these findings by showing that a high expression of genes associated with immune 
reaction predicted a poor response to endocrine therapy.20
Aromatase inhibitors might also play a role in modulating the local immune response. 
For example, according to the study of Generali et al., aromatase inhibitors are capable 
of lowering the number of tumour-infiltrating regulatory T-cells, and thereby may 
improve treatment outcome.21 Similar results were shown by Chan et al., who studied 
the ratio of cytotoxic T-cells and regulatory T-cells during neoadjuvant endocrine 
treatment and observed a significant increase of this ratio in responders, as opposed to 
non-responders.22 Moreover aromatase inhibitors have been shown to enhance cytokine 
excretion and the severity of experimental polyarthritis in murine models, indicating 
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an activation of the immune system.23 Furthermore, auto-immune conditions have 
been suggested as a contributing factor to often reported arthralgia.24 Based on these 
abovementioned findings, it could be hypothesized that aromatase inhibitors exert 
part of their function by activating both the systemic and the local immune response. 
Therefore, patients with a weaker local immune response at baseline will benefit 
more from AIs, since the immunomodulation will yield more effect in those patients 
compared to patients who already have a strong local immune response.
Another theory for explaining the possible differential effect of AIs and tamoxifen 
between TIL-rich and TIL-poor tumours, is that the number of infiltrating CD8+ 
TILs is a proxy variable for another tumour characteristic, which might be the 
mutational load. Earlier, it was established that the mutational load in the tumour, 
and therefore the number of neo-epitopes, is associated with the local immune 
response.25 Furthermore, it has been shown that more aggressive Luminal B-type 
tumours, which are generally considered less responsive to endocrine therapy, have 
a higher mutational load compared to the more responsive Luminal A subtype.26, 27 
Hypothetically, tumours with a lower mutational load might be more dependent 
on ER-pathway signalling since they are less likely to acquire activating mutations 
in other oncogenes, whereas tumours with a higher mutational load have activated 
other growth stimulating pathways and are therefore less dependent on ER-signalling 
for their survival. These results suggest that AIs would be the most optimal strategy 
for strongly ER-dependent (lower mutational load) tumours, whereas tamoxifen and 
AIs are equally good for less ER-dependent tumours. 
In summary, the current study provides the first suggestion that the number of CD8-
positive TILs could be used as a predictive marker in the endocrine treatment of 
breast cancer. Upon further validation in a trial with a similar design as IES in which 
tamoxifen monotherapy is compared to an AI-containing regime, patients with low 
numbers of CD8-positive TILs could have more benefit from AIs than from tamoxifen, 
whereas patients with a strong infiltration of CD8-positive TILs have a similar outcome 
on both treatment strategies. Future studies will be directed towards validation of 
these findings for other aromatase inhibitors, to show whether the results observed 
for exemestane can be extrapolated to letrozole or anastrozole as well. Our findings 
might contribute to a more optimized treatment of hormone-receptor-positive 
breast cancer using the local immune system as a predictive biomarker for adjuvant 
endocrine therapy.
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Multiple studies showed the prognostic capacities of tumor-infiltrating lymphocytes 
(TILs) in triple-negative breast cancer (TNBC), but not in other subtypes. We 
evaluated tumor expression of FAS, a key receptor in T-cell mediated apoptosis, as 
possible explanation for this differential prognostic value of TILs. Furthermore, we 
evaluated the prognostic relevance of FAS, both as an independent biomarker and 
in relation to CD8-positive T-cell presence. The study cohort consisted of 667 breast 
cancer patients treated in the LUMC between 1997 and 2009. FAS expression was 
determined using immunohistochemistry and the percentage of FAS-positive tumor 
cells was quantified. Furthermore, the number of CD8-positive infiltrating cells was 
determined, and its prognostic relevance was associated to FAS-expression using 
stratified survival analysis. In TNBC, FAS was averagely expressed in 49% of tumor 
cells, whereas ER-positive subtypes showed an average Fas expression of 16-20%. In 
the entire cohort, FAS was identified as significant prognostic marker for recurrence 
(adjusted HR 0.53, 95% CI 0.36-0.77) and borderline significant marker for overall 
survival (adjusted HR 0.72, 95% CI 0.52-1.01). Upon stratification for FAS-expression, 
CD8+ TILs were only prognostic at high levels (above median) of FAS expression in 
ER-negative disease. In summary, FAS was identified as an independent prognostic 
marker for recurrence free survival in breast cancer, with large variation in expression 
by receptor subtypes. Interestingly, the prognostic effect of CD8+ TILs in ER-negative 
disease was only valid for tumors with a high FAS expression. 
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For decades the local immune response, among others represented by quantification 
of tumor-infiltrating lymphocytes (TILs), has been studied in breast cancer.1-3 Although 
most studies observed a prognostic value of TILs, these studies have not resulted in 
any change in clinical practice. Studies have shown TILs to have strong prognostic 
impact in ER-negative, HER2-negative and triple negative breast cancer (TNBC), but 
not in ER-positive tumors.4-14 In a recent meta-analysis by Ibrahim et al combining 
the results of 8 studies, a 30% reduction in disease recurrences and a 22% decrease 
in distant recurrences was shown for triple-negative patients having high amounts 
of TILs.14 Furthermore, a hazard ratio 0.66 (95% CI 0.53-0.83) for overall survival was 
shown for these patients, providing robust evidence for the prognostic value of TILs. 
It is known that although TILs might be present in the tumor, their functioning might 
be hampered 3. One of the most studied factors involved is classical HLA class I, which 
was shown to be downregulated in breast cancer and other malignancies.15, 16 Another 
protein on tumor cells that determines function of T cells is Fas cell surface death 
receptor, abbreviated as FAS. FAS is broadly expressed on most normal tissue, and 
is a crucial link between T-cell mediated immunity and induction of apoptosis.17, 18 
When a cytotoxic T-cell binds to a target cell, FAS-ligand (FASL) is upregulated by the 
T-cell. FASL subsequently binds to the target cell-expressed FAS, thereby initiating the 
activation of a caspase cascade leading to apoptosis of the target cell. Together with 
perforin-induced apoptosis, these are the two main mechanisms by which a cytotoxic 
T-cell can induce apoptosis.19, 20 It could be hypothesized that downregulation of 
FAS is a mechanism of tumor immune evasion, since this disables a crucial step in 
T-cell mediated immunity. Therefore, tumor expression of FAS could act as a clinical 
prognostic marker in breast cancer.
Hypothetically, the expression of FASL by tumor cells could lead to induction of 
apoptosis in the cytotoxic T-cells which could be a second method of FAS-FASL-
mediated immune evasion. A number of studies have been performed evaluating the 
prognostic relevance of FAS and FASL in breast cancer, focusing mainly on the FASL/
FAS ratio.21-23 These studies indeed reported that a higher tumor expression of FASL 
and/or a lower expression of FAS, resulting in an increased FASL/FAS ratio, associated 
with a worse disease free and overall survival.21 Other studies reported that this 
was mainly due to an increase in FAS-expression, whereas FASL did not influence 
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outcome.23 Furthermore, the theory of immune evasion by upregulation of FASL in the 
tumor has never been shown in vivo.24 Therefore, it is expected that most effects seen 
for the FASL/FAS ratio in tumors are attributed to a downregulation of FAS.
Although TILs have shown to be of prognostic relevance, it is highly unlikely that the TILs 
in the primary tumor will determine survival outcome. Most likely the amount of TILs in 
the primary tumor is a proxy variable for a yet undefined tumor characteristic, making 
the tumor more or less susceptible for an immune response. This process could lead to 
an aberrant pattern of metastasizing, or an effect on growth speed of the metastasis. 
When FAS is differentially expressed among different tumor subtypes, it could be 
hypothesized that FAS is a key explanatory factor for the fact that TILs are prognostic 
in one subgroup, but not in other subgroups. Furthermore, combining recent evidence 
regarding TILs in TNBC with the earlier evidence on FAS expression, we suggest that FAS 
is a clinical prognostic in breast cancer as an independent alternative for TILs. 
Therefore, three main aims of this study are identified: To evaluate the expression of 
FAS among different tumor subtypes in order to explain variances in the prognostic 
value of TILs. The second aim is to evaluate the expression of FAS as a prognostic 
marker in breast cancer, both in general and in selected subtypes. Finally, the third aim 
of this study was to evaluate the prognostic value of CD8 in the presence or absence of 
FAS-expression, since we hypothesize that CD8-positive T-cells will only be prognostic 
in the presence of tumor FAS expression.
Results
Baseline characteristics
667 patients were included in this observational cohort of patients treated in the 
LUMC (Table 1). Most tumors were categorized as ductal carcinomas (80,8%); 10,2% 
were determined to be lobular carcinoma. Approximately 75% of the tumors showed 
ER positivity, 55% PR positivity and 25% HER2 positivity. For HER2 expression, nearly 
50% of the records was missing. Missing of these data was strongly correlated to the 
year of diagnosis. Before 2003, 89% of HER2 scores was missing (322 of 360 patients), 
whereas from 2003 onwards it was only missing in 5% of patients (14 of 307 patients). 
The percentage of triple negative tumors was 16%, whereas ER+PR+HER2- was the 
most prevalent subtype with 42%. The majority of tumors were small and early stage 
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(stage II or lower), only approximately 10% was stage III or IV. Most patients (91,8%) 
did not receive neoadjuvant systemic therapy. These percentages show that the 
cohort is representative for the general breast cancer population.
FAS-expression
From the 667 patients included in this observational cohort, immunohistochemical 
staining for FAS expression was successful for 640 patients. 27 patients were excluded 
due to a lack of tumor tissue on the TMA, either as an artefact or because only non-
tumorous tissue was included on the TMA (Figure 1). In the remaining 640 patients, 
FAS expression was observed ranging from 0% to 100% of the tumor cells, with a 
median expression of 13.3% (Figure 2). The correlations with baseline characteristics 
are shown in Table 1. A small difference in FAS expression was shown for age, in which 
younger (<40 years) patients showed a higher expression of FAS, whereas patients 
between 60 and 69 showed a slightly lower FAS-expression (column proportion test 
p-value <0.05). No associations were found for histological subtype or tumor stage. It 
was observed that grade 3 tumors had a significantly higher FAS expression compared 
to grade 1 and 2. ER-negative tumors showed almost a doubling of the average 
expression of FAS compared to ER-positive tumors (37% vs 19% FAS-positive tumor 
cells per sample, p<0.05)). For HER2, limited data were available (n=320), showing no 
statistical differences. Combining ER, PR and HER2, it was shown that triple negative 
tumors showed significantly higher FAS-expression (average of 49% positive tumor 
cells) compared to the other subtypes (Bonferroni multiple comparisons test p-values 
<0.001), especially ER-positive subtypes (FAS expression ranging from 16% to 18% 
positive tumor cells) (Figure 3). Pre-treatment with either neo-adjuvant chemotherapy 
or endocrine therapy was not associated with different FAS-expression patterns.
In the provisional TCGA dataset, levels of FAS expression were compared to the 
expression of ESR1, the gene encoding for ER. We observed a Pearson correlation of 
-0.35, meaning that a higher FAS expression is correlated to a lower expression of ER. 
This is in accordance with our findings that in ER-negative tumors, there is a higher 
FAS expression. To supplement these findings, we analyzed the TCGA dataset as 
published in Nature in 2012, for which more clinical data are available.25 In this cohort, 
we observed that of the 14 patients who have an upregulation of FAS at transcriptional 
mRNA level , 13 of them are ER-negative and for one patient ER-staining was not 
performed. In contrast, of the 17 patients with a downregulation of FAS, 13 were ER-
positive. This further validated our finding, that high levels of FAS are associated to 
low levels of ER-expression, both at transcriptional and protein level.
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Figure 1 – Consort diagram of the included patients, which were present on the TMA, for analysis. The causes for 
missing samples were a lack of tumor in the punches or artefacts like folded or missing parts of the punches.
FAS-expression as clinical prognostic marker
To evaluate the clinical prognostic value of FAS-expression, Kaplan Meier curves were 
plotted for the general study population (Figure 4A,B). It was shown that a high FAS 
expression correlated with a longer recurrence free and overall survival time (log-
rank p-values of 0.009 and 0.02 respectively) in the entire cohort. In a univariate 
cox-regression analysis, a hazard ratio of 0.65 (95% CI 0.47-0.90, p=0.01) and 0.72 
(95% CI 0.55-0.95, p=0.02) was seen for RFS and OS respectively. In a multivariate cox 
regression analysis, corrected for age, histological subtype, tumor grade, tumor stage, 
ER-expression, year of diagnosis, neo-adjuvant treatment, adjuvant chemotherapy, 
and adjuvant endocrine therapy, an adjusted HR of 0.53 (95% CI 0.36-0.77, p=0.001) 
was seen for RFS. For OS, an adjusted HR of 0.72 was observed, with a borderline 
significance (95% CI 0.52-1.01, p=0.055).
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Figure 2 – Representative examples of immunohistochemical staining for FAS expression and CD8-positive TILs 
(10x magnification). The FAS-negative sample only contains some FAS-positive infiltrating lymphocytes (A), 
whereas the FAS-positive sample shows homogenous membranous FAS expression in the tumor cells (B). The 
CD8-low sample showed no infiltration of CD8-positive TILs (C), whereas the CD8-high sample shows large 
numbers of CD8-positive TILs (D).
Figure 3 – The average percentage of FAS expressing tumor cells, as determined by immunohistochemical 
staining, according to molecular subtypes. *Significantly different from all other individual subgroups using 
Bonferroni’s multiple comparisons test (all adjusted p-values <0.001). ** Unpaired t-test p-value <0.001
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Figure 4 – Kaplan Meier survival estimates based on immunohistochemical FAS expression both for recurrence 
free survival (A) and overall survival (B). Furthermore, the prognostic effect of CD8-positive TILs is shown in both 
ER-negative (C. RFS, D. OS) and ER-positive tumors (E. RFS, F. OS). P-values represent log-rank survival test.
Upon stratification on ER-expression, it was shown that both in ER-negative (HR 0.48, 
95% CI 0.27-0.86, p=0.01) and ER-positive (HR 0.65, 95% CI 0.43-0.97, p=0.04) tumors, 
FAS expression was prognostic for RFS (Supplemental fig S2A,B). In multivariate 
analysis, a HR of 0.36 (95% CI 0.17-0.76, p=0.01) was shown in ER-negative tumors, 
whereas a HR of 0.58 (95% CI 0.37-0.90, p=0.02) was shown for ER-positive tumors. 
For OS, no statistical significant differences regarding level of FAS expression were 
shown for ER-negative tumors in univariate (HR 0.78, 95% CI 0.45-1.35, p=0.38) or 
multivariate (HR 0.65, 95% CI 0.33-1.30, p=0.23) modelling (Supplemental fig S2C). 
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In ER-positive tumors, a strong benefit of FAS-expression was shown for OS (HR 0.59, 
95% CI0.42-0.83, p=0.003), but this failed to show in multivariate analysis (HR 0.76, 
95% CI 0.52-1.12, p=0.16) (Supplemental fig S2D). No significant interaction between 
ER-status and FAS-expression was observed for either RFS or OS (HRs 0.70 (p=0.32) 
and 1.15 (p=0.66) respectively), meaning that the effect of FAS expression on survival 
is not significantly different between ER-negative and ER-positive patients.
In summary, an above median level of FAS expression was a statistically significant 
independent prognostic marker for RFS, and a borderline significant prognostic 
marker for OS. Both effects were conserved in ER-negative and ER-positive tumors.
Supplementary Figure 2: The prognostic effect of FAS expression, stratified on ER-status. The effect is conserved 
in both ER-negative A, C. and ER-positive tumors B, D. for both RFS and OS. P-values represent log-rank survival 
test.
CD8+ lymphocyte infiltration
For the evaluation of CD8+ tumor infiltrating lymphocytes (TILs), TILs were counted 
in both the tumor and the directly adjacent stromal tissue, only when the punch 
contained tumor tissue. Therefore, 27 cases were excluded due to artefacts (missing 
punches) or a lack of tumor tissue in the sample. For the remaining 640 patients, the 
number of CD8+ TILs ranged from 0 to 369, with a median value of 28 per punch (1mm). 
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The distribution of CD8+ TIL infiltration over basic clinicopathological subgroups is 
shown in Table 1. Young patients (<40 and 40-49) showed an increased amount of 
infiltration compared to other age categories. Furthermore, ER-negative and grade 3 
tumors showed increased rates of infiltration. 
Over the whole cohort, CD8+ TILs showed no correlation with RFS (HR 1.16, 95% 
CI 0.84-1.60, p=0.36) (Supplementary Fig. S1A). However, when corrected for age, 
histological subtype, tumor grade, tumor stage, ER-expression, year of diagnosis, 
neo-adjuvant treatment, adjuvant chemotherapy, and adjuvant endocrine therapy, 
an adjusted HR of 0.55 (95% CI 0.37-0.81, p=0.003) was observed for RFS for patients 
with an above-median level of CD8+ TILs. Similar effects were shown for OS (HR 1.23, 
95% CI 0.94-1.62, p=0.14; adjusted HR 0.78, 95% CI 0.56-1.10, p=0.16), although not 
statistically significant (Supplementary Fig. S1B).
Supplementary Figure 1: Kaplan Meier survival analysis, comparing groups with either low or high presence of 
CD8-positive TILs in the general study population for either RFS A. or OS B. P-values represent log-rank survival 
test.
In earlier studies, it was observed that CD8+ TILs were only prognostic in ER-negative 
or triple negative breast cancer.4 Upon stratification on ER-expression, similar results 
were observed in this cohort (Figure 4C-F). In ER-positive patients, high levels of CD8+ 
TILs were associated with a HR for recurrence of 1.03 (95% CI 0.69-1.54, p=0.88), 
whereas in ER-negative disease a HR of 0.42 (95% CI 0.23-0.76, p=0.004) was observed 
(HR for interaction 2.64, p=0.007). A similar pattern was observed for OS (ER+ HR 
0.86, 95% CI 0.61-1.21, p=0.39; ER- HR 0.48, 95% CI 0.28-0.81, p=0.007). 
Combined FAS-CD8 analysis
In order to determine the hypothesized pivotal effect of FAS expression on the 
function, and therefore prognostic effect of CD8+ TILs, a survival analysis was 
performed on the presence of CD8+ lymphocytes, stratified on FAS expression.  In the 
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complete cohort, there was no difference between the prognostic relevance of CD8 
TILs for either high or low expression of FAS on RFS (HR for interaction 1.51, p=0.24) or 
OS (HR for interaction 1.24, p=0.45).
Upon stratification on ER expression, a similar analysis was performed. In ER-negative 
disease, it was shown that CD8 was prognostic for RFS in the presence of high FAS 
expression (HR 0.42, 95% CI 0.19-0.96, p=0.04), but not with low FAS expression 
(HR 0.54, 95% CI 0.23-1.29, p=0.17), with a HR for interaction of 0.80, (p=0.71) (Figure 
5A,B). In ER-positive disease, CD8 was reversely prognostic for RFS with at high levels 
of FAS expression (HR 2.01, 95% CI 1.01-4.04, p=0.05) and not prognostic at low FAS 
expression (HR 0.80, 95% CI0.46-1.39, p=0.43), with a HR for interaction of 2.42, p=0.05 
(Figure 5C,D). For OS, a similar pattern was observed (ER-negative, high FAS: HR 0.49 
(95% CI 0.25-0.97, p=0.04), ER-negative, low FAS: HR 0.51 (95% CI 0.20-1.26, p=0.14) 
(Supplementary Fig. S3A,B); ER-positive, high FAS: HR 1.22 (95% CI 0.70-2.12, p=0.48), 
ER-positive, low FAS: HR 0.78 (95% CI  0.48-1.25, p=0.30) (Supplementary Fig. S3C,D). In 
summary, CD8+ TILs were only prognostic for both RFS and OS in ER-negative tumors at 
high levels of FAS, but not in tumors with low expression of FAS or in ER+ tumors.
Figure 5 - Kaplan Meier survival estimates based on CD8+ tumor infiltrating lymphocytes (TILs) stratified on FAS 
expression in both ER-negative and ER-positive tumors. In patients with ER-negative tumors with high FAS 
expression, the high presence of CD8-positive is prognostic for a significantly higher survival (A). This prognostic 
effect is not observed in ER-negative tumors with low FAS expression (B), nor in ER-positive tumors (C, D). 
P-values represent log-rank survival test.
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Supplementary Figure 3: The effect of CD8+ TILs on overall survival, stratified on both ER-status and FAS 
expression. In ER-negative tumors with high FAS expression, there is a significant benefit on OS of high CD8+ TIL 
presence, which is not observed in tumors with low FAS expression B. Furthermore, this effect is not shown in 
ER-positive tumors, either with high. C. or low D. FAS expression.
Discussion
This study is the first study to determine the influence of the immune-editing protein 
FAS on the prognostic value of TILs. Our studies shows that besides ER-negative status, 
also a positive FAS-status is required for CD8+ TILs to be prognostic in breast cancer.
Furthermore, we assess the value of FAS as an independent prognostic marker. It was 
shown that patients with a higher FAS-expression have a longer recurrence free and 
overall survival, even when corrected for age, histological subtype, tumor grade, tumor 
stage, ER-status, year of diagnosis, neo-adjuvant treatment, adjuvant chemotherapy 
and adjuvant endocrine therapy. This indicates that, irrespective of the amount of 
TILs, FAS serves as a prognostic marker. In our subgroup analysis, we confirmed that 
this effect was conserved in both ER-negative and ER-positive disease for recurrence 
free survival, but not for overall survival. 
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We also observed that FAS was expressed in nearly twice as much tumor cells in ER-
negative tumors, compared to ER-positive tumors, which also explains the higher 
expression of FAS in younger patients, since those are more often ER-negative.26 Even 
more, triple negative tumors had more than twice as much FAS-positive tumor cells 
compared to ER-positive tumors. This difference in FAS expression might explain 
the observation in earlier studies that infiltrating lymphocytes are only prognostic 
in ER-negative or triple negative tumors.4 Since T-cell mediated immunity depends 
on FAS-expression of the target cell, a higher expression of FAS as observed in TNBC 
may render the cells more susceptible for infiltrating T-cells. With lower amounts of 
FAS-expression, as observed in ER-positive disease, infiltrating T-cells may have less 
possibilities to induce apoptosis, and will therefore be much less or even not prognostic 
since their functioning will be hampered. This explains why in ER-positive disease 
there is no additional value of CD8+ TILs over the prognostic value of FAS. However, 
we observed that in ER-positive tumors with high expression of FAS, there was even 
a significant negative effect of CD8-positive TILs on survival. This indicates that 
there is a FAS-independent, unknown factor which prevents CD8-positive TILs from 
functioning in ER-positive breast cancer Furthermore, since FAS itself is prognostic in 
ER-positive breast cancer, it indicates that there are more anti-tumor mechanisms of 
FAS expression besides the T-cell mediated immunity, which were described in detail 
earlier.27 These mechanisms could have contributed to the favorable prognostic effect 
of FAS expression on clinical survival. 
In ER-negative disease, it was observed that CD8+ TILs were only prognostic in the 
presence of high FAS expression, confirming the pivotal role of FAS in T-cell mediated 
immunity. Recently, immunotherapy has gained many interest in different fields of 
oncology, including breast cancer.28, 29 These therapies are based on targeted agents 
(e.g. PD1 or PDL1 inhibitors), which enhance the immune response against the 
tumor.30 We observed that TILs are only prognostic, and therefore perhaps are only 
functional, in the presence of FAS expression in ER-negative breast cancer. It could be 
hypothesized that FAS expression might therefore act as a predictive factor for these 
new emerging therapies. 
Due to the retrospective, observational design of the cohort, there are some limitations 
to this study. First, HER2 was missing in nearly half of all patients based on the year 
of diagnosis, limiting the power for HER2-specific subgroup analyses). Therefore the 
year of diagnosis could have acted as a confounder, influencing both HER2-expression 
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and outcome. To overcome this confounding, the year of diagnosis was included as a 
corrective factor in multivariate analysis. Furthermore, since including HER2 in the 
multivariate model would lead to a skewed cohort only consisting of patients diagnosed 
after 2003, HER2 was not included as a corrective factor in multivariate analysis.
In summary, this study is the first study reporting a differential expression of FAS 
among tumors with different receptor subtypes; TNBC shows nearly twice as much 
expression compared to other subtypes. Furthermore, we showed that FAS is an 
independent prognostic marker in breast cancer, independent from estrogen receptor 
status or other possibly confounding factors. Finally, we showed that in ER-negative 
disease, FAS expression is necessary for the prognostic effect of TILs. 
Materials & Methods
Patient cohort
The cohort of patients used for this study consisted of a consecutive series of female 
breast cancer patients treated in the Leiden University Medical Center (LUMC) with 
surgery between 1997 and 2009 (n=667). Data regarding age, year of diagnosis, 
estrogen and progesterone receptor expression, human epidermal growth factor 
receptor 2 (HER2) expression (when available), TNM stage31, tumor differentiation 
grade32 and morphology, local and systemic therapy, secondary tumors, local, 
regional, distant, recurrence free and overall survival time and status was known 
for these patients. Formalin-fixed paraffin-embedded (FFPE) tumor samples were 
collected, and a tissue microarray (TMA) was created with three 1mm tumor tissue 
punches from each tumor. 
Immunohistochemistry
For immunohistochemical staining of FAS, 4.5 µm slides were cut from the 
aforementioned TMA and stored at +4 °C until use. Colon tissue was shown to be 
positive for FAS expression, therefore this tissue was used as positive control.18 Slides 
were deparaffinized in xylene and rehydrated in serial dilutions of ethanol-H2O. 
Antigen retrieval was performed by placing the section at 95°C for 10 minutes in Target 
Retrieval Buffer Low pH (DAKO) in a PT Link (DAKO). Endogenous peroxidase and 
phosphatase was blocked by incubation of the sections in BloxAll (Vector, Burlingame, 
USA) for 10 min. LS-B2820 (LifeSpan BioSciences, Seattle, USA) was used as anti-FAS 
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antibodies for IHC. The antibodies were diluted in phosphate-buffered saline with 1% 
of bovine serum albumin (1% PBS/BSA), and the optimal dilution was determined by 
titration. Incubations with primary antibodies were performed overnight. Envision 
HRP-labeled polymer anti-mouse (Dako, Carpinteria, USA) was used as secondary 
antibodies and incubated for 30 minutes. Slides were developed with DAB (Dako, 
Carpinteria, USA). Similar procedures were performed for a staining against CD8 to 
identify CD8+ cytotoxic T-cells (clone 4B11, Monosan).
In order to allow specific scoring of epithelial tumor cells, a counterstaining against 
stroma was performed using anti-rabbit polyclonal antibodies ab34710, ab6588 and 
ab23747 (Abcam, Cambridge, UK), targeting collagen I and IV and elastin respectively. 
Swine-anti-rabbit-AP (Dako, Carpinteria, USA) was used as secondary antibodies, 
incubated for 30 minutes and developed in the dark using VectorBlue Kit (Vector, 
Burlingame, USA). Finally, methyl green (Vector, Burlingame, USA) was used for 
staining of the nuclei. For this purpose, the section were incubated with methyl green 
for 5 min at 56 °C. After washing with demineralized water followed by acetone-HAc 
0.05%, the sections were dehydrated by gradients of ethanol and dried by dipping in 
xylene. Slides were mounted in Vectormount (Vector, Burlingame, USA) and stored 
until further analysis.   
Quantification of IHC stainings 
The Philips Ultra Fast Scanner 1.6 RA (Philips, Eindhoven, the Netherlands) was used 
for digitalization of the immunohistochemically stained sections of the TMA. For 
FAS, the percentage of tumor cells showing membranous staining was assessed by 
two independent observers. The scores of the three punches were combined to one 
average score per patient. Based on the whole cohort, the median value was used as a 
cut-off value to create a dichotomous value distinguishing low and high expression of 
FAS. For the evaluation of CD8, the number of CD8+ cells in the tumor was counted per 
punch, and the average of three punches was used for dichotomization based on the 
median value. Punches were only analyzed when more than 30% consisted of tumor 
tissue. Images were acquired using a Leica ICC50 camera system (Leica Microsystems, 
Wetzlar, Germany).
mRNA expression analysis
To assess the correlation between FAS expression and ER-status at transcriptional 
level, the publicly available TCGA dataset  was used using cBioPortal to assess the levels 
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of mRNA gene expression, in comparison to clinical ER-status and the expression of 
ESR1, the gene encoding for ER.33, 34
Statistical analysis
SPSS (version 23 for Windows) was used for statistical analysis. Chi-square, column 
proportion tests, Bonferroni’s multiple comparisons test and unpaired t-tests 
were used to identify associations between FAS expression, CD8+ TIL presence and 
baseline clinicopathological parameters. Kaplan Meier analysis was used to calculate 
recurrence free (RFS) and overall survival (OS) for the complete cohort and subgroups; 
log-rank tests were used to assess any differences between survival curves. RFS was 
defined as the time without local, regional or distant recurrence, whereas OS was 
defined as death from any cause. Death from breast cancer (disease-specific survival) 
was not recorded for this cohort. Cox regression analysis was used for univariate and 
multivariate analyses for RFS and OS. Furthermore, interaction tests were performed, 
to assess the marker interaction effect. This test assesses whether the prognostic 
value of a marker in one subgroup is significantly different from its value in a different 
subgroup. For all tests, p-values <0,05 were considered to be significant. 
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Gene expression profiles with prognostic capacities have shown good performance in 
multiple clinical trials. However, with multiple assays available and numerous types of 
validation studies performed, the added value for daily clinical practice is still unclear. 
In Europe, the MammaPrint, OncotypeDX, PAM50/Prosigna and Endopredict assays 
are commercially available. In this systematic review, we aim to assess these assays 
on four important criteria: Assay development and methodology, clinical validation, 
clinical utility and economic value.  
We performed a literature search covering PubMed, Embase, Web of Science and 
Cochrane, for studies related to one or more of the four selected assays. 
We identified 147 papers for inclusion in this review. MammaPrint and OncotypeDX 
both have evidence available, including level IA clinical trial results for both assays. 
Both assays provide prognostic information. Predictive value has only been shown 
for OncotypeDX. In the clinical utility studies, a higher reduction in chemotherapy 
was achieved by OncotypeDX, although the number of available studies differ 
considerably between tests. On average, economic evaluations estimate that 
genomic testing results in a moderate increase in total costs, but that these costs are 
acceptable in relation to the expected improved patient outcome.  PAM50/prosigna 
and EndoPredict showed comparable prognostic capacities, but with less economical 
and clinical utility studies. Furthermore, for these assays no level IA trial data are 
available yet.
In summary, all assays have shown excellent prognostic capacities. The differences in 
the quantity and quality of evidence are discussed. Future studies shall focus on the 
selection of appropriate subgroups for testing and long-term outcome of validation 
trials, in order to determine the place of these assays in daily clinical practice.  
Keywords: Breast cancer, gene expression, OncotypeDX, MammaPrint, Prosigna, 
Endopredict
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In the past decades, there has been a steady increase in the survival rates of patients 
with breast cancer. Among other factors like early screening and awareness, the 
majority of this effect is attributed to the concept of adjuvant therapy.1,2 However, 
among all patients receiving adjuvant chemotherapy, the majority would not have 
developed metastases even without adjuvant therapy, whereas in contrast some 
patients without the indication for adjuvant therapy still develop distant metastases. 
A recent progress in this optimal selection is the development of genomic profiling 
assays.3 We chose four crucial criteria for determining the value of these assays.
Assay development and methodology
The first criterion is the methodological robustness, both during development and 
during the commercial activities. For example, the tests should be validated in a 
cohort independent from the training cohort, and should not be used in a patient 
population in which the test was not validated unless re-validation is performed. 
Furthermore, there should be little to no inter-test variation when the same tissue 
samples are tested multiple times.  
Another aspect of assay development is determining the target population. 
Therefore, studies need to focus on identifying subgroups which do not benefit from 
genomic testing since the outcome of the test overlaps with the stratification by the 
clinicopathological factors (e.g. when all or almost all triple-negative breast cancers 
are considered high-risk by the test).
Clinical validation
A second important factor is the effect on clinical outcome between the different test-
outcome groups. Similar to classical biomarkers, a distinction can be made between 
the prognostic and the predictive value of a test.4 Since the utility of genomic testing 
is in particular aimed at guiding decisions regarding chemotherapy, a predictive test, 
able to predict which patients will benefit from chemotherapy or not, is more valuable 
than a solely prognostic test which is only associated with the  patient prognosis. 
Clinical utility
The third criterion is the clinical utility of the test. Applying the test should lead to a 
shift in the indication of chemotherapy as compared to indication based on traditional 
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parameters. In other words, if the patients using chemotherapy based on the test 
results are exactly the same patients as the ones using chemotherapy based on the 
traditional clinicopathological parameters, the test has no additional value. 
Economic value
The fourth, and last criterion for genomic testing is the economic value of the test. 
Due to the commercialisation of the assays, the tests are more expensive than the 
regular pathological assessment, with costs ranging from €1800 to €3700 per test. In 
an era of emphasis on healthcare efficiency, the costs of the test should be justified 
by its clinical and health benefits, and the reduction in costs by reducing adjuvant 
therapy use.  
Test descriptions
The first test, which was first developed in 2002 by van ‘t Veer et al and for which the 
prognostic capacities were shown simultaneously by van de Vijver et al, is the 70-
gene prognosis profile, better known as MammaPrint (Agendia BV, Amsterdam, The 
Netherlands).5,6 This assay uses the mRNA expression of 70 genes using microarray 
technology, to categorize patients in either a low or high risk . These 70 genes were 
identified from a total of 25,000 genes using supervised clustering. 
The second test in this review is the 21-gene Recurrence Score, also known as the 
OncotypeDX Recurrence Score (RS) (Genomic Health Inc., Redwood City, CA). The test 
is based on the expression of 21 genes in FFPE cancer tissue, determined using reverse 
transcriptase PCR (RT-PCR)7. Of these genes, 16 genes are cancer-related and were 
selected out of 250 rationally selected candidate genes based on their prognostic 
capacity and consistency in test performances.7  Based on these relative expressions, 
the Recurrence Score is calculated ranging from 0 to 100, with low risk ranging from 
0 to 17, intermediate risk ranging from 18 to 30, and high risk ranging from 31 to 100. 
However, for the most important validation trial of this test, the risk categories in this 
trial were adjusted to 0-10, 11-25 and 26-100 for the low-, intermediate- and high risk 
respectively.8 
The third test included in this review is the Prosigna, based on the better-known 
PAM50 test (NanoString Technologies, Seattle, WA). This test, based on the expression 
of 46 genes using quantitative PCR (qPCR) is able to distinguish between the 
molecular subtypes of breast cancer (luminal A, luminal B, HER2-enriched, normal-
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like and basal-like).9 Furthermore, it provides the risk of recurrence score (ROR) and 
the subsequent risk category. The test was adapted by NanoString in order to allow 
the use in local pathology laboratories.10 
The fourth and last test which will be discussed in this systematic review is the 
EndoPredict (Myriad Genetics Inc, Salt Lake City, UT). This assay uses the expression 
of 8 cancer-related and 3 reference genes determined by RT-PCR, which results in a 
risk score from 0 to 15 (EP), which is subsequently divided into low and high risk.11 A 
special feature of the EndoPredict is the integration of tumour size and nodal status, 
resulting in an EP clinical score (EPclin). The EndoPredict can be performed in local 
laboratories, in contrast to the MammaPrint and OncotypeDX which are centrally 
determined and therefore need more elaborate logistical planning.
In this review, we evaluate four genomic assays available in Europe using a systematic 
evaluation focusing on all four major criteria with the aim to assess each test 
individually for its strengths and weaknesses. 
Methods
Search strategy 
This systematic review was to comprehensively cover all four aspects of the four 
commercially available genomic profiling tests in Europe on four different aspects: 
developmental and methodological robustness, extend of clinical validation, clinical 
utility and economic value. These items were chosen after a consensus meeting and 
cover those  evaluation criteria we deemed most important. We searched PubMed, 
Embase, Web of Science and Cochrane for articles published before April  2016. The 
search strategy (supplementary document 1) was applied on April 7th 2016, and after 
evaluation of all abstracts it was updated at September 9th 2016. Abstracts were 
screened for relevance based on the title and abstract, and remaining full-text articles 
were screened based on the inclusion criteria. 
Selection criteria 
Articles were selected if they studied one of the four tests available in Europe: 
OncotypeDX, MammaPrint, Prosigna or Endopredict. Furthermore, the article should 
be original peer-reviewed research; abstracts, posters, reviews and meta-analyses 
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were excluded. The article needed to cover one of the four criteria: development of 
the test, clinical validation, clinical utility or an economical evaluation.  For the clinical 
validation studies, survival analysis was required, evaluating either the differences 
in survival between test-outcome groups, or the benefit of therapy in one or more 
test-outcome groups. For the clinical utility studies, decision impact studies were to 
be available in a representative cohort, and had to report both the absolute increase 
or decrease in chemotherapy as well as the shift from one treatment category to the 
other. Retrospective large-scale population-based impact studies were also included, 
reporting real-life shifts in the use of genomic testing and the subsequent changes in 
therapy decisions. Two reviewers (EJB, EB) independently selected articles that met 
the above inclusion criteria based on title and abstracts. Next, full-texts of potentially 
relevant articles were screened. Agreement concerning eligibility was achieved 
during consensus. 
Data extraction and statistics 
Data extraction was independently performed by the two reviewers. Data was collected 
concerning the performed test, the number of included patients, the results of the test, 
and survival outcome or change in treatment where appropriate. Disagreements in 
data extraction and interpretation were resolved during a consensus meeting. There 
were no changes in eligibility criteria during the selection of articles. All studies that 
fulfilled the inclusion criteria were included, independent of their methodological 
quality; no risk of bias assessment was performed. Both retrospective and prospective 
studies were included without exclusion of particular study designs with an emphasis 
on prospective RCTs (where available). Data were recorded in the tables as mentioned 
in the articles, no additional statistics were performed. Both point estimates and 
95%CI were recorded, where appropriate and mentioned in the selected articles. 
Due to the heterogeneity of the studies chosen, the patient selection and endpoints 
reported, no further statistical analyses could be performed. Results were stratified in 
(1) one of the four tests and (2) lymph node positive or lymph node negative patients 
or articles where the distinction could not be made or both groups were included.  
For the clinical utility, extracted data from decision-impact studies were pooled 
(weighted by the number of patients) to give an estimate of the chemo-reduction and 
shift in therapy a test can establish. We only considered a change in chemotherapy 
and recorded the percentage of patients who would receive chemotherapy before 
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the test, and after the test (as mentioned in the included articles). For the table on 
clinical validation, the number of patients who were high or low risk according to 
the test were recorded and the outcome in the groups. Outcomes were recorded as 
mentioned in the articles: distant metastasis or distant recurrence free survival, 
breast cancer specific survival, and overall survival were most frequently reported. 
Where known, both the point estimate and the 95%CI were recorded. The Hazard 
Ratio and corresponding 95%CI for the difference in outcome between the risk groups 
was recorded if this was mentioned in the articles. For the economic review, original 
evaluations were included if they compared costs beyond the assay costs alone. 
Evaluations could be cost minimization analyses (CMA), cost effectiveness analyses 
(CEA, comparing costs to life years) or cost utility analyses (CUA, comparing costs to 
quality-adjusted life years (QALYs)). To aggregate, QALYs were imputed for CMAs and 
CEAs (as predicted by the average and the life year gain, respectively) and costs were 
updated to Euros at price level 2016. When more than one (non) genomic strategy 
was included in an economic evaluation, the (non-) genomic strategy with the highest 
QALYs was used in the review.
Results 
Using our search strategy, we identified 1345 unique titles and abstracts. Limiting 
ourselves to the manuscripts only related to the topics of this review, we selected 
280 studies for further full-text evaluation. From these 280 full-text manuscripts, we 
selected 149 papers for inclusion in this review: 11 about developmental validation, 
12 about biomarker prediction, 50 about clinical studies, 28 about clinical utility 
and the effect on chemotherapy reduction, 44 economic evaluations and 4 studies 
making direct head-to-head comparisons on test outcome between two or more of 
the included tests (figure 1). 
Assay development and methodology
In the development of MammaPrint, multiple evolutions were necessary to allow 
high-throughput screening of FFPE tissue. Glas et al first converted the original 
research-based micro-array containing approximately 25,000 probes to a mini-assay 
with good concordance and reproducibility.12,13
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Figure 1. A diagram showing the inclusion of relevant papers in the systematic review
A second step was the conversion from frozen to FFPE tissue by Mittempergher et 
al, with an R2 of 0.94.14 After this proof of principle, Sapino et al further developed 
the MammaPrint towards an FFPE platform, again with a good correlation between 
FFPE and frozen tissue (r=0.92), and a high concordance between high- and low-
risk classifications between both methods (κ-score 0.82).15 Beuner et al validated 
both the conversion to a mini-assay and the conversion from frozen tissue to FFPE 
retrospectively, by comparing the scores of both methods.16  
Gyanchandani et al studied whether intratumoral heterogeneity might influence 
the outcome of a gene expression test in 74 ER-positive cases using most included 
gene expression panels, by assessing different tumor regions from the same FFPE 
block.17 They showed that genomic assays with a higher number of included genes 
resulted in a lower rate of discordant samples. Drury et al studied the use of 0.6mm 
cores and compared these with full sections, to establish whether tissue-microarrays 
(TMAs) could be used for genomic profiling using OncotypeDX.18 Although the total 
RNA yield was lower from tissue cores compared to full sections, the OncotypeDX 
Recurrence Score results from individual cores clustered closely, and had an excellent 
correlation with full-section RS (Spearman R=0.91). 
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For the Endopredict, the use of pre-surgery biopsies and surgical sections from 40 
ER-positive HER2-negative tumors was compared. It was shown that comparing 
both results resulted in a Pearson correlation coefficient of 0.92, showing that core 
needle biopsies can be used for genomic profiling using Endopredict.19 Another 
aspect of the EndoPredict is decentral assessment, meaning that every individual 
pathological laboratory can perform this test and thereby reducing the logistical 
strain on the testing procedure. Denkert et al tested this decentral evaluation.20 The 
Pearson correlation coefficient for all measurements was a near-perfect 0.994, and 
100% of the samples were assigned to the same EP risk group as the reference test. 
Furthermore, Kronenwett et al showed that this decentral approach had excellent 
precision and reproducibility, although with a small sample size.21 
Although these published studies showed a good  reliability and reproducibility, 
the MINDACT trial shows that there can be problems which hamper the reliability 
and feasibility of a test. Between May 2009 and January 2010, 162 patients were 
falsely identified as being high risk, due to a change in RNA-extraction solution.22 
Furthermore, of all 11,288 screened patients, there was a screening failure in 1182 
patients (10%) in which the MammaPrint was not feasible.22 
Another concern for the reliability of test results is the ratio between tumor and 
normal tissue in the tested specimen. Elloumi et al showed that an increase of normal 
tissue in the specimen leads to biased test results when compared to uncontaminated 
tumor tissue test results.23 For the PAM50 this bias was linear, showing a more 
favourable outcome with increasing normal tissue content. For the MammaPrint and 
OncotypeDX the bias was unpredictable, switching both from low to high risk and vice 
versa with increasing normal tissue content. All tests have since developed strategies 
to mitigate this bias.
A couple of studies directly compared the test results of multiple tests performed on 
one tumour. In the OPTIMA Prelim trial, patients were randomized between standard 
therapy or OncotypeDX-directed therapy.24,25 Among others, also MammaPrint and 
Prosigna tests were performed. Strikingly, the kappa measurements were between 
0.40 and 0.53. In the same cohort of patients, OncotypeDX predicted 17.9% to be 
high risk, compared to 38.6% and 34.5% for MammaPrint and Prosigna respectively. 
This pilot trial is now followed by the OPTIMA trial, in which treatment directed by 
the Prosigna assay is compared with regular care. In a smaller prospective study, 52 
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samples were analysed with both the OncotypeDX and Prosigna, showing a Spearman 
correlation coefficient of 0.08.26 Remarkably, 57.1% of the patients classified as 
high risk by Prosigna were classified as low risk by OncotypeDX. In a similar study 
comparing Endopredict and OncotypeDX results in 34 samples, a Pearson correlation 
of 0.65 was shown, with a concordance between risk categories of 76%.27 
Prediction of test results
Theoretically, a genomic profile can have an excellent prognostic value, but is 100% 
predicted by the occurrence of other markers and therefore has no added value. 
Therefore, it is crucial to establish the added value of the test, by testing whether the 
test result can be predicted by standard clinicopathological parameters. This testing 
could identify subgroups for which the test is not valuable. We identified 12 studies 
evaluating this effect, which are reported in table 1. In general, tumours which are (a 
combination of) grade 1, PR-positive and/or have a Ki-67 expression lower than 10%, 
are almost always low risk when genomic testing is performed. Similarly, tumours 
which are (a combination of) grade 3, PR-negative and/or have a Ki-67 score of more 
than 40%, are almost always high-risk. For these subgroups, genomic profiling 
provides little additional information.
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Table 1 Marker prediction, according to test and nodal status
Marker prediction




R2 best fit 
model
Subgroups little/no benefit of testing 
(>75% in risk category)
MammaPrint 
Early stage breast cancer (combined LN- and LN+, other groups or not specified)  
Cardoso*22 2016 NA NA Grade 1 
Grade 3 
ER- PR-
93% low risk 
75% high risk 
96% high risk
Gevensleben28 2010 140 NA NA St. Gallen high risk











Chaudhary29 2016 350 NA NA PR+ 95% low or 
intermediate risk
Dialani30 2016 319 ER, PR, HER2, 
tumor grade
0.55 NA NA









PR <2, np-score 3
100% low or 
intermediate risk
100% high risk
Sahebjam32 2011 53 PR, Ki-67 0.84 Ki-67 <10% 100%= low or 
intermediate risk
Auerbach33 2010 138 Mitotic count, PR NA PR+ &Mitotic count 
1 or 2
PR- & Mitotic count 
2 or 3
100%= low or 
intermediate risk
75%= high risk 
(0% low risk)





100% low or 
intermediate risk
83.3% high risk 
(0% low risk)
Wolf35 2008 300 NA NA PR+ & Grade 1/2 94% low or 
intermediate risk
Early stage breast cancer (combined LN- and LN+, other groups or not specified)  
Gluz36 2016 2642 NA NA Grade 1
Ki-67 <20%, PR 
>20%
Ki-67 >40%
~90% low or 
intermediate risk
~95% low or 
intermediate risk
~90% high risk
Bradshaw37 2013 158 ER (allred), PR 
(allred), Ki-67
0.62 NA NA
Allison38 2012 173 PR, tumor grade Unknown 
(p<0.001)
Grade 1 & PR >5 
(allred)
Grade 3 & PR <5 
(allred)
100% low or 
intermediate risk
80% high risk (0% 
low risk)
Williams39 2011 133 NA NA Ki-67 <10% 99%= low or 
intermediate risk
*Not designed to predict test results, but data are provided in the manuscript
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A total of 50 studies was identified assessing the clinical benefit of the genomic 
assays; 21 assessing the MammaPrint, 20 assessing the OncotypeDX, 5 assessing 
the PAM50/Prosigna and 4 assessing the Endopredict. Most of the studies were 
retrospectively stratifying the cohort in separate risk categories determined by the 
test, and showing a difference in either distant metastasis-free, disease-free or overall 
survival. Table 2 shows the results of the retrospective included studies, according 
to test and patient inclusion. In general, the studies are difficult to compare due to 
different patient inclusion and outcome measures. All published studies showed 
a good differentiation in high and low risk and were associated with survival (both 
Distant Metastases/Recurrence Free Survival (DMFS/DRFS) as Overall Survival (OS)). 
In more detail, MammaPrint was reported to be of significant prognostic value for 
patients with lymph node negative breast cancer and the results of the test correlated 
well with Adjuvant!, St Gallen and NIH guidelines and the NPI. For lymph node 
positive disease, the hazard ratios for DMFS and Breast Cancer Specific Survival 
(BCSS) showed a significant difference in prognosis for low versus high risk according 
to MammaPrint. In the remaining articles (without specific classification or LN- and 
LN+ combined) the MammaPrint was also of prognostic value; most of the results 
showed a significant difference in outcome between low and high risk.
With respect to OncotypeDX, most of the studies in patients with LN negative disease 
studied the DRFS and showed a significant difference in outcome between low, 
intermediate and high risk patients. Paik et al showed a statistical different effect of 
chemotherapy in the three risk groups with a significant interaction term between 
chemotherapy and the Recurrence Score. One case-control study showed a significant 
difference between both groups. Besides, the study in LN+ disease also showed a 
significant interaction between the RS and clinical benefit of chemotherapy for the 
first 5 years after treatment. The remaining studies (combined LN- and LN+ and one 
study in patients with metastatic disease) showed a good discrimination between the 
three risk groups and a significant difference in outcome in most of the studies. 
Studies that used the PAM50 showed a good discrimination, and a significant 
interaction between treatment and outcome in one study, this was however not 
confirmed in Liu et al. Three studies showed a significant association with distant 
recurrences. For studies that used EndoPredict differences between high and low risk 
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were associated with outcome or showed a low proportion of distant metastases in 
the low risk group. 
Both the PAM50/Prosigna and EndoPredict have a quality B level of evidence in all of 
their validation studies by performing them in established clinical trials, according 
to Simon et al.83 For MammaPrint one level A trial is available22, all other studies are 
level C quality or lower. For  OncotypeDX, there is a mix of two level A trials8,36, some 
level B studies showing predictive capacities of OncotypeDX, and level C/D studies in 
retrospective or case-control studies. All level A evidence will be discussed in the next 
paragraphs.
MINDACT
The MINDACT trial evaluated the use of the MammaPrint together with Adjuvant 
Online, an online tool using clinicopathological information for risk stratification.22 
Patients with discordant risks based on the clinical and genomic assessment, were 
randomized between chemotherapy or no chemotherapy.  The primary study 
subgroup were the patients with a clinical high and genomic low risk tumour who were 
randomly allocated to receive no chemotherapy. The distant metastasis-free survival 
of this group was 94.7% at 5 years, which was significantly higher compared to a pre-
determined null hypothesis of 92%. Therefore, it was concluded that the prognosis of 
these clinically high-risk, but genomic low risk patients without chemotherapy was 
good enough to justify the abstention of chemotherapy.  
The trial is labelled as phase 3 RCT and the results are regarded as level IA evidence. 
However, the design of the primary analysis is that of a cohort study, since it only 
assessed the patients who had a discordant risk and did not receive chemotherapy. 
In a secondary per-protocol analysis, comparing the c-high/g-low patients with and 
without chemotherapy, a HR of around 0.65 was shown in favour of chemotherapy, 
which was significant for DFS (90.3% vs 93.3%, p=0.026), but not for DMFS (94.8 vs 
96.7, p=0.106) or OS (97.3 vs 98.8, p=0.245). In summary, although the prognosis of 
this clinically high-risk group is good without chemotherapy, it is significantly better 
when receiving chemotherapy. 
Another secondary outcome is the effect of chemotherapy in patients who were 
clinically assessed as low-risk, but with a genomic high risk profile. In this subgroup, 
no statistically significant benefit of chemotherapy was observed for either DMFS (HR 
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0.90 95% CI 0.40-2.01), DFS (HR 0.74 95% CI 0.40-1.39) or OS (HR 0.72, 95% CI 0.23-
2.24), indicating that a high-risk MammaPrint test result does not predict an effect 
of chemotherapy for these low-risk patients. Although this analysis is underpowered, 
and no formal interaction test was performed, the authors conclude that the 
MammaPrint failed to show its value as a predictive biomarker, not being capable of 
identifying patient who would benefit from chemotherapy. 
TAILORx
The TAILORx trial was designed to assess the clinical use of OncotypeDX to decide 
on the chemotherapy administration, especially in the intermediate risk group. For 
this, 10,273 patients were enrolled, who all had ER- and/or PR-positive, node-negative 
disease but did have an indication for chemotherapy based on the NCCN-guidelines. 
Low-risk patients (based on Recurrence Score) received endocrine therapy only; high 
risk patients received both endocrine and chemotherapy. Intermediate risk-group 
patients were randomly allocated to either endocrine therapy alone or a combination 
of endocrine and chemotherapy. Until now, only the results of the low-risk patients 
were published.8
A total number of 1626 patients with a low-risk OncotypeDX test received no 
chemotherapy. The rate of DFS at 5 years was 93.8%, the freedom from distant 
recurrence was 99.3% and the overall survival was 98%. Similar to the MINDACT trial, 
this shows that genomic testing can identify patients with a good prognosis without 
chemotherapy, despite a clinical indication for chemotherapy. 
In a similarly designed trial (RxPonder), node-positive patients with HR+ breast 
cancer and a low or intermediate test result are randomly assigned to hormone 
therapy with or without chemotherapy.84 Results of this trial will show whether it is 
safe to withhold chemotherapy based on a low or intermediate test result population 
despite the high-risk nodal status.
WSG PlanB
In the West German Study Group Phase III PlanB Trial, 3198 clinically high-risk patients 
were enrolled, including 41.1% with node-positive disease. Although originally 
designed to compare two regimes of chemotherapy, after inclusion of 274 patients the 
study was amended to omit chemotherapy in patients with a low-risk OncotypeDX 
test result, despite their high clinical risk.36
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In this high-risk population, 348 patients received no chemotherapy based on a 
low-risk Recurrence Score of <12. At 3 years of follow-up, the disease-free survival 
was 98.4% in this subgroup, indicating again that genomic subtyping can identify 
a clinically high-risk subgroup with an excellent prognosis without chemotherapy, 
although longer follow-up is warranted for definite conclusions. Similar to the 
TAILORx, this study used an alternative cut-off for low-risk scores, which needs to be 
considered when interpreting the results. 
Clinical Utility
A total of 28 studies which evaluated the clinical utility of assays has been identified, 
of which 22 for OncotypeDX, four for MammaPrint, and one for both Prosigna 
and Endopredict. Almost all studies compared the (hypothetical) application of 
chemotherapy for the same patient, with and without the results of the genomic 
test. In general, de-escalation from chemotherapy to no therapy or endocrine 
therapy alone was higher than the escalation towards chemotherapy, which led to a 
decrease in chemotherapy use for all tests. When the results were pooled per assay, 
the decrease in chemotherapy was the most pronounced for OncotypeDX (45.7% 
from chemotherapy to endocrine therapy alone or no adjuvant therapy) compared 
to MammaPrint (32.2% decrease) (table 3). However, these pooled results should be 
interpreted carefully, since there is a large difference  in the number of studies per test, 
the baseline patient populations and study designs.
For OncotypeDX, three other studies evaluated the use of chemotherapy in population 
studies.113-115 Two of them observed a decrease in chemotherapy use during the 
designated years, and an increase in genomic testing.114,115 However, no direct relation 
was observed between both results. In the study of Su et al, performed in a US medicare 
population between 2008 and 2011, no difference in the use of chemotherapy was 
observed despite an increase of assay use from 9 to 17.2%.113
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Table 3 Clinical utility, according to test and nodal status  
Clinical utility












Lymph node negative 
Drukker85 2014 N=414, T1-3 49 37 4.3 29.1
Early stage breast cancer (combined LN- and LN+, other groups or not specified)  
Pohl86 2016 N=107, HR+HER2- 56.1 39.2 40 62
Exner87 2014 N=75, grade 1 or 2, T 
1-3cm, HR+HER2-
41.3 33.3 9.1 32.3
Cusumano88 2014 N=194, T1-3N0-1 60.8 60.8 34.6 22.3
Subtotal MammaPrint
N=790 52.1 42.8 17.0 32.2
OncotypeDX
Lymph node negative
Ozmen89 2016 N=165, T1-3N0-1mic, 
HR+HER2-
55.8 37 13.7 44.6
Levine90 2016 N=972, T1-4N0-1mic, 
HR+HER2-
22* 20.7 10.9 62.6
Leung91 2016 N=146, T1-3N0-1mic, 
HR+
52.1 37.7 4.3 31.6
Gligorov92 2015 N=100, T1-3N0-1mic, 
HR+HER2-
52 25 10.9 61.2
Lee93 2015 N=212, T1-3N0-1mic, 
HR+
70.7 22.1 9.7 72.7
Jaafar94 2014 N=47, T1-2N0, 
HR+HER2-
48.9 25.5 4.2 52.2
Davidson95 2013 N=150, T1-3N0, 
HR+HER2-
41.3 31.3 17 48.4
Holt96 2013 N=142, T1-3N0-1mic, 
HR+
40.1 30.3 14.1 45.6
Biroschak97 2013 N=50, T1-3N0, HR+ 72 70 28.6 13.9
Ademuyiwa98 2011 N=276, T1-3N0 
HR+HER2-
45.3 32 22.5 56.8
Albanell99 2011 N= 107, T1-3N0, 
ER+HER2-
37 27 17.6 56.4
Lo100 2010 N=89, T1-2N0, HR+ 47.2 25.9 6.5 47.6
Henry101 2009 N=29, T1-3N0, HR+ 45 28 13 54
Oratz102 2007 N=74, T1-3N0, HR+ 48 48 20 21.2
Early stage breast cancer (combined LN- and LN+, other groups or not specified)  
Kuchel103 2016 N=137, T1-3N0-1, 
HR+HER2-
50.4 27.7 18.2 62.3
Bargallo104 2014 N=96 , T1-3N0-1 
ER+HER2-
48 31 16 45.7
Yamauchi105 2014 N=124, T1-3N0-1, 
HR+HER2-
51 24 11.5 63.5















Fried106 2014 N=111, T1-3N0-1, HR+ 29.7 27.9 14.1 39.4
Cheung107 2014 N=64,T1-2N0-1, 
HR+HER2- 
61 55 16 20.5
Eiermann108 2013 N=366, T1-3N0-1, 
HR+HER2-
57 46 25 38
De Boer109 2013 N=151, T1-3N0-1, 
HR+HER2-
44.4 37.1 15.5 35.8
Geffen110 2011 N=135, T1-2N0-1 47 36 13.9 38.1
Subtotal OncotypeDX  
N=3743 50.2 30.6 14.6 51.1
PAM50 / Prosigna
Martin111 2015 N=200, T1-2N0, 
HR+HER2-
30% 28% 12.9% 37.3%
EndoPredict 
Muller112 2013 N=167, T1-3N1-3, 
HR+HER2-
63.8% 47.7% 34% 53.2%
*not included in pooled data, since pre-test chemotherapy also included 34% unsure
Two other studies evaluated the use of chemotherapy between patients with and 
without genomic testing.116,117 In the large study performed by Ray et al (n=7004), 
22% of chemotherapy was observed in patients without testing, whereas 26% used 
chemotherapy after genomic profiling. In contrast, Stemmer et al (n=951) observed 
in a node-positive population, a 70% chemotherapy use without testing and a 24.5% 
chemotherapy use after genomic testing. 
In a similar study design, Kuijer et al observed a 10% lower rate of chemotherapy for 
patients with genomic testing using MammaPrint.118
Economic value
Forty-four original economic evaluations were found, of which 32 on Oncotype DX, 
7 on MammaPrint, 1 on EndoPredict and 4 direct comparisons between tests (Table 
4). Most evaluations compared genomic testing to a variety of strategies without 
genomic testing; four evaluations were head-to-head comparisons between genomic 
policies. Of the evaluations, 5 only estimated costs (CMAs), 1 estimated life years 
without QALYs (CEA) and 38 estimated QALYs (CUAs). 
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Methodologically, only 2 evaluations (both CMA) compared measured outcomes 
between two actual patient groups with and without genomic testing.113,119 The 
remaining 42 evaluations all used mathematical (mostly Markov) modelling to compare 
estimated outcomes for different policies, for the same actual or hypothetical group of 
patients. These mathematical models typically estimated a decrease in chemotherapy 
(because the shift to low risk exceeds the shift to high risk), a decrease in recurrence 
(because the decrease in high risk exceeds the increase in low risk), and an increase in life 
years and QALYs (due to the decrease in recurrence and toxicity). Total health care costs 
may go up or down, depending on the balance between the assay costs and savings on 
chemotherapy and recurrence. Three studies also included savings on productivity.120-122
Figure 2 shows the estimated impact of genomic testing on QALYs and costs, according 
to the 40 evaluations comparing genomic testing to a strategy without genomic testing. 
The horizontal axis shows the impact on QALYs: all studies but one123 reported that 
genomic testing resulted in better patient outcome with a positive impact on QALYs. 
The vertical axis shows the impact on costs: genomic testing was cost saving in 14 (35%) 
evaluations and cost increasing in 26 (65%) of the evaluations. On average, total costs 
increased by 449 euro per patient with an improvement on patient outcome of 0.16 
life years and 0.20 QALYs. In general, there were no apparent differences between 
the estimated outcomes for the different genomic tests. Also, the range of costs was 
comparable in node-negative and node-positive patients, but the estimated QALY gain 
was larger in node-negative patients (on average, 0.24 versus 0.07 QALYs). Considering 
the improvement in patient outcome, genomic testing was cost-effective in 36 (90%) 
of the evaluations, i.e. below the dashed 40,000 euro-per-QALY line. 
Figure 2. Estimated impact on costs and quality-adjusted life years (QALYs) per economic evaluation, according 
to test and nodal status
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Table 4 Economic evaluations, according to test and nodal status
Authors Year Comparator Patient 
group










MammaPrint compared to no genomic testing
Lymph node negative
Bonastre124 2014 Adjuvant! 
Online
N0 France € 2037 0.02 0.01 € 134,000 
per QALY
Chen125 2010 Adjuvant! 
Online
N0 US $ 1440 0.153 0.143 $ 10,000 
per QALY
Exner87 2014 Usual care N0 HR+ 
HER2-
NL € -3779 0.73 - Dominant
Kondo126 2012 Best practice N0 ER+ 
HER2-
Japan $ 2571 0.06 0.048 $ 43,044 
per QALY
Retèl127 2010 Adjuvant! 
Online
N0 ER+ NL € 1130 0.24 0.2 € 4,614 per 
QALY
Retèl128 2013 Adjuvant! 
Online
N0 ER+ NL € -2401 0.62 - Dominant
Lymph node positive (or mixed)
Oestreicher123 2005 Best practice N≥0 stage≤II 
pre-
menopausal
US $ -2882 -0.21 - $ 13,724 per 
QALY  
(in favor of 
BP)
OncotypeDX compared to no genomic testing
Lymph node negative
Bacchi129 2010 Usual care N0 ER+ Brazil $ -794 - - Cost saving
Cosler130 2009 Chemotherapy+ 
Tamoxifen
N0 ER+ US $ -2256 0 - Dominant
Davidson95 2013 Usual care N0 ER+ 
HER2-
Canada CAN$ 2188 0.33 0.31 CAN$ 6,630 
per QALY
Epstein119 2015 Usual care N0 ER+ US $ 1367 - - Cost in-
creasing
Hannouf131 2012 Usual care N0 HR+ Canada CAN$ 2879 0.059 - CAN$ 
48,493 per 
QALY
Holt96 2013 Usual care N0-1 ER+ UK £ 888 0.14 0.16 £ 6,232 per 
QALY
Hornberger132 2005 Usual care N0 ER+ US $ -1160 0.162 - Dominant
Hornberger 
133
2011 Best practice N0 ER+ US $ -2028 0.086 -0.0421 Dominant




Austria € 2750 0.46 0.59 € 5,978 per 
QALY
Katz120 2015 Usual care N0 HR+ 
HER2-
France € -602 0.17 0.18 Dominant
Klang135 2010 Usual care N0 ER+ Israel $ 1828 0.17 - $ 10,770 per 
QALY
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Authors Year Comparator Patient 
group










Kondo136 2008 Best practice N0 HR+ Japan $ 2516 0.097 0.083 $ 30,137 per 
QALY
Kondo137 2011 Best practice N0 ER+ Japan $ 2407 0.63 - $ 3,848 per 
QALY
Lamond138 2012 Usual care N0 ER+ Canada CAN$ 2585 0.27 - CAN$ 9,591 
per QALY




Ontario CAN$ 4168 1.3 - CAN$ 3,206 
per QALY




Canada CAN$ 2460 0.429 0.53 CAN$ 5,734 
per QALY
Reed121 2013 Adjuvant! 
Online
N0 ER+ US $ 1741 0.16 0.19 $ 10,788 per 
QALY
Smyth141 2015 Best practice N0 ER+ Ireland € -1361 - - Cost saving
Su113 2016 Usual care N0 HR+ 
HER2-
US $ 400 - - Cost in-
creasing
Tsoi142 2010 Adjuvant! 
Online
N0 HR+ Canada CAN$ 4102 0.065 0.064 CAN$ 
63,064 per 
QALY
Vataire122 2012 Usual care N0 ER+ 
HER2-
France € -1600 0.14 0.15 Dominant
Ward143 2013 Usual care N0 ER+ 
HER2-
UK £ 2575 0.1 - £ 29,502 per 
QALY
Yamauchi144 2014 Usual care N0 ER+ Japan $ 1536 0.241 - $ 6,368 per 
QALY
Lymph node positive (or mixed)
Bargalló-
Rocha145 
2015 Usual care N3 HR+ 
HER2-
Mexico $ 129 - 0.068 $ 1,914 per 
LY
Blohmer146 2013 Usual care N3 ER+ 
HER2-
Germany € -561 0.06 0.06 Dominant
Hall147 2012 Chemotherapy N+ ER+ UK £ 860 0.16 0.15 £ 5,529 per 
QALY
Hannouf148 2014 Usual care N+ HR+ 
post-
menopausal
Canada CAN$ 36.2 0.08 - CAN$ 464 
per QALY
Kip149 2015 Usual care N1 ER+ NL € 1236 0.11 - € 11,236 per 
QALY
Kondo137 2011 Best practice N+ ER+ Japan $ 3434 0.07 - $ 49,059 
per QALY
Lamond138 2012 Usual care N+ ER+ Canada CAN$ 864 0.06 - CAN$ 
14,844 per 
QALY
Nerich150 2014 Usual care N1 ER+ 
HER2-
France € -128 - - Cost saving
Vanderlaan151 2011 Best practice N+ ER+ 
HER2-
US $ -384 0.127 - Dominant




Authors Year Comparator Patient 
group










EndoPredict compared to no genomic testing
Lymph node positive (or mixed)
Blank152 2015 Best practice N≥0 ER+ 
HER2-
Germany € -3388 0.002 -0.037 Dominant
Head-to-head comparisons
Mislick153 2014 Mammostrat vs 
OncotypeDX
N0 ER+ US $ -2268 -0.005 -0.002 $ 453,600 




Retèl154 2012 MammaPrint vs 
OncotypeDX
N0 ER+ NL € -1475 0.08 -0.14 Mammap-
rint domi-
nant




Spain € 1085 0.745 0.863 € 1,457 per 
QALY  
(in favor of 
Mammap-
rint)
Yang156 2012 MammaPrint vs 
OncotypeDX




In this systematic review, we evaluated four commercially available prognostic 
genomic profiles on four selected crucial aspects. On all aspects, the tests are well-
studied, with multiple well-designed and well-performed studies available. It is 
apparent that on the level of quantity, MammaPrint and especially OncotypeDX are 
more extensively studied compared to the more recently developed Endopredict 
and Prosigna/PAM50 assay. At this time of development, both OncotypeDX and 
MammaPrint are suitable assays which can be helpful in the clinical setting. However, 
this review also identified some caveats which will need to be addressed before 
genomic profiling can be optimally applied.
Assay development and methodology
The first topic for improvement is the identification of a subgroup that benefits most 
from genomic profiling. This has already been investigated for OncotypeDX, and to 
a lesser extent for MammaPrint. For Prosigna and Endopredict we did not identify 
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studies that studied for which clinicopathological subtypes genomic profiling is 
valuable. In general, the studies show that patients with grade 3, PR- and a high Ki-
67 have no benefit from testing, since they are almost always high-risk. In contrast, 
patients with grade 1, ER+PR+ and Ki-67 <10% have no benefit from testing either, 
since (almost) all of them had a low-risk result. As suggested by the flowchart build 
by Allison et al, all other patients would have an indication for genomic profiling.38 
However, most of these studies were performed in a node-negative cohort. MINDACT 
has shown that despite node-positive disease, it could be considered to withhold 
chemotherapy at a low genomic risk score. Therefore, it is crucial that this test-result 
predicting model is validated and adjusted in large trial cohorts like MINDACT and 
the WSG Plan-B trial. 
Clinical validation
One of the most important (theoretical) benefits of a genomic profiling test is the 
selection of patients in which the treatment with adjuvant chemotherapy will have 
a significant benefit. Currently, this task of genomic profiles is mainly performed by 
their prognostic capacities; i.e. the ability to identify patients with a poor prognosis 
for recurrence or survival. However, the results of the studies in this review, especially 
that of MINDACT, show that this does not automatically translate into a benefit of 
chemotherapy for these higher-risk patients. So far, no genomic test has shown it’s 
predictive capacities in a prospective trial design. The only evidence for a predictive value 
was obtained in two prospective studies conducted on archived tissue (prospective-
retrospective design) in which the OncotypeDX retrospectively identified patients that 
benefit more from chemotherapy to which they were randomly allocated.62,65  
Clinical utility
Currently, the clinical consensus on adjuvant chemotherapy is that we are most 
likely over-treating our patients, since we are not capable of identifying patients that 
will or will not benefit from chemotherapy using the current clinicopathological 
parameters.157,158 It is no surprise that the studies evaluating the clinical utility of 
genomic profiling especially show a reduction in chemotherapy use. However, 
absolute numbers should be interpreted carefully, since some tests are less frequently 
studied than others, which increases the risk of bias and skewed data. Interestingly, 
in retrospective population-based cohorts, implementation of genomic testing did 
not lead to a reduction in chemotherapy use.113-115 This is in accordance with Petkov 
et al, who retrospectively matched OncotypeDX use with SEER registry data for 
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over 40,000 patients.159 Although the risk categories were indeed prognostic for 
five-year breast-cancer-specific mortality in this real-life population, patients with 
node negative, HR+, HER2- breast cancer which underwent testing (n=40,134, 22.7% 
chemotherapy) had no lower chemotherapy use compared to patients that were not 
tested (n=144,056, 22.2% chemotherapy). Therefore,  conclusions about genomic 
profiling leading to decrease in chemotherapy cannot be drawn from these analyses.
Economic value
Our review of economic evaluations identified 44 original publications, where earlier 
reviews included at most 11 or 18 published evaluations.160,161 Except for the oldest 
evaluation123, all studies reported improved patient outcome in terms of QALYs. 
Despite estimated savings on chemotherapy, recurrence and productivity, a small 
majority (65%) of the evaluations estimated that genomic testing resulted in an 
increase in total costs. Nevertheless, most evaluations (90%) estimated that genomic 
testing is cost-effective, with costs that are acceptable in relation to patient outcome. 
These economic results should be considered with caution. Firstly, the separate 
evaluations should not be interpreted as independent primary studies, because the 
models obtain their data from overlapping sources: mostly the diagnostic data are 
taken from the landmark trials and then applied to the care patterns of a particular 
country. Secondly, the economic studies generally evaluate the use of genomic testing 
in large groups of women, instead of trying to combine genomic profiling with other 
prognostic factors to identify those individual women for whom genomic testing 
does not have sufficient added value or could even be harmful. And thirdly, compared 
to trials, economic evaluations are more likely to suffer from publication bias.
Future perspectives
In the near future, trial results from RxPonder, TAILORx and WSG plan-B will become 
available, contributing to understanding the role of OncotypeDX in daily practice 
in both node-positive and node-negative disease. Furthermore, subgroup analyses 
and long-term follow-up of MINDACT will follow later and help define the place 
for MammaPrint in the diagnostic process, and the long-term safety of withholding 
chemotherapy in high-risk patients, based on a low-risk test result. The OPTIMA 
trial, randomizing high-risk ER+HER2- patients between standard chemotherapy, 
or treatment directed by Prosigna test-results will be the first trial to show level A 
evidence for the Prosigna/PAM50 test.
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Another interesting development is the use of gene expression assays for the 
indication of endocrine therapy. Very recently, a retrospective analysis from Sweden 
identified an ultra-low category within the low-risk category of MammaPrint (15% of 
all patients, 26% of low-risk patients).162 Patients with this ultra-low risk score (n=98) 
had a breast cancer specific survival of 94% at 20 years without any adjuvant therapy, 
and 97% at 20 years with just 2 years of tamoxifen, whereas 5+ years of therapy is 
the current standard for these patients.163 Upon validation, these findings could 
lead to the implementation of gene expression assays in the indication for adjuvant 
endocrine therapy.
Conclusions
In summary, in this systematic review we have evaluated the four most frequently 
used assays in Europe on four relevant aspects. Regarding the amount of evidence, 
there is a clear separation between the more established MammaPrint and 
OncotypeDX on one hand, and the newer Prosigna and Endopredict on the other 
hand. Comparing MammaPrint and OncotypeDX, both assays have shown to be a 
useful prognostic tests which could lead to a reduction in chemotherapy use, with 
in general a favourable cost-benefit ratio. Both the MammaPrint and OncotypeDX 
have shown in prospective trials that a patient with a low-risk result can safely forego 
chemotherapy, despite clinical risk factors. In contrast, the benefit of chemotherapy 
with a high-risk test result has so far only been shown for OncotypeDX, albeit in 
retrospective analyses of archived tissue of prospective trials. Therefore, there is still a 
need for further prospective studies on all evaluated assays. 
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The results of the study by Cardoso et al. (Aug. 25 issue)1 suggest that chemotherapy can 
be safely withheld from patients who are clinically at high risk for recurrence but have 
a low-risk 70-gene signature (MammaPrint). However, the subgroup analysis does 
not show whether this finding was also true for patients with grade 3 tumors (found 
in 29% of the patients), who usually have an increased benefit from chemotherapy. 
Besides this factor, an underexposed finding of this study is that MammaPrint was not 
useful in at least 60% of the patients, particularly those at low clinical risk and those 
at high clinical risk with triple-negative tumors.
There were major differences between the characteristics of the patients at high 
clinical risk but low genomic risk and the characteristics of those at high risk in both 
categories. Among patients at high clinical risk but low genomic risk, 90% of the 
tumors were luminal and negative for human epidermal growth factor receptor 
2 (HER2), and 71% of the tumors were grade 1 or 2. In contrast, among the patients 
at high clinical and genomic risk, only 50% of the tumors were luminal and HER2-
negative, and 76% were grade 3. We calculated that among the patients at high 
clinical risk, 82% of luminal grade 1 or 2 tumors would be classified as genomic low 
risk.
Genomic assays are expensive and should be used efficiently. It may be possible to 
perform a decision-tree analysis on the basis of chi-square automatic interaction 
detection (CHAID)2 using primary intrinsic tumor characteristics (e.g., the presence 
or absence of estrogen receptor and HER2, along with Ki-67 status and tumor 
grade) as predictors for the MammaPrint outcome. On the basis of the outcome of 
such a study, the use of MammaPrint could be restricted to patients for whom the 
clinicopathological risk assessment is insufficient.
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In the past decades, adjuvant endocrine therapy has increased substantially in 
popularity and has become one of the mainstays in the treatment of patients with 
breast cancer. Current international guidelines state that all patients with >1% 
of tumour cells expressing ER are eligible to receive adjuvant endocrine therapy.1 
Although the Dutch guidelines are a bit less stringent (>10% ER expression, and <2 
cm and grade 1, or <1cm and grade 1 or 2 tumours are excluded), still the majority of 
ER-positive patients receives adjuvant endocrine therapy.2-4 The treatment durations 
have escalated over the years. Starting initially with just a few months of adjuvant 
tamoxifen, trials have been performed studying up to 15 years of adjuvant endocrine 
therapy.5
Both the relative low threshold for ER-positivity and the increasing treatment 
durations contribute to the risk of overtreatment. In a meta-analysis performed by 
the Early Breast Cancer Trialists Collaborative Group (EBCTCG), 5 years of tamoxifen 
was compared to no adjuvant therapy. At 15 years after diagnosis, there was an 
absolute benefit of 12% in recurrences (45% vs 33%), and an absolute benefit of 9% 
(35% vs 26%) on breast cancer mortality.6 However, this also suggests that for 88% of 
the patients there was no benefit of tamoxifen (55% because they wouldn’t develop 
a metastasis anyhow, and 33% because they still develop a metastasis despite their 
therapy). Identification of these patients is crucial, either to de-escalate therapy for 
the ones that would not develop a metastasis even without therapy, or to escalate 
therapy for the patients that would develop a (late) metastasis despite their therapy. 
In this thesis, we have studied and discussed multiple aspects of tailoring this adjuvant 
endocrine therapy.
Extended adjuvant endocrine therapy
Extended therapy beyond 5 years is one of the strategies to escalate therapy, in 
order to prevent late relapses of HR-positive breast cancer. Especially after 5 years 
of tamoxifen, it is often considered to be standard of care, which is reflected in most 
international guidelines and is summarized in chapter 2. The leading study in this field 
is the MA.17 trial, which was published in 2003 by the group of Paul Goss in the New 
England Journal of Medicine.7 In this study, over 5000 women who earlier received 
5 years of tamoxifen, were randomized between 5 years of extended letrozole, or 5 
years of placebo. At interim analysis after 2.4 years, the disease-free survival in the 
treated group was 93%, versus 87% in the placebo group (HR 0.57, 95% CI 0.43-0.75, 
p<0.001). Although impressive at first glance, the absolute differences in terms of 
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distant recurrences are less impressive. In the letrozole group 47 (out of 2593) patients 
had a distant recurrence (1.8%), in the placebo group 76 (out of 2594) had a distant 
recurrence (2.9%). Based on these absolute numbers, it can be questioned whether 
this 1.1% of absolute difference in distant metastasis justifies 5 years of additional 
therapy. This doubt is strengthened by the 5 year follow-up publication, which showed 
no significant difference in distant metastasis-free survival (HR 0.80, 95% CI 0.62-
1.03, p=0.08) or overall survival (HR 0.98, 95% CI 0.78-1.22, p=0.85).8 That DFS was 
still significantly improved in both analyses, is explained by the fact that death due 
to other causes was not included in the definition of DFS. Furthermore, prevention 
of local relapse and secondary breast cancer in the contralateral breast (which is not 
regarded as a treatment aim for systemic adjuvant therapy) also strongly influenced 
the differences in DFS.
In a recent meta-analysis, it was confirmed that in general the added effect of 
extended endocrine therapy is limited, especially when overall survival is used as 
outcome measure.9 For recurrences, the same meta-analysis shows that the effect is 
isolated to patients with positive lymph nodes.9 In chapter 3 of this thesis, we describe 
the results of the phase III IDEAL trial, in which postmenopausal patients with early 
HR+ breast cancer were randomized between either 2.5 or 5 years of letrozole, after 
finishing 5 years of regular adjuvant endocrine therapy. In this chapter, we conclude 
that longer (5 versus 2.5 years) extended therapy has little value for the full population 
(chapter 3). However, other groups studying extended endocrine therapy, suggested 
that for patients with node-positive disease, there might be a benefit of longer AI 
therapy after using sequential therapy of tamoxifen followed by an AI for 5 years.10 
In chapter 4, we describe a subgroup analysis in the IDEAL trial, in this particular 
subgroup (node-positive disease, pre-treated with tamoxifen followed by an AI). In 
this chapter, we have shown that a longer use of letrozole in this particular subgroup 
might be beneficial. Still, despite the significant value in node-positive disease, the 
absolute benefits of extended therapy remain small. Therefore, shared decision-
making between patients and physicians plays a major role, balancing the (small) 
benefits and side effects.
Another reason why shared decision-making is particularly important for extended 
endocrine therapy, is the compliance to therapy. In the primary analysis of the IDEAL 
trial (chapter 3), we have shown that 25% of patients in the 2.5 years, and 45% in the 
5 years group are unable to finish therapy, in majority explained by adverse events. 




In chapter 5, we further investigated this phenomenon, by evaluating the factors 
associated to participating in the IDEAL, the factors associated to early treatment 
discontinuation, and the effect of early treatment discontinuation on survival 
outcome. We showed that factors associated to participation are high risk factors like a 
younger age and nodal status, whereas the factors associated to early discontinuation 
are more patient-centred factors like the type of earlier endocrine therapy, the 
amount of time between treatments, and the occurrence of side effects. Remarkably, 
we have shown that patients who decide to cease therapy after an adverse event, 
have an equal survival outcome compared to those who continue with therapy after 
an adverse event. This emphasizes the need for shared decision-based, personalized 
treatment regimes. 
One of the outcomes that shows a consistency under extended endocrine therapy, is 
the lower occurrence of contralateral breast cancer, which was also shown in chapter 
3. This preventive effect of endocrine therapy on the occurrence of new primary breast 
tumours is well studied, and has increasing popularity.11 However, the differences 
in absolute and relative risk reductions play a major role in this discussion. One of 
the most well-known studies in the field of primary breast cancer prevention is the 
International Breast Intervention Study II (IBIS-II). They randomized 3864 patients 
between anastrozole or placebo. After 5 years, there was a 50% reduction in the 
incidence of breast cancers (32 vs 64 respectively). This absolute reduction of 32 cases 
represents an absolute decrease of 1.7%, which already sounds much less impressive. 
Combined with the fact that only ER-positive breast cancer is prevented, which in 
general has a more favourable prognosis (approximately 85-90% survival at 5 years), 
the effect on overall survival is almost non-existent. Therefore, we feel that the 
preventive effect of extended endocrine therapy should not be used as an argument 
for the use of (extended) endocrine therapy.
Biomarker-based personalized endocrine therapy
One approach to improve the effect of (extended) endocrine therapy is to identify the 
patients that will benefit most from it, using biomarkers. Or, vice versa, use biomarkers 
to identify the patients that will not benefit from it, so that other types of therapy can 
be considered. Roughly, there are two approaches in the development of biomarkers, 
which we will call biology-based and risk-based biomarkers. 
49021 Erik Blok.indd   205 03-04-18   11:44
Chapter 11
206
The first approach, biology-based biomarkers, are biomarkers that are designed 
based on the biological mechanism of an intervention. A current example which 
is already widely used, is the tumor expression of hormone receptors (HRs). When 
these receptors are not expressed, endocrine therapy is not expected to cause any 
therapeutical effect. However, as shown in the previous section, the expression of 
hormone receptors is not a guarantee for treatment success. A possible mechanism 
to improve the use of information on the tumour expression of hormone receptors as 
predictive biomarkers for endocrine therapy, is described in chapter 6. By determining 
the activity of the ER-pathway, you could distinguish for which patients the estrogen 
receptor is not only expressed, but indeed active and therefore a suitable target for 
therapy. In chapter X, we adapted this procedure for evaluation in the TEAM IIA trial, 
in which patients were treated with neo-adjuvant endocrine therapy, we showed 
that non-response and progressive disease during therapy were associated to a 
lower baseline ER-pathway activity. Furthermore, in a public dataset, the decrease 
in ER-pathway activity was associated to therapy response. Therefore, this technique 
might be a way to monitor the efficacy of endocrine therapy, since the receptor 
pathway activity is expected to diminish upon successful treatment. Currently this is 
only applicable to the neo-adjuvant and metastatic setting, since these are the only 
settings with a tumour in situ for monitoring. However, with increasing utility of 
circulating tumour cells, this technique might become feasible for adjuvant therapies 
as well. Furthermore, future analyses are planned to assess whether a lack of decrease 
in ER-pathway activity might be explained by baseline mutations in ESR1, the gene 
coding for ER. If this is the case, patients with such a mutation might be spared from 
endocrine therapy since they will have no clinical response, and they should be treated 
with other types of adjuvant therapy (i.e. chemotherapy).
A second biology-based biomarker approach highlighted in this thesis, is the tumour-
immune environment, specifically the tumour-infiltrating lymphocytes (TILs). TILs, and 
specifically CD8-positive TILs are effector cells of the adapted immune system, capable 
of targeting tumour cells which they recognize as being ‘foreign’ due to expression of 
tumour neo-epitopes. However, since TILs are depending on these neo-epitopes for 
their activation, tumours with a lower mutational load are usually considered to be 
less responsive against TIL-infiltration.
It has been shown that ER-positive tumours have a lower mutational load compared 
to ER-negative tumours.12o Therefore, it is no surprise that TILs have no prognostic 




value in ER-positive disease, in contrast to ER-negative disease in which high numbers 
of TILs predict for a better survival.13, 14 The lack of prognostic value of TILs in ER-
positive disease was confirmed in this thesis in multiple cohorts (chapter 7 and 8). In 
contrast, TILs have prognostic capacities in ER-negative disease, in particular in triple-
negative breast cancer (TNBC). 15-19 In chapter 8 we explored the role of FAS, a key 
mediator in cytotoxic T-cell based immunity, in the distinction between ER-positive 
and ER-negative disease. We showed that CD8-positive TILs only had prognostic value 
in the presence of FAS expression , and that FAS was expressed twice as frequent in 
ER-negative disease compared to ER-positive disease.
In chapter 7, we evaluated the predictive capacity of CD8-positive TILs in the Dutch 
population of the Intergroup Exemestane trial (IES), which randomized patients 
between tamoxifen or exemestane after 2-3 years of tamoxifen. In this analysis, 
we have shown a strong predictive value of TILs in ER-positive disease, with regard 
to a differential treatment response to either tamoxifen or an AI. Patients with low 
numbers of TILs had a more favourable prognosis when treated with an AI compared 
to tamoxifen, whereas patients with a high number of TILs had a similar prognosis on 
both treatments. 
We have two different hypotheses for this observation. A first explanation might 
be a direct influence of endocrine therapy on lymphocytes in general, and TILs in 
particular. It is known that ER is expressed in lymphocytes, and the response in 
these cells to estrogen depletion (with an AI) might be different from the response 
to receptor modulation by tamoxifen.20 This could theoretically lead to altered 
functionality of the TILs, and thereby a difference in clinical prognosis. The second 
theory to explain the findings of TILs as predictive markers for endocrine therapy, 
could be that the number of TILs are a proxy marker for the mutational load. Tumours 
with higher numbers of TILs have a higher mutational load21, more resembling ER-
negative tumours and less dependent on ER-signalling. In that case, the type of 
endocrine therapy would make little difference. In contrast, tumours with lower 
levels of TILs may have a lower mutational load, thereby being more dependent on 
ER-signalling. This strong ER dependency might magnify the differences between AIs 
and tamoxifen with regard survival benefits. Future studies will need to show which 
of these two theories explains our results best, and validation is required before this 
marker can be used in a clinical setting. 




Risk-based biomarkers are capable of discriminating between patients with a high 
or low risk of tumour recurrence. Even when the relative treatment benefit (hazard 
ratio) is equal in the low-risk and high-risk subgroup, the treatment will have an 
higher impact when the a priori chance of recurrence is higher. For example, when a 
group of patients with a 50% chance and a group with a 10% chance of recurrence a 
being treated with a therapy that has a hazard ratio of 0.5, the first group will have an 
absolute risk reduction of 25% (1 in 4 patients has a benefit), whereas the second group 
has an absolute risk reduction of only 5% (1 in 20 patients has a benefit). Therefore, 
selection of either high-risk or low-risk patients might help in selective escalating and 
de-escalating of endocrine therapy.
One of the most popular new strategies to identify patients with a lower or higher risk 
of recurrences, is the use of gene expression profiles (GEPs). These assays determine 
the risk of recurrence, based on the expression of selected genes in the tumour. These 
assays are thoroughly discussed in chapter 9 and 10. In chapter 9, we performed an 
elaborate systematic review, to assess the assay development, clinical validation, 
clinical utility, and economic value of the four most frequently used GEPs in Europe. In 
this review, we conclude that in particular OncotypeDX and Mammaprint are both well 
studied, having level IA evidence available from large randomized trials. In chapter 10, 
we comment on MINDACT, one of these large trials assessing the clinical functioning 
of the Mammaprint test together with traditional clinicopathological guidelines. In 
this letter, we emphasize the need for subgroup analysis and the selection of patients 
for which testing is the most beneficial, and ask for careful interpretation of the trial 
results.
The use of GEPs to select patients for endocrine therapy is still limited. Only recently, a 
relative small study using GEP in an old trial (1976-1990) randomizing between 2 years 
of tamoxifen and no endocrine therapy, showed that a group of ER-positive patients 
with ultralow risk had an excellent prognosis, even without endocrine therapy.22 
Upon validation, this or similar other assays could be used to identify the patients for 
who endocrine therapy can be safely withheld. On the other end, these assays could 
perhaps be used to identify the patients with a higher risk for tumour recurrence, who 
might benefit from extended endocrine therapy. This use will be the topic of further 
investigations, both in the IDEAL trial and in other studies.





The trend of personalized and precision medicine in oncology is unstoppable, and 
will change the field completely. The field of breast cancer was one of the first to 
adopt personalized targeted medicine with endocrine and HER2-targeted therapy. 
This thesis has shown that for endocrine therapy a further personalization is likely 
and, upon validation of our findings, will lead to a more optimal treatment for 
every individual patient. However, there are some challenges which will need to be 
addressed before personalized endocrine therapy will become standard of care.
The first challenge will be to validate the initial results in a way, that can reliably 
be applied in the clinical setting. In the current situation, in which endocrine 
therapy regimes only become longer, especially de-escalation will be challenging. 
Prospective-retrospective studies, in which an earlier randomized trial is used to 
assess the predictive capacity of a new biomarker, is a popular method to validate 
a biomarker for treatment decisions. However, trials with ER-positive breast cancer, 
without any endocrine therapy in one arm (which would be needed to show the safety 
of biomarker-based de-escalation) are rare and usually old.6 It can be questioned 
whether these cohorts are still representative enough for current practice. The 
validation of biomarker-based differentiation between tamoxifen and AIs might be 
easier, since these trials (like BIG 1-98 and ATAC) are more recent and are suited for 
validation.
A second challenge is the remaining risk of tumour recurrence beyond 5 years of 
standard endocrine therapy.23 This thesis has shown that extending adjuvant therapy 
is not the solution for this problem, and there remains a continuous risk despite 
the extended therapy. A possible explanation might be that endocrine therapy is 
considered as cytostatic treatment, slowing down or stopping tumour growth without 
actually inducing cell death. Therefore, one extra step has to be taken in the field of 
endocrine therapy in order to use it as cytotoxic therapy. Whether this step will be 
taken using immunotherapy or ER-targeted cytotoxic therapy is not clear yet, and will 
take many years to develop.
Another challenge, which applies for personalized endocrine therapy but also for 
personalized medicine in general, is the validation of personalization as the most 
optimal treatment strategy. In classic evidence-based medicine, trials with thousands 
of patients are conducted, in which one arm is using the new therapy, and the other 
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arm is using standard therapy. However, the ultimate goal of personalized medicine, is 
that every treatment strategy is unique for every patient, and per definition therefore 
cannot be validated using ‘regular’ clinical trials. A work-around for this problem 
might be the development of trials that validate a treatment concept, instead of an 
individual therapy. In that case, you might randomize between ‘therapy according 
to biomarker-protocol’ and ‘therapy according to standard protocol’. However, 
financing this kind of trials for personalized endocrine therapy conserving patient 
numbers would become complicated, since all (adjuvant) endocrine therapy agents 
are off-patent, and benefits for industry would be low. For the development of new 
personalized agents (e.g. combination inhibitors, tailored to the tumour molecular 
make-up), other problems arise when this new concept of protocol-based treatment 
validation would be used. In order to be accepted to the US and EU markets, 
individual agents now have to be registered with evidence from a registration trial, 
in which the new drug is showing superiority over standard therapy. However, when 
these agents are tailored to individual patients, these trials are impossible to conduct. 
The unregistered use of agents in protocol-based trials as described above, would 
therefore require a paradigm shift in evidence-based medicine and pharmaceutical 
regulations.
When these challenges are met, the future of endocrine therapy will become a 
personalized treatment strategy combining targeted cytostatic and cytotoxic 
approaches. Decisions whether endocrine therapy should be started will be made 
using clinical and genomic risk evaluations, whereas decisions which type of endocrine 
therapy will be most effective will be made using biology-based biomarkers like 
tumour lymphocyte infiltration and ER pathway activity. Combining both approaches 
will lead to more effective endocrine therapy strategy for every individual patient. 
Only when we are able to select the most optimal endocrine therapy, we will be able 
to determine the optimal duration for each approach. Until then, 5 years of adjuvant 
therapy is sufficient for the majority of patients, and extended endocrine therapy 
should only be considered for a small subgroup of high-risk, tamoxifen treated 
patients.
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Borstkanker is na longkanker de meest voorkomende soort kanker, en met 17.000 
gevallen per jaar de meest voorkomende soort kanker bij vrouwen in Nederland. De 
behandeling van borstkanker is gebaseerd op drie pijlers: chirurgie om de primaire 
tumor te verwijderen, radiotherapie om locoregionale uitbreiding te voorkomen of 
te behandelen, en systemische therapie om uitzaaiingen op afstand te voorkomen of 
te behandelen. 
De mogelijkheden voor systemische therapie worden steeds uitgebreider. Over 
het algemeen wordt er onderscheid gemaakt tussen chemotherapie, targeted 
therapie, bijvoorbeeld gericht tegen de HER2-receptor, en hormoontherapie. De 
rationale achter hormoontherapie bestaat uit het feit dat in ongeveer 80% van alle 
borstkankers, de oestrogeenreceptor (ER) of progesteronreceptor (PR) tot expressie 
komt. De tumor ‘gebruikt’ deze expressie om zichzelf groeisignalen te geven. Het doel 
van hormoontherapie is deze activatie te voorkomen.
De eerste vermelding van hormoontherapie ontstond in 1896, toen dr. Beatson 
operatief de eierstokken verwijderde bij een vrouw met uitgezaaid borstkanker. 
Vervolgens bleken de uitzaaiingen kleiner te worden. Vanaf dat moment is 
duidelijk dat er een hormonale invloed is op borstkanker, en werd een ovariëctomie 
standaardbehandeling bij borstkanker. Pas veel later, vanaf de jaren 70, kwamen 
er ook medicinale oplossingen voor hormoontherapie. In eerste instantie werd 
tamoxifen ontwikkeld, wat de oestrogeenreceptor (deels) blokkeert. In het begin 
werd dit alleen gebruikt voor de behandeling van uitzaaiingen, maar later werd ook 
via diverse klinische trials ontdekt dat een preventieve (adjuvante) behandeling met 
tamoxifen ook uitzaaiingen kan voorkomen. Lange tijd is 5 jaar therapie hiervoor de 
standaard behandelduur geweest.
In de tussentijd is er ook een tweede klasse van hormoontherapie ontwikkeld, de 
zogeheten aromataseremmers (AI). Deze remmen het enzym aromatase, wat er normaal 
voor zorgt dat mannelijke hormonen worden omgezet in de vrouwelijke oestrogenen. 
Door dit enzym te blokkeren wordt dus de aanmaak van oestrogeen voorkomen. Ook 
van deze klasse is aangetoond dat deze metastasen kan voorkomen, en met 5 jaar 
behandeling zelfs nog wat beter dan met 5 jaar tamoxifen.1 Ook de behandelswitch van 
tamoxifen naar een AI halverwege de 5 jaar is beter dan 5 jaar tamoxifen.1




Ondanks het succes van de hormoontherapie, is de behandeling nog steeds niet 
optimaal. Ongeveer 20% van de patiënten heeft baat bij hormoontherapie, wat een 
groot aantal is. Echter, dit betekent ook dat ongeveer 80% voor niets wordt behandeld: 
60% omdat ze toch geen uitzaaiingen zouden krijgen ook als ze niet behandeld 
zouden worden, en nog eens 20% omdat er ondanks de behandeling alsnog 
uitzaaiingen ontstaan.2 Er zijn twee belangrijke knelpunten: Wie hebben er precies 
wel of geen baat van de hormoontherapie? En wat is de optimale behandelduur? 
Wat betreft de optimale patiëntselectie, vind er op dit moment een selectie plaats 
op basis van de aankleuring van ER door de patholoog. Internationaal is de richtlijn 
dat indien de ER wordt gezien in meer dan 1% van de tumorcellen, de tumor wordt 
beschouwd als hormoongevoelig, en de patiënt in principe in aanmerking komt voor 
hormoontherapie. In Nederland zijn we al iets strenger, en houden we 10% aan en 
moet er ook sprake zijn van enkele andere ongunstige tumorkarakteristieken (zoals 
tumorgrootte, lymfeklierstatus en tumorgraad). Echter, er zijn veel patiënten die 
sowieso geen uitzaaiing zouden hebben gekregen, en er zijn ook nog steeds patiënten 
die ondanks de therapie alsnog een uitzaaiing krijgen. Van deze patiënten zou je 
kunnen zeggen dat ze onnodig zijn behandeld met hormoontherapie. Daarom is het 
belangrijk om van tevoren te kunnen voorspellen welke patiënten dit betreft, zodat je 
ze gerichter kunt behandelen. 
Wat betreft de optimale behandelduur, is 5 jaar adjuvante therapie lange tijd de 
standaard geweest. Echter, we weten ook dat meer dan de helft van alle recidieven, 
ná de eerste 5 jaar van follow-up valt. Daarom lijkt het niet onlogisch om ook de 
adjuvante therapie langer te maken, om die late recidieven ook te voorkomen. Na 5 
jaar tamoxifen, is al in meerdere studies aangetoond dat een behandeling tot 10 jaar 
(of met tamoxifen, of met een AI) beter is dan 5 jaar3-5, alhoewel dit effect beperkt 
lijkt tot patiënten met een relatief hoog risico (met lymfekliermetastasen).6 Voor de 
behandeling van 5 jaar met een aromataseremmer, is het op dit moment nog niet 
duidelijk of langere therapie zinvol is en zo ja, voor welke subgroep patiënten. 
In dit proefschrift wordt ingegaan op deze twee belangrijke aspecten om de 
behandeling met hormoontherapie te optimaliseren. In de eerste hoofdstukken ga 
ik in op de verlengde hormoontherapie, terwijl ik in de latere hoofdstukken me richt 
op het gebruik van biomarkers om de patiënten te selecteren die het meeste baat 
hebben van adjuvante hormoontherapie.




Hoofdstuk 2 behandelt al het huidige bewijs wat er voor aanvang van dit proefschrift 
bestond voor verlengde hormoontherapie. Hierin wordt er getoond dat tot nu toe er wel 
bewijs was voor een verlenging na tamoxifen, maar nog niet na een aromataseremmer. 
Ook wordt er een overzicht gegeven van alle huidige studies, die vooral de waarde van 
verlengde hormoontherapie na aromataseremmers onderzoeken.
Eén van die studies is de IDEAL-studie, waarvan de primaire resultaten beschreven 
staan in hoofdstuk 3. In de IDEAL studie zijn patiënten die eerder behandeld zijn met 5 
jaar hormoontherapie (tamoxifen, AI of een combinatie van beiden), gerandomiseerd 
tussen 2.5 en 5 jaar extra letrozol (een AI). De primaire uitkomstmaat was ziektevrije 
overleving. Na meer dan 5 jaar follow-up, was er geen verschil in ziektevrije overleving 
tussen beide groepen. Ook was er geen verschil in totale overleving. Wel werd een 
verschil gezien op het ontstaan van nieuwe borstkankers, dit was meer dan de helft 
minder in de langer behandelde groep (hazard ratio 0.39). Echter, in absolute zin was 
het verschil maar 2% (3% in 2.5-jaar groep, en 1% in 5-jaar groep, en hiermee is er dus 
niet voldoende waarde van de langere hormoontherapie voor de gehele groep.
Ondertussen was er ook een andere studie gepubliceerd, de eveneens Nederlandse 
DATA trial. Hierin werden patiënten na 3 jaar tamoxifen, gerandomiseerd tussen 3 of 6 
jaar anastrozol. In die studie, werd er aangetoond dat voor patiënten met uitzaaiingen 
in de lymfeklieren er wel baat is bij langere therapie, terwijl dit niet voor de hele groep 
geldt. Daarom hebben wij in hoofdstuk 4 een uitgebreidere subgroepanalyse gedaan 
in de IDEAL studie, om te kijken naar het effect van langere behandeling bij patiënten 
die alleen zijn voorbehandeld met tamoxifen én uitzaaiingen in de lymfeklieren 
hebben.  Inderdaad blijkt in deze analyse dat er voor deze specifieke subgroep wél 
een voordeel is van langere therapie. Echter, de analyse is gebaseerd op een klein 
aantal patiënten, en er kunnen nog geen definitieve conclusies uit worden getrokken.
Een ander probleem bij verlengde hormoontherapie, is het feit dat veel patiënten niet 
in staat zijn om de behandeling vol te houden. Dit fenomeen hebben we onderzocht 
in hoofdstuk 5. In die IDEAL studie werd het merendeel van de uitval (58%) verklaard 
door bijwerkingen van de hormoontherapie. Vooral bijwerkingen als depressie, 
gewrichtspijn en vermoeidheid leidden vaak tot het stoppen van de behandeling. 
Opmerkelijk genoeg had het stoppen van hormoontherapie nadat er een bijwerking 
is opgetreden, geen nadelig effect op de overleving. 





Eén van de manieren waarop patiënten beter geselecteerd kunnen worden voor de 
hormoontherapie, is het gebruik van biomarkers. Zoals hierboven reeds beschreven, 
wordt op dit moment in de tumor gekeken bij hoeveel procent van de tumorcellen de 
oestrogeenreceptor aanwezig is. Als dit bij meer dan 10% van de cellen is, noemen 
we de tumor hormoongevoelig. Echter, het feit dat deze receptor aanwezig is, wil niet 
per se zeggen dat deze ook actief is. In hoofdstuk 6 beschrijven we een nieuwe en 
nog ongebruikte methode, waarmee we kunnen bepalen of de oestrogeenreceptor 
ook daadwerkelijk actief is. Hiermee hebben we gekeken naar patiënten die neo-
adjuvant zijn behandeld met letrozol. Zowel voor als na de behandeling hebben we 
de activiteit van de oestrogeenreceptor bepaald. We hebben gezien dat bij patiënten 
die vooraf een hogere activiteit hadden, de behandeling beter aansloeg, en we 
hebben ook gezien dat bij deze patiënten de activiteit sterker af nam. Deze techniek 
kan wellicht in de toekomst gebruikt worden om patiënten te selecteren die meer, of 
juist geen baat hebben bij hormoontherapie. Als je in staat zou zijn om van tevoren 
te voorspellen wie er geen baat heeft, zou je de behandeling kunnen aanvullen met 
gerichte therapie zoals een CDK4/6 remmer, of vervangen door chemotherapie.7
Een andere mogelijke biomarker is het immuunsysteem, en tumorinfiltrerende 
T-cellen (TILs) in het bijzonder. Al eerder is aangetoond dat bij hormoongevoelig 
borstkanker, er geen prognostische waarde is van TILs, terwijl deze wel voorspellen 
voor een gunstige uitkomst bij hormoonongevoelig (met name triple-negatief) 
borstkanker. Echter, een biomarker kan predictieve waarde hebben, zonder op 
zichzelf prognostisch te zijn. Derhalve hebben wij in hoofdstuk 7 onderzocht wat 
de predictieve waarde is van CD8-positieve (cytotoxische) TILs bij hormoongevoelig 
borstkanker. Dit onderzoek is gedaan in het Nederlandse deel van de IES studie, waarin 
patiënten werden gerandomiseerd tussen 5 jaar tamoxifen, of 2.5 jaar tamoxifen 
gevolgd door exemestaan (een AI). Onze resultaten tonen dat wanneer er weinig 
TILs aanwezig zijn, er veel voordeel is van de behandeling met exemestaan (HR 0.27, 
p<0.001), terwijl als er veel TILs zijn er geen verschil is tussen beide behandelingen 
(HR 1.34, p=0.36). Deze analyse is herhaald in de TEAM, waar in de eerste periode ook 
tamoxifen met exemestaan is vergeleken. Ook hierin werd gezien dat bij weinig TILs 
er een voordeel is van exemestaan (HR 0.67, p=0.048), maar niet bij veel TILs (HR 
0.82, p=0.32), alhoewel het verschil in deze studie minder groot is. Als deze resultaten 
worden herhaald in een andere studie, zou dit kunnen leiden tot een beslissing over 
het type hormoontherapie op basis van de aanwezigheid van TILs.
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Om te onderzoeken waarom TILs geen prognostische waarde hebben bij HR-positief, 
maar wel bij HR-negatieve tumoren, hebben we in hoofdstuk 8 onderzocht of FAS 
hierin wellicht een rol speelt. FAS is beter bekend als de ‘death receptor’, en moet 
op een cel zitten om door een cytotoxische T-cel te kunnen worden aangevallen. 
Downregulatie van deze receptor kan dus zorgen voor een escape van het 
immuunsysteem, en zou een strategie van de tumor kunnen zijn. We hebben gezien 
dat FAS twee keer zoveel tot expressie komt in HR-negatieve tumoren. Daarnaast 
hebben we gezien dat CD8-positieve TILs bij HR-negatieve tumoren, alleen maar 
prognostisch zijn als ook FAS tot expressie komt in deze tumoren. De combinatie 
van deze twee conclusies zou wellicht (deels) kunnen verklaren waarom TILs wel 
prognostisch zijn bij HR-negatieve tumoren.
Een andere manier om biomarkers te gebruiken bij borstkanker, is het gebruik van 
genexpressie. Er zijn meerdere commerciële tests beschikbaar, die op basis van de 
expressie van verschillende genen in de tumor het risico op terugkeer van de ziekte 
kunnen bepalen. Hiermee kan dus vooraf een inschatting worden gemaakt of 
de patiënt een hoog of laag risico heeft op terugkeer van de ziekte, waardoor je in 
theorie meer of minder winst van de behandeling kunt verwachten. In hoofdstuk 9 
presenteren we een uitgebreide systematische review over de vier meest gebruikte 
testen in Europa: OncotypeDX, MammaPrint, Endopredict en Prosigna. Deze review 
richt zich op 4 belangrijke aspecten: de ontwikkeling van de test, de klinische validatie, 
het effect van de testen op gebruik van chemotherapie, en de economische waarde van 
de test. Wij concluderen dat zowel de Amerikaanse OncotypeDX als de Nederlandse 
MammaPrint goed zijn onderzocht, en op enkele verschillen na gelijkwaardig zijn 
voor klinisch gebruik. Voor beide testen zijn al grote klinische studies verricht om 
de waarde in de praktijk te laten zien. Voor de MammaPrint is dat de MINDACT 
studie geweest, waarover we in hoofdstuk 10 een ingezonden brief schrijven waarin 
we oproepen om goed te kijken bij welke subgroepen een dergelijke gentest echt 
meerwaarde heeft, en bij welke subgroep een bepaalde risico-uitslag al voor de hand 
ligt vanwege de klinische karakteristieken. Indien genexpressie testen daadwerkelijk 
bij de juiste subgroep ingezet kunnen gaan worden, zullen deze wellicht ook een 
rol kunnen spelen bij de selectie van patiënten met zo’n gunstig risicoprofiel, dat 
hormoontherapie voor deze patiënten weinig toegevoegde waarde zal gaan hebben.
Samenvattend behandelt dit proefschrift diverse aspecten van personali-
satiemogelijkheden voor de hormoontherapie van patiënten met hormoongevoelig 




borstkanker, zowel qua behandelduur als qua inzet van diverse soorten biomarkers. In 
de toekomst zal deze personalisatie over het algemeen waarschijnlijk leiden tot een 
gerichter gebruik van hormoontherapie, omdat we beter in staat zullen zijn om de 
patiënten te selecteren die baat hebben bij de therapie, in plaats van dat vrijwel alle 
patiënten vrijwel ongericht behandeld worden. Daarnaast zal er een klein deel zijn 
waarin de hormoontherapie juist geëscaleerd wordt tot een langere therapieduur 
of een gebruik van aromataseremmers in plaats van tamoxifen. Hiermee zal de 
behandeling van de patiënt met borstkanker, en daarmee ook de prognose, nog 
verder kunnen verbeteren.
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